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Summary  
Introduction: Multiple myeloma is a plasma cell malignancy that causes extensive 
osteolytic bone disease. Present treatments target end stage disease but understanding 
how bone lesions are initiated may offer new approaches to prevent/suppress 
colonization. It is clear that myeloma cells form specific interactions with the bone 
microenvironment, where they can remain dormant and protected from current therapy 
to eventually proliferate and cause disease progression. N-cadherin is an adhesion 
molecule that has been implicated in the localization of haematopoietic stem cells 
(HSCs) to ‘niches’ containing osteoblasts on endosteal bone surfaces. In this study, we 
have tested the hypothesis that myeloma cells utilise N-cadherin to adhere to osteoblasts 
in vitro and in vivo during the colonization into the bone.  
 
Findings: N-cadherin mRNA and protein were expressed by osteoblasts and myeloma 
cells. We showed focal expression of N-cadherin in myeloma cells, whereas expression 
was observed contiguously on the membranes of adjacent osteoblasts. N-cadherin 
expression significantly increased during osteoblastogenesis. Immunohistochemistry 
demonstrated staining of N-cadherin when myeloma cells were in contact with 
osteoblasts in vitro and in vivo. Blocking N-cadherin mediated interactions, using 
specific antibodies against N-cadherin, significantly reduced adherence of myeloma 
cells to osteoblasts in vitro. Attempts were made to block the adhesion of myeloma cells 
to bone cells in calvarial bones in vivo. These studies were in conclusion suggested that 
there may be a role of N-cadherin in these interactions.  
 
Conclusion: These studies provide evidence that adherence of myeloma cells to 
osteoblasts is mediated by N-cadherin in vitro and in vivo, suggesting that myeloma 
cells may occupy a niche similar to that used by HSCs in bone.  
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1.1 Bone Biology  
1.1.1 General structure and function of bone  
The mammalian skeleton is formed by two different tissues, bone and cartilage. Bone is 
a dynamic connective tissue composed of an organized matrix of collagen proteoglycan 
that supports and protects the various organs of the body, hardened by mineralization 
with calcium phosphate in the form of hydroxyapatite ([Ca3(PO4)2]Ca(OH)2). Bone 
structure is not a uniformly solid material, but composed of outside solid bone, cortical 
or compact, and inside spongy bones, trabecular (Figure 1.1). Cortical bone is an 
outside solid bone, which is dense, ordered structure and found mainly in the shaft of 
long bones and the surfaces of flat bones. Trabecular bone is an inside spongy bones, 
which is lighter, less compact and has an irregular structure (Datta et al., 2008). Bone 
types include long bones such as those in limbs, short bones such as wrist and ankle, flat 
bones such as skull and irregular bones such as spine and hips. Osteoclasts, osteoblast, 
bone lining cells and osteocytes are the cell types responsible for bone turnover and 
maintenance of bone cells (Karsenty, 1999, Watkins et al., 2001). The essential role of 
bone is to provide structural anchorage between muscles, movement of the body, 
providing mineral, chiefly calcium and phosphate, balance for the body, in addition to 
protection of the brain, spinal cord, heart and lungs (Cohen, 2006).  
 
The marrow cavity within bone is the main site of hematopoiesis in the adult human and 
comprises of extracellular matrix (ECM), Hematopoietic stem cells (HSCs), 
Mesenchymal stem cells (MSCs), blood cells, osteoblasts, osteoclasts, fibroblasts, 
endothelial cells and adipocytes. The ECM is composed of an organic component and 
an inorganic component, in which organic matrix represents approximately 35% of the 
total weight of bone compared with inorganic matrix which represents 65% (Downey 
and Siegel, 2006). Bone growth, metabolism and remodeling are regulated by two 
interacting, coupled processes; bone resorption and bone formation. Bone remodeling 
regulates calcium homeostasis and repairs micro-damaged bones in addition to 
maintaining the shape and sculpture of the skeleton during growth. Osteoclasts resorb 
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bone while osteoblasts produce bone matrix and facilitate mineralization. The 
cooperative activities of osteoclasts and osteoblasts results in a healthy bone and 
maintain normal skeletal development. (Fliedner, 1998, Wang et al., 2006, Muguruma 
et al., 2006).  
 
 
 
 
 
 
 
 
 
 
 
 
1.1.2 Cells of bone  
Within the skeleton there are 4 basic types of bone cells; osteoclasts, osteoblast, bone 
lining cells and osteocytes. Osteoclasts (Figure 1.2A) are multinucleated cells derived 
from monocytes that are ultimately from HSCs first discovered in 1873 by Kolliker. 
Osteoclast maturation requires the presence of receptor activator of nuclear factor κβ 
ligand (RANKL) and Macrophage colony-stimulating factor (M-CSF) (Nijweide et al., 
1986, Teitelbaum, 2000, Watkins et al., 2001). Overexpression of osteoprotegerin 
Figure 1.1: Structure 
of the long bone (tibia) 
of C57BL/KalwRij 
male mice. Bone is a 
dynamic connective 
tissue is composed of 
cortical and trabecular 
bones. Cortical bone is 
composed of the hard 
outer layer of bones. 
Trabecular bone is 
composed of spongy 
bones, which is lighter, 
less compact and has an 
irregular structure. 
Images were captured at 
2.5x resolution using 
osteomeasure software 
with a Leitz DMRB 
microscope.  
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(OPG), soluble receptor that competes with RANK for RANKL, reduces 
osteoclastogenesis in mice. On the other hand, lack of OPG has been shown to 
accelerate osteoclastogenesis and OPG Ko mice (OPG
−/−
 mice) develop severe 
osteoporosis (Bucay et al., 1998).  
 
Osteoclasts form at skeletal sites, in which stromal cells and osteoblasts express 
RANKL and M-CSF and it is the interaction of these ligands with their receptors on 
monocyte/macrophage cells that induce commitment to the osteoclast phenotype. 
Osteoclasts have a critical role in the regulation of bone formation and regulation of 
bone mass, in which mature and active osteoclasts are responsible for resorbing 
mineralized bone matrix and breaking up the organic bone (90% collagen). 
Differentiated osteoclasts express αvβ3 integrin, which binds to bone matrix via RGD-
containing proteins leading to the formation of sealed pocket for the secretion of 
cathepsin K, the major protease involved in the degradation of type I collagen 
(Nakamura et al., 1996, Nakamura et al., 2007a). After attachment, osteoclasts exhibit a 
highly polarized cytoplasmic organization. The intracellular pH of osteoclasts is 
maintained by HCO3
-
/Cl
-
 exchanger at the antiresorptive surfaces. Activated osteoclasts 
generate ruffled membranes in which Cl
-
 ions pass through the membrane increasing the 
acidity charge-coupled to the vacuolar H
+– adenosine triphosphatase (ATPase) results in 
secretion of hydrogen chloride (HCl) into the resorptive microenvironment and increase 
the pH to ~4.5. These acidify an extracellular microenvironment resulting in 
demineralization of the organic component of bone (Karsenty, 1999, Teitelbaum, 2000).  
 
Osteoblasts (Figure 1.2B) are mononucleate cells derived from putative MSCs that are 
responsible for bone formation and for a regulation of osteoclast differentiation. Bone 
morphogenic proteins (BMPs), Wnt/β-catenin and Notch signalling all play a major role 
in osteoblastogenesis (Chen et al., 2004, Milat and Ng, 2009, Engin and Lee, 2010). In 
addition, Runt-related transcription factor 2 (RUNX2) has been shown to be an essential 
transcription factor for osteoblastogenesis. It was found that Runx2-/- mice failed to 
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develop calvarial bones and mice died at birth. Runx2 also regulates another 
transcription factor necessary for osteoblastogenesis, osterix (Lian and Stein, 2003). 
Osteoblast differentiation from MSCs can be characterized in multiple commonly 
accepted stages, pre-osteoblasts, osteoblasts, bone lining cells and osteocytes (Yin and 
Li, 2006, Wu et al., 2009). Mature osteoblasts are identified by their cuboidal structure 
and their location on the endosteal surface. Type I collagen is the major product of the 
bone-forming osteoblast, in addition to osteocalcin and osteonectin (Di Lullo et al., 
2002). In addition, osteoblasts express relatively high amounts of alkaline phosphatase 
(Ducy et al., 1996). Terminally differentiated osteoblasts either become bone lining 
cells or differentiate into osteocytes surrounded by mineral matrix or undergo apoptosis 
by activation of intrinsic (mitochondria) death signals. Apoptosis can mediated by cell 
surface death receptors of the tumour necrosis factor (TNF) receptor superfamily such 
as osteoprotegerin (OPG), which subsequently activates caspases inducing cell death 
(Manolagas, 2000, Hock et al., 2001).  
 
Bone lining cells (Figure 1.2C) are elongated cells with slightly ovoid nuclei. The non-
remodelling bone surface is covered by a thin layer of bone lining cells (Everts et al., 
2002). Mineralized collagen matrix synthesis stops once bone formation is inactivated 
by the conversion of osteoblasts into bone lining cells in a reversible process which 
represents one of the fates of osteoblasts that have completed their bone forming 
function. It is suggested that bone lining cells have a little involvement in the bone 
formation mechanism (Manolagas, 2000).  
 
Following active bone formation some osteoblasts are eventually embedded within the 
matrix. Matrix-producing osteoblasts express alkaline phosphase and collagen, which 
are necessary for the production of osteoid, unmineralized bone matrix. A 
subpopulation of osteoblasts becomes encased in osteoid as osteoid osteocytes, which 
regulate mineralization, then into mineralizing osteocytes and mature osteocytes. When 
osteoblasts are differentiated into osteocytes, alkaline phosphatase is reduced and casein 
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kinase II is increased (Mikuni-Takagaki et al., 1995, Bonewald, 2011). Osteocytes 
(Figure 1.2D) are the most numerous cells found in mature bone and are characterized 
by a stellate morphology with a dendritic network similar to that of the nervous system. 
These cells, embedded in mineralized matrix, directly contact with each other or with 
osteoblasts via long cytoplasmic extensions passing through bone in canals called 
canaliculi (Aarden et al., 1994, Bonewald, 2011). Although osteocytes are relatively 
inert cells, they have an important function. Osteocytes act as mechanosensor cells, in 
which they are sensitive to applied stress of bone loading to maintaining bone structure. 
The need for bone increase or bone reduction during functional adaptation of the 
skeleton in addition to repair of micro-damage can be detected by osteocytes. 
Osteocytes express some molecules such as, phosphate-regulating neutral 
endopeptidase, X-linked (PHEX), dentin matrix acidic phosphoprotein-1 (DMP-1), 
matrix extracellular phosphoglycoprotein (MEPE) and fibroblast growth factor 23 
(FGF-23) that play an important role in phosphate homeostasis (Klein-Nulend et al., 
2003, Bonewald, 2011). Osteocytes can also detect changes in the levels of hormones, 
such as estrogen and glucocorticoids (Manolagas, 2000). In addition, they control the 
bone formation via sclerostin, SOST gene, a BMP antagonist.Winkler et al (2003) 
demonstrated that sclerostin released from osteocytes mediates bone homeostasis 
(Winkler et al., 2003). Osteocytes also act as inducers of osteoclast activation. Zhao et 
al (2002) demonstrated that osteocyte-like cells, MLO-Y4, support osteoclast formation 
and activation by expressing RANKL on their surface and by expression and secretion 
large amounts of M-CSF (Zhao et al., 2002).  
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Figure 1.2: Cells of bone on the cortical surfaces of the calvarial bones in male 
C57BL/KalwRij mice aged 6 weeks. Panel A shows positive tartrate resistant acid 
phosphatase (TRAP) stain for osteoclast (denoted by black arrow) on the endosteal 
surfaces of calvarial bones. Panel B shows osteoblasts (denoted by black arrows) 
cover the cortical bone surface of calvarial bones. Panel C shows the bone lining cells 
(denoted by black arrows) cover the cortical bone surface of calvarial bones. Panel D 
shows the osteocytes (denoted by black arrows) embedded within the mineralized 
matrix. Bar size equal 50 μm. CB is cortical bone. 
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1.1.3 Bone modeling  
In order to maintain its functions and maintain serum calcium levels during vertebrate 
life, bone is regulated by two processes; modeling and remodeling. Bone modeling is an 
adaptive process of generalized and continuous growth in bone shape, length and width 
until the adult bone structure is attained. This growth requires normal activity of bone 
cells; osteoblasts and osteoclasts. The modeling process differs from remodeling which 
is a locally coupled process of bone resorption and formation maintaining skeletal mass 
and morphology. During development approximately 100% of bone surfaces are active 
during the modeling process until proper bone size and shape is achieved. In contrast, 
only 20% of bone surfaces are active in remodeling processes at any given time 
(Watkins et al., 2001).  
 
During foetal development, bone formation is regulated through two unique 
mechanisms: intramembranous ossification and endochondral ossification. In 
intramembranous ossification, some bones such as the prefiguring part of the skull and 
the clavicles are developed through differentiation of MSCs into osteoblasts directly, 
which subsequently form woven bone with characteristic irregular calcification and an 
assembly of collagen fibres. In endochondral ossification, the rest of the bones, long 
bones, are developed through differentiation of MSCs into chondrocytes forming the 
cartilage anlagen. Cells from the perichondrium of cartilage anlagen differentiate into 
osteoblasts, and the periphery of the cartilage anlage become hypertrophic. Finally, the 
matrix surrounding these hypertrophic chondrocytes calcifies and longitudinal growth is 
stimulated as cartilaginous matrix. Once bone becomes mature, the remodelling process 
starts to control the reshaping, replacement of bone following injuries and maintains 
calcium homeostasis (Karsenty, 1999, Ferretti et al., 2002, Robling et al., 2006).  
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1.1.4 Bone remodeling  
In order to maintain stability and integrity of bone in addition to calcium homeostasis, 
bones are continuously undergoing remodeling (Figure 1.3). Bone remodelling is a 
complex process, in which mature bone tissue is removed by a process called bone 
resorption and new bone tissue is formed by a process called bone formation. In this 
process, cellular activity and molecular mechanisms are closely coordinated to ensure 
the bone resorption-formation sequence is carried out at a mutual location thus 
sustaining bone mass. Cells responsible for bone resorption are osteoclasts, and cells 
responsible for bone formation are osteoblasts. The remodeling cycle is divided into 
four consecutive phases: activation, resorption, reversal, and formation, which is 
regulated both systemically and locally by cytokines, hormones and growth factors, 
affecting tissue quality and mass. Disruptions in the interaction of osteoclasts or 
osteoblasts and imbalance in the regulation of bone remodeling can result in irregular 
bone turnover cycles and subsequently results in many metabolic bone diseases such as 
Multiple Myeloma (MM) bone disease (Hadjidakis and Androulakis, 2006, Proff and 
Romer, 2009, Raggatt and Partridge, 2010).  
 
During the bone remodeling process, old bone is resorbed and replaced with new bone 
by osteoclasts and osteoblasts, respectively. The cellular mechanism of bone 
remodeling process starts with an activation phase, in which osteoclasts precursors are 
recruited and differentiated into pre-osteoclasts then into mature osteoclasts. After 
osteoclast activation, the resorption phase takes place in which mature osteoclasts resorb 
bone surfaces. Following resorption, the reversal phase, in which mature osteoclasts go 
into apoptosis and osteoblast precursors are recruited and differentiated into pre-
osteoblasts then into mature osteoblasts at resorbed bone surfaces. Ultimately, the 
formation phase takes place in which mature osteoblasts secrete new bone matrix which 
mineralized to generate new bone (Raggatt and Partridge, 2010).  
 
Determining the role of N-cadherin in the formation of the myeloma niche 
  
 Page 10 
 
1.1.4.1 Regulation of osteoclast activity  
Osteoclastic bone resorption is controlled by receptor activator of nuclear factor kappa-
B ligand (RANKL), growth factors, cytokines and hormones. RANKL is a tumour 
necrosis factor (TNF)-related cytokine expressed by osteoblasts and stromal cells. 
RANKL has an important role in osteoclast differentiation, in which it binds to its 
receptor, receptor activator of nuclear factor kappa-B (RANK) on the surface of 
osteoclast precursors. Binding of RANKL to RANK starts the osteoclastogenesis 
process and stimulates osteoclast activity and bone resorption (Boyle et al., 2003). 
Simonet et al (1997) demonstrated that using recombinant osteoprotegerin (OPG), an 
osteoclastogenesis inhibitory factor blocked the differentiation of osteoclasts from 
precursor cells in vitro. In vivo, overexpression of OPG in transgenic mice induced a 
reduction in the later stages of osteoclast differentiation resulting in non-lethal 
osteopetrosis (Simonet et al., 1997).  
 
Transforming growth factor β (TGF-β), Bone morphogenetic proteins (BMPs) and 
fibroblast growth factor (FGF) all have important roles in the regulation of osteoclast 
activity. TGF-β is a factor released during bone resorption. Quinn et al (2001) 
demonstrated that TGF-β regulated osteoclast differentiation. In culture TGF-β inhibited 
osteoclast formation, osteoclastogenesis in addition to decreased RANKL (Quinn et al., 
2001). BMPs are a group of growth factors that induce formation of bone and cartilage. 
It was found that BMPs stimulate the differentiation of osteoclasts and osteoblasts 
during bone development. Okamoto et al (2006) demonstrated that mice overexpressing   
BMP-4 in bone developed severe osteopenia in addition to increased osteoclast 
numbers. In contrast, mice overexpressing noggin (a BMP antagonist) had increased 
bone volume and decreased osteoclast numbers (Okamoto et al., 2006). The FGF has 
been shown to family of growth factors also has been shown to be involved in the 
regulation of bone formation: FGF stimulate osteoclast recruitment, osteoclast 
differentiation and bone resorption (Hurley et al., 1998, Collin-Osdoby et al., 2002).  
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In addition to RANKL and growth factors discussed upon, cytokines have been shown 
to play an important role during bone remodeling. Interleukin-1 (IL-1), interleukin-6 
(IL-6) and Tumour Necrosis Factor-α (TNF-α) all play a major role in induction of 
osteoclast differentiation and mediation of bone resorption. Thomson et al (1986) 
demonstrated that osteoblasts mediate IL-1 stimulated osteoclast activity and increase 
osteoclastic bone resorption (Thomson et al., 1986). Kurihara et al (1990) demonstrated 
that adding 10 to 100 pg/ml of IL-6 significantly increased the formation of 
multinucleate osteoclasts in cultures. Use anti-human IL-1 inhibited the increase of 
multinucleate osteoclasts stimulated by IL-6. Furthermore, adding IL-6 in culture 
increased the elevated level of IL-lβ. These results suggested that IL-6 stimulated the 
formation of multinucleate osteoclasts is mediated by induction of release of IL-1β 
(Kurihara et al., 1990). TNF-α is a multifunctional cytokine produced by activated 
macrophages. It was found that TNF-α together with IL-1 induced osteoclast 
differentiation and mediated bone resorption (Wei et al., 2005).  
 
Osteoclastic bone resorption is controlled systemically by four main hormones: 
parathyroid hormone (PTH), 1,25-Dihydroxycholecalciferol (1,25(OH)2D3), calcitonin 
and oestrogen. PTH is a potent stimulator of osteoclast function by binding to its 
receptors on osteoblasts and bone marrow stromal cells. This activates expression of 
MCSF and RANKL, thereby indirectly stimulating osteoclastic bone resorption 
(McSheehy and Chambers, 1986a, McSheehy and Chambers, 1986b). On the other 
hand, there has been evidence that PTH could be directly stimulating osteoclast-like cell 
formation from hemopoietic blast cells (HSCs) (Sugimoto et al., 1993). It has been 
postulated that PTH also stimulates the production of 1,25-Dihydroxycholecalciferol 
(1,25(OH)2D3) from a circulating inactive precursor. 1,25-Dihydroxycholecalciferol 
(1,25(OH)2D3) positively regulates bone resorption indirectly, which increases RANKL 
and M-CSF expression (McSheehy and Chambers, 1987). Calcitonin hormone binds to 
its receptors that are expressed on osteoclasts and inhibits osteoclastic resorption 
directly (Zaidi et al., 2002). Estrogens have an important function in the skeletal system 
in female, in with they act as a bone-sparing hormone. Estrogens bind to receptors 
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expressed on both osteoclasts and osteoblasts causing osteoclast apoptosis (Nakamura et 
al., 2007b, Krum et al., 2008). Nakamura et al (2007) demonstrated that activated 
osteoclastic estrogen receptor α (ERα) by estrogen induced apoptosis for osteoclasts 
through activation of the Fas/Fas ligand (FasL) system, in which oestrogen up-regulated 
FasL expression in osteoclasts. In vivo, ERα ablation in transgenic mice induced 
trabecular bone loss in females, but not males (Nakamura et al., 2007b). Krum et al 
(2008) demonstrated that oestrogen induced FasL expression in osteoblasts and not in 
osteoclasts in vitro and in vivo. Osteoclasts do not undergo oestrogen-induced apoptosis 
unless osteoblasts were added. Co-cultures of osteoblasts and ERαKO bone marrow-
derived osteoclasts mediated osteoclast apoptosis suggesting oestrogen protects bone by 
inducing FasL in osteoblasts to regulate osteoclast survival (Krum et al., 2008).  
 
1.1.4.2 Regulation of osteoblast activity   
The differentiation of osteoblasts is controlled by key signaling systems Wnt, Dickkopf 
(DKK), BMPs and Insulin-like growth factors (IGFs). The Wnt signaling pathway is a 
network of proteins that has an important role in postnatal bone formation and bone 
turnover. Wnt stimulates osteoblast proliferation, function and survival though binding 
to Frizzled that subsequently binds to lipoprotein receptor related protein-5/6 (LRP-5/6) 
(Westendorf et al., 2004). Gong et al (2001) demonstrated that expression of LRP-5 by 
osteoblasts in situ can transduce Wnt signalling in vitro. In addition, a mutant-secreted 
form of LRP-5 can reduce bone thickness in mouse in vivo (Gong et al., 2001). Tamai et 
al (2000) demonstrated that LRP-6 binds to Wnt-1 to activate Wnt signalling in 
Xenopus embryos. Furthermore, LRP6 mutant lacking the carboxyl intracellular domain 
blocked Wnt signalling indicating that LRP-6 may be a component of the Wnt receptor 
complex (Tamai et al., 2000). Day et al (2005) demonstrated that controlling Wnt/β-
catenin signalling is essential to control osteoblast and chondrocyte (cells found in 
healthy cartilage) differentiation. Wnt/β-catenin signalling enhanced osteoblast 
differentiation, ossification and suppressed chondrocyte formation. In contrast, 
inactivation of β-catenin caused chondrocyte differentiation in vitro (Day et al., 2005).  
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Wnt antagonist, (DKK), plays an important role in regulation of osteoblast activity. 
Four members of the DKK family; DKK-1, DKK-2, DKK-3 and DKK-4 have been 
identified. Wnt/β-catenin pathway can be inhibited by DKK-1 and DKK-2 by binding to 
LRP-5/6 and single transmembrane protein, Kremen, preventing their interaction with 
Wnt, which is essential for osteoblast activation (Niehrs, 2006). Mao et al (2001) 
demonstrated that LRP-6 is required for Wnt/β-catenin signaling in drosophila, xenopus 
and mouse. Dkk-1 and Dkk-2 interact with domains of LRP-6 that are required for 
Wnt/Frizzled interaction and blocks Wnt/β-catenin signaling (Mao et al., 2001). 
Furthermore, Mao et al (2002) demonstrated that transmembrane proteins Kremen-1 
and Kremen-2 are high-afﬁnity Dkk-1 receptors inducing rapid endocytosis and 
removal of the Wnt receptor LRP-6 from the plasma membrane. This result suggested 
Kremen-1 and Kremen-2 are modulating canonical Wnt signaling through LRP-6 in 
vertebrates (Mao et al., 2002).  
 
BMPs are a group of growth factors that belong to TGF-β superfamily initially 
identified by their ability to induce bone development. BMPs are stored in the bone 
matrix and released during bone resorption, stimulating osteoblast proliferation and 
skeletogenesis by binding to two different types of serine-threonine kinase receptors, 
termed type I and type II receptors. Activities of BMPs are regulated by BMP-binding 
proteins; Noggin and Chordin (Kawabata et al., 1998, Yamaguchi et al., 2000). King et 
al (1994) demonstrated that BMP-5 was expressed in the early stage of skeletal 
development and that it was expressed in some soft tissues suggesting that BMP-5 is a 
signal for both skeletal and soft tissue development (King et al., 1994). Lyons et al 
(1995) demonstrated that BMP-2 and BMP-7 were expressed in midgestation embryos 
suggesting their roles during skeletal development (Lyons et al., 1995). Yamaguchi et al 
(1996) demonstrated that BMP-2, BMP-4 and BMP-6 stimulated the differentiation of 
osteoblast cell lines, ST2 and MC3T3-G2/PA6 in vitro. BMP-2, BMP-4 and BMP-6 
stimulated ALP activity, induced PTH and generated mineralized bone in these 
osteoblastic cells suggesting that BMPs induce differentiation of bone marrow stromal 
cells into osteoblasts (Yamaguchi et al., 1996).  
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The insulin-like growth factor (IGF) signalling system is comprised of two receptors 
(IGF1R and IGF2R), two ligands (IGF-1 and IGF-2) and six binding proteins (IGFBP-1 
to IGFBP-6). It was found that IGFs stimulate osteoblast activity and increase bone 
formation, and bone matrix mineralization. Overexpression of IGF-1 in transgenic mice 
indicated increased trabecular bone volume compared with control mice (Zhao et al., 
2000a). Osteoblast-specific knockout of IGF receptor gene induced decrease in 
cancellous bone volume, trabecular number and decrease in the rate of mineralization of 
osteoid (Zhang et al., 2002).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.3: Diagrammatic summary of bone remodeling cycle. Bone remodeling is 
regulated by a couple of bone cells; osteoclasts and osteoblasts. Remodeling cycle 
firstly starts with activation phase; receptor activator of nuclear factor kappa-B ligand 
(RANKL) and Macrophage colony-stimulating factor (M-CSF) activate and recruit 
osteoclasts. Secondly bone resorption phase; the activity of osteoclasts and bone 
resorption controlled by RANKL, FGF, IL-1, IL-6, TNF-α, PTH, 1,25(OH)2D3,   
TGF-β, BMPs, calcitonin and oestrogens. Thirdly reversal phase; osteoclasts are 
removed and osteoblasts are activated and recruited by Runx2, BMPs, Wnt and Notch. 
Fourthly bone formation phase; osteoblasts secrete new bone matrix which 
mineralized to generate new bone. The bone formation is regulated by Wnt, BMPs 
and IGFs.  
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1.2 Multiple myeloma  
1.2.1 Epidemiology of multiple myeloma  
Multiple myeloma (MM) is the second most common hematologic cancer after non-
Hodgkin lymphoma and represents 10% of all hematologic malignancies and 1% of all 
deaths caused by cancers (British Committee for Standards in Haematology, 2001). 
2,223 new cases of MM in men and 1,817 new cases of MM in women were reported in 
2007 in the United Kingdom. The five year survival rates for MM patients are 
approximately 20% (Collins, 2005, Raab et al., 2009).  
 
1.2.2 Pathophysiology of multiple myeloma  
MM is a plasma cell malignancy of the B lymphocytes that secrete antibodies. 
Proliferation of B cells and antibody secretion are processes controlled by the immune 
system, which can be lost when chromosomes and genes are damaged. B cells are 
generated in the bone marrow (BM) in the form of precursors and differentiated into 
immature B cells.  Immature B cells that express functional surface IgM exit the bone 
marrow into secondary lymphoid tissues and differentiated into mature B cells. 
Interaction of mature B cells with antigen results in the generation of short-lived plasma 
cells, which usually secrete IgM. Some mature B cells differentiated into memory B 
cells or plasma cells and are retained back into the BM as long-lived plasma cells. 
Complex chromosomal abnormalities and some genetic events are likely to be 
responsible for MM disease when B cells are at the secondary lymphoid tissues (Kuehl 
and Bergsagel, 2002). For example, a chromosomal translocation between the 
immunoglobulin heavy chain gene leads to dysregulation of oncogenes at translocation 
partner regions (cyclin D1 at 11q13, FGFR3/MMSET at 4p16.3, c-MAF at 16q23, and 
cyclin D3 at 6p21) and is thought to be an important initiating event for MM. In 
addition, deletions of 13q14, the site of a putative tumour suppressor gene, are observed 
in about 50% of MM cases. Other molecular events, epigenetic changes and activation 
of oncogenes (mutations of N-RAS and K-RAS, and changes in c-MYC) have been 
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reported to be associated with disease progression (Seidl et al., 2003, Kyle and 
Rajkumar, 2004). Furthermore, imbalances between RANKL and osteoprotegerin in 
addition to some osteoclastic activity factors (in particular macrophage inflammatory 
protein-1α (MIP-1α) and interleukin-3 (IL-3)) are major factors responsible for the 
development of myeloma bone disease (Croucher et al., 2001, Choi et al., 2000, Lee et 
al., 2004).  
 
1.2.3 Homing of multiple myeloma cells to bone marrow  
The mechanisms of MM cells trafficking or homing to the BM are not well understood. 
The most studied factors shown to regulate MM cells homing to the BM are C-X-C 
chemokine receptor type 4 (CXCR-4), hypoxia and E-cadherin. During the 
differentiation of B cells, plasma cells become increasingly sensitive to C-X-C 
chemokine ligand 12 (CXCL12). It was found that MM cells in the peripheral blood 
express high levels of CXCR-4, but this expression level decreased in the BM 
suggesting that this receptor-cytokine system important in homing of MM cells to the 
BM, but less involved in retention of cells. The CXCR-4 inhibitor, AMD3100, and the 
anti-CXCR4 antibody, MAB171, inhibited the migration of MM cells in vitro and the 
homing of MM cells to the BM in vivo (Alsayed et al., 2007). In addition, CXCR-4 
knockdown demonstrated that CXCL12/CXCR4 is a critical regulator of MM migration 
and homing was regulated by the phosphatidylinositide 3-kinases (PI3K) and mitogen-
activated protein kinases/ extracellular signal-regulated kinases (MAPK/ERK) pathways 
but not by p38 MAPK (Alsayed et al., 2007). In another study, it was found that 
hypoxia increased the expression of CXCR-4 in MM cells resulting in increased the 
migration and homing of MM cells from the peripheral blood to the BM (Azab et al., 
2012). E-cadherin is adhesion molecule that may have role in homing of MM cells into 
the BM. Azab et al 2012 demonstrated that the expression of E-cadherin decreased in 
MM cells isolated from MM patients with tumour progression. In addition, it was found 
that MM cells circulated in peripheral blood expressed low level of E-cadherin 
compared with MM cells in the BM in mice (Azab et al., 2012).  
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1.2.4 Multiple myeloma bone disease  
MM is predominantly a malignancy of bone marrow, but tumour is observed in non-
skeletal sites such as spleen and liver in end stage disease demonstrating that myeloma 
is not necessarily dependent on the BM in the later stages. Within bone, myeloma 
induces a ‘vicious cycle’ resulting in osteolytic bone lesions in multiple skeletal 
locations, including long bones, vertebrae and calvariae. It was reported that 90% of 
MM patients develop osteolytic bone lesions and 60% of these patients develop 
pathologic fractures over the course of the disease (Kyle and Rajkumar, 2004, Esteve 
and Roodman, 2007). Healthy bone is regulated and coordinated by bone remodeling 
cycle, bone formation and bone resorption throughout the skeleton. As stated above, one 
of the most important consequences of myeloma bone disease is the induced imbalance 
in bone remodelling between osteoblasts and osteoclasts affecting bone resorption and 
bone formation, which is eventually responsible for the formation of osteolytic bone 
lesions (Figure 1.4). This appears to be mediated at a cellular level with increased 
numbers of osteoclasts and decreased numbers of osteoblasts. This imbalance between 
osteoclasts and osteoblasts is responsible for an increase in bone resorption and a 
reduction in bone formation resulting in osteolytic bone lesions (Heider et al., 2006, 
Esteve and Roodman, 2007, Datta et al., 2008, Edwards et al., 2008).  
 
1.2.4.1 Multiple myeloma induced bone resorption  
The identification of MM signalling pathways and their interactions with the 
surrounding BM microenvironment are providing insights into the molecular 
mechanisms which govern tumour–host interactions. Croucher et al (2001) 
demonstrated that 5T2MM cells express RANKL and suggested that this was at least in 
part responsible for the development of osteolytic bone lesions in C57BL/KaLwRij 
mice. Carrying this model for myeloma treatment of mice with OPG protein prevented 
osteolytic bone lesions and increased bone mineral density (BMD) in femoral, tibial, 
and vertebral bones, suggesting that RANKL/RANK/OPG system may play a potential 
therapeutic target to prevent osteolytic bone disease in MM (Croucher et al., 2001).  
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Another factor found to induce increased bone resorption is MIP-1α. Uneda et al (2003) 
demonstrated that MIP-1a mRNA was expressed in freshly purified myeloma cells in 
vitro. Immunohistochemical staining showed that MIP-1a expressed in the cytoplasm of 
myeloma cells. In patients, mRNA expression of MIP-1a was detected in relation to 
inducing bone lesions (Uneda et al., 2003). In addition, Choi et al (2001) demonstrated 
that this chemokine stimulated osteoclast formation in vivo in SCID mice. Blocking 
MIP-1α activity in human MM-derived cell line ARH cells, by transfection with an 
antisense construct to MIP-1α (AS-ARH) demonstrated that both bone lesion and 
tumour burden were significantly decreased in mice treated with AS-ARH, suggesting 
that MIP-1α may have an important role in mediating both myeloma cell growth and 
myeloma bone disease (Choi et al., 2000).  
 
Bone resorption is also induced by the activity of interleukin-3 (IL-3). Lee et al (2004) 
demonstrated that MM cell line ARH-77 and MM.IS express IL-3 and MIP-1α in vitro. 
IL-3 mRNA and protein were increased in CD138
+
 myeloma cells isolated from MM 
patients. Also, it was found that IL-3 in combination with RANKL or MIP-1α 
significantly increased osteoclast formation and bone resorption comparing with 
RANKL or MIP-1α alone in culture. Targeting IL-3 by anti-IL-3 neutralising antibodies 
inhibited the formation of osteoclasts from mononuclear cells derived from MM 
patients growing in vitro suggesting that IL-3 may have an important role in mediating 
myeloma growth and bone disease (Lee et al., 2004).  
 
1.2.4.1.1 Targeting increased bone resorption in MM bone disease  
In addition to targeting the factors discussed previously; RANKL, MIP-1α and IL-3 as a 
treatment to supress the increase in bone resorption in myeloma bone disease, other 
therapies can also be used to generally suppress bone resorption in myeloma. In 
particular various bisphosphonates have been used. Croucher et al (2003) investigated 
the effect of the bisphosphonate zoledronic acid on osteolytic tumour-bone disease. 
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C57BL/KaLwRij mice were injected with 5T2MM cells, resulting in induced osteolytic 
bone lesions. Treatment of mice with zoledronic acid prevented the formation of lytic 
bone lesions and bone loss as well as reducing tumor burden (Croucher et al., 2003).  
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.4: Mechanisms responsible for multiple myeloma bone disease. 
Imbalance in bone remodelling between osteoblasts and osteoclasts in the latter stage 
of MM induces more bone resorption. During bone resorption, growth factors such as 
TGF-β, IGFs, FGFs, PGFs and BMPs released by osteoclast cells permit myeloma cell 
survival. Important factors such as RANKL, IL-3 and MIP-1α released by MM cells 
activate osteoclasts. In addition, some factors such as Dkk1, sFRP-2, IL-3 and activin 
A released by MM cells suppress osteoblasts. These together induce osteolytic bone 
lesions in the late stage disease. Picture adapted from (Roodman, 2007). 
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1.2.4.2 Multiple myeloma suppress bone formation  
As mentioned before, Wnt signaling pathway has an important role in postnatal bone 
formation and bone turnover. Wnt signalling pathway has a critical role in the 
proliferation, expansion and survival of osteoblasts though binding to Frizzled that 
subsequently binds to lipoprotein receptor related protein-5/6 (LRP-5/6). Binding of 
Wnt with its receptor complexes stimulates phosphorylation of LRP5/6, which 
subsequently degrade β-catenin inducing osteoblast differentiation (Westendorf et al., 
2004). It was found that MM cells produce high level of Dkk1, Wnt signalling 
antagonist, in patients with multiple myeloma compared with control (Tian et al., 2003). 
Heath et al (2009) showed 5T2MM cells expressed Dkk1 an osteoblastogenesis 
inhibitory factor and proposed that this contributed to the development of osteolytic 
bone lesions in C57BL/KaLwRij mice. Targeting Dkk1 by anti-Dkk1 antibody 
(BHQ880, 10 mg/kg) demonstrated a reduction in the development of osteolytic bone 
lesions supporting the suggestion that Dkk1 plays a role in bone formation in myeloma 
(Heath et al., 2009). In addition, Fowler et al (2012) showed that there was an increase 
in the host-derived Dkk1 in myeloma-permissive KaLwRij mice resulting in a 
significant reduction in trabecular bone volume. Knockdown of Dkk1 in bone marrow 
stromal cells (BMSCs) demonstrated a reduction in the development of osteolytic bone 
lesions in mice suggesting that novel roles of BMSC-derived Dkk1 in bone formation in 
myeloma in vivo (Fowler et al., 2012).  
 
As mentioned before, Wnt signalling has important roles in the mediation of osteoblast 
differentiation and induces bone development. Qiang et al (2008) demonstrated that 
Wnt signalling is necessary to promote BMP-2-mediated osteoblast differentiation. This 
study suggested that overexpression of Dkk1 inhibit osteoblast differentiation inducing 
myeloma bone disease (Qiang et al., 2008). MM cells produce another Wnt signalling 
antagonist factor, soluble frizzle-related protein-2 (sFRP-2). Oshima et al (2005) 
demonstrated that primary MM cells from patients with advanced bone lesion and 
human MM cell lines, RPMI8226 and U266 expressed the Wnt antagonist sFRP2 in 
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vitro. This study also showed that sFRP2 suppressed osteoblast differentiation and 
significantly inhibited mineralised nodule formation in osteoblast cell line MC3T3-E1 
cells in vitro suggesting that sFRP2 has a role in the impairment of bone formation 
induced by myeloma cells (Oshima et al., 2005).  
 
Another factor found to supress bone formation is IL-3. Ehrlich et al (2005) 
demonstrated that human and murine osteoblasts express IL-3 receptor (IL-3R) in vitro, 
which may allow these cells to respond to IL-3 produced by osteoblast precursors. 
Furthermore, it was found that the levels of IL-3 were increased in the bone marrow of 
myeloma patients compared with healthy controls. This study demonstrated that 100 
pg/ml of IL-3 significantly inhibited osteoblast differentiation in both primary human 
and murine culture, but not in MC3T3-E1 cells or C2C12 cells in vitro. Targeting IL-3 
using anti-IL-3 demonstrated partial inhibition in the suppression of osteoblast 
differentiation induced by bone marrow plasma from patients with high IL-3. This study 
suggests that IL-3 may play an indirectly role in the impairment of bone formation in 
MM bone disease, in addition to stimulating osteoclasts (Ehrlich et al., 2005).  
 
The TGF-β superfamily is intimately increased an osteoblast differentiation in bone loss 
in myeloma. Activin A is a member of the TGF-β superfamily expressed abundantly in 
bone. Activin A inhibits osteoblast differentiation in MM bone disease. Activin A is 
increased in MM patients with osteolytic disease potentially inhibiting osteoblast 
differentiation via activation of mothers against decapentaplegic homolog 2 (SMAD2). 
Vallet et al (2010) demonstrated that inhibiting activin A with a soluble receptor, RAP-
011, increased osteoblast differentiation and inhibited tumour growth. These results 
suggest that inhibition of activin A have potential new therapeutic strategy in tumour-
related bone disease (Vallet et al., 2010). In addition, Chantry et al (2010) demonstrated 
that treatment of animals with an activin receptor type IIA fusion protein, 
ActRIIA.muFc, could increase osteoblast differentiation, bone formation and bone mass 
in vivo (Chantry et al., 2010).  
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1.3 Mouse models of multiple myeloma  
1.3.1 History and characterisation of the 5TMM series  
To support our understanding of MM bone disease, preclinical mouse models have been 
developed. C57BL/KalwRij mice develop a high frequency of monoclonal proliferative 
B-cell disorders. Most of C57BL/KalwRij mice have monoclonal gammopathy of 
undetermined significance (MGUS) similar to humans. 5TMM series of myeloma 
models originate from spontaneously developed MM in aging C57BL/KalwRij mice 
and have many of the features of the disease in humans. Several murine models of MM 
exist, but 5T2, 5T33 and 5TGM1 are the best characterized and used in most recent 
studies. 5TMM series of models share some common features including the selective 
localization of MM cells in the BM, presence of serum M-component, expression of 
LFA-1, CD44, VLA-4 and VLA-5 adhesion molecules, and some induce osteolytic 
bone disease similar to the human disease (Radl et al., 1978, Radl et al., 1979, 
Vanderkerken et al., 1997).  
 
1.3.2 5T2 multiple myeloma model  
5T2MM model originated from spontaneously developed myeloma in aging mice and 
represents a model for the most common forms of human MM. These cells only grow 
slowly in vivo and are mainly localised in the BM in addition to spleen. C57BL/KalwRij 
mice injected with 5T2MM cells develop high levels of tumour-related monoclonal 
immunoglobulins in their serum with reduction in the level of normal polyclonal 
immunoglobulins. Radiography and histology show 5T2MM cells induce osteolytic 
bone lesion similar to the human disease. Treatment of tumour bearing animals with 
bisphosphonate zoledronic acid significantly reduced the production of osteolytic bone 
lesions and decrease tumour burden in bone in 5T2MM-bearing mice (Radl et al., 1985, 
Vanderkerken et al., 1997, Asosingh et al., 2000b, Croucher et al., 2003).  
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1.3.3 5T33 multiple myeloma model  
5T33MM model originated from a spontaneously developed myeloma in aging mice. 
These cells can grow in vitro as well as in vivo. In culture, 5T33MM cells grow as non-
adherent single cells or in small loosely adherent clusters. 5T33MM grow rapidly in 
C57BL/KaLwRij mice and mainly localised in the BM in addition to spleen and liver. 
5T33MM cells cause myeloma disease in inoculated C57BL/KaLwRij mice after 5-8 
weeks of injection with 10
5
 marrow cells of 5T33 myeloma mice. C57BL/KalwRij mice 
post injected with 5T33MM cells develop high levels of tumour-related monoclonal 
immunoglobulins in their serum with reduction in the level of normal polyclonal 
immunoglobulins similar to 5T2MM cells. In contrast to human disease, radiography 
and histology show 5T33MM cells do not induce osteolytic bone lesions (Manning et 
al., 1992, Vanderkerken et al., 1997, Asosingh et al., 2000b).  
 
1.3.4 5TGM1 multiple myeloma model  
5TGM1 model was derived from the 5T33 model. 5T33MM cells were passaged in 
mice, and cells were then obtained from the marrow of 5T33MM-bearing mice cultured 
and cloned. These cells have all the features of human disease including the 
characteristic lytic bone lesions, in contrast to 5T33MM cells that do not induce 
osteolytic bone lesions in mice. 5TGM1 cells grow rapidly in vitro as well as in vivo. In 
culture, 5TGM1 cells grow as non-adherent single cells or in small loosely adherent 
clusters. C57BL/KalwRij mice injected with 5TGM1 cells develop high levels of 
tumour-related monoclonal immunoglobulins in their serum similar to 5T2MM cells 
and 5T33MM cells. Radiography and histology shows that 5TGM1 cells produce 
osteolytic bone lesions similar to the human disease. The bisphosphonate ibandronate 
has been shown significantly reduce the osteolytic bone lesions in 5TGM1-bearing mice 
(Garrett et al., 1997, Dallas et al., 1999).  
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1.4 The early stages of multiple myeloma disease and the myeloma niche  
The general localisation of myeloma to the skeleton and recent studies suggest that the 
early stages of myeloma development are dependent on the surrounding BM 
microenvironment, however the characteristics of the early stage ‘BM-dependent’ 
microenvironment remains unknown. In contrast, in late stage disease; the myeloma 
cells are not BM microenvironment dependent, but appear to survive and grow 
interdependent of the bone (Pagnucco et al., 2004, Damiano et al., 1999, Hideshima et 
al., 2002, Damiano and Dalton, 2000). It is unclear whether myeloma cells attach to 
sites of bone formation, quiescent bone lining cells or remain close to a collagen matrix, 
a known store of growth factors. The effects of colonising myeloma cells on the 
adjacent micro-anatomical sites post-attachment are also unknown. Despite the present 
therapeutics there is an urgent clinical need for new therapies, and one such strategy 
targets the early stages of disease including myeloma cell colonisation and survival, 
where myeloma is more dependent on the bone microenvironment. Characterising the 
putative ‘myeloma niche’ (a myeloma permissive microenvironment) may offer novel 
therapeutic targets to treat patients. It is not unfeasible that colonising myeloma cells 
may retain the molecular machinery of haematopoietic stem cells (HSCs) and modify 
the HSC niche into a myeloma permissive niche or exploit the HSC niche to establish 
disease. These following sections will describe HSCs and the HSC niche, and evaluate 
the potential mechanisms colonising myeloma cells may exploit to establish colonies 
within the BM microenvironment.  
 
1.4.1 The haematopoietic stem cell niche  
The marrow cavity within bone is the main site of haematopoiesis in adult human. Adult 
BM comprises of ECM, HSCs, MSCs, blood cells and their precursors, osteoblasts, 
osteoclasts, fibroblasts, endothelial cells, and adipocytes (Fliedner, 1998, Wang et al., 
2006, Muguruma et al., 2006). Stem cells are defined as the earliest undifferentiated cell 
types characterised by extensive capacity for self-renewal and the ability to differentiate 
into a range of specialized cell types (Zhang et al., 2003). HSCs differentiate into blood 
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progenitor cells and all blood cell types that have characteristic morphologies and 
specialized functions including myeloid; monocytes, granulocytes, erythrocytes and 
megakaryocytes, lymphoid cells; natural killer cells, T-cells and B-cells (Figure 1.5) 
(Akashi et al., 2000, Kondo et al., 1997). HSCs can be divided into two groups: long-
term reconstituting (LTR) cells, which are seen frequently at the bone-lining 
osteoblastic cell surface and the short-term reconstituting (STR) cells. The LT-HSCs are 
characterised by their ability to support haematopoiesis for more than six months while 
ST-HSCs are characterised by their ability to repopulate blood elements for several 
weeks (Harrison and Zhong, 1992, Zhong et al., 1996, Zhao et al., 2000b).  
 
The term ‘niche’ was firstly described by Schofield in 1978, who proposed HSCs are 
associated with bone by cell-cell contacts providing a microenvironment for HSCs self-
renewal, proliferation and preventing their differentiation (Schofield, 1978). The HSC 
niche is defined as a specific regulatory microenvironment in adult bone marrow, which 
acts as a soil for HSCs where these stem cells are housed and maintained by self-
renewal. Outside this niche HSCs cannot self-renew, but differentiate to large numbers 
of progeny as well as to other cell types and ultimately produce mature blood cells 
(Wilson and Trumpp, 2006, Yin and Li, 2006). The HSC niche is composed of the 
osteoblastic niche (endosteum) and vascular niche (sinusoidal vessels) (Figure 1.6). 
Zhang et al (2003) showed that an increase in trabecular bone and/or trabecular           
N-cadherin
+
 osteoblasts correlated to an increase in HSCs (Zhang et al., 2003). 
Subsequently, Visnjic et al (2004) identified a reduction of HSCs can be observed in the 
bone marrow following ablation of osteoblast-lineage cells in transgenic mice.  
Extramedullary hematopoiesis was found in alternative sites such as spleen and liver 
(Visnjic et al., 2004). These together provide strong evidence that osteoblastic niche 
supports hematopoiesis in the HSC niche.  
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Zhang et al (2003) used immunohistochemistry technology to identify the HSC niche. It 
was found that LT-HSCs reside in the osteoblastic niche (Figure 1.5) and were only 
attached to the N-cadherin
+
 osteoblasts (Zhang et al., 2003). Xie et al (2009) developed 
new ex vivo real-time imaging technology. Green fluorescent protein expressing (GFP
+
) 
HSCs homed through the vascular niche to the osteoblastic niche and attached to         
N-cadherin
+
 osteoblast cells in irradiated mice (Xie et al., 2009). Lo Celso et al (2009) 
Figure 1.5: Differentiation of HSCs in bone marrow. ST-HSCs differentiate to CLP 
(common lymphoid progenitor) and CMP (common myeloid progenitor). GMP 
(granulocyte-macrophage precursor) and MEP (megakaryocyte-erythrocyte precursor) 
are progeny of the CMP, generating monocytes, granulocytes megakaryocytes and 
erythrocytes respectively. On the other hand, pro-T cell and pro-B cell are the progeny 
of the CLP, generating T-cells and B-cells, which differentiation into plasma cells in 
lymph nodes. MM cells are terminal plasma B cell malignancy derived from bone 
marrow plasma cells. Picture adapted from (Huntly and Gilliland, 2005). 
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used a combination of high resolution confocal microscopy and two-photon video 
imaging technology that allowed observation of homing of individual HSC in calvarial 
bone marrow of living mice in real time. HSCs have been observed closer to bone and 
osteoblasts in irradiated and c-Kit-receptor-deficient recipient mice (Lo Celso et al., 
2009). It is only by using modern microscope that has permitted researchers to identify 
the stem cells in the niche. In relation to MM disease, no study has shown the location 
of colonising myeloma cells in relation to osteoblasts on the endosteal surface. It is 
unclear if MM cells have the ability to adhere to N-cadherin
+
 osteoblasts.  
 
Another specialized microenvironment used by HSC is the vascular niche, sinusoid 
vessels. Sinusoid endothelial cells are differentiated from the MSCs. The vascular niche 
together with osteoblastic niche support the HSCs in the HSC niche, in which the 
vascular niche promotes HSCs proliferation and further differentiation. It was reported 
that the sinusoid vessels are surrounded by endothelial cells secreting a high amount of 
CXCL12 chemokine. This chemokine is required for the maintenance of HSCs in the 
vascular niche as well as the maintenance of sinusoidal adjacent HSCs (Sugiyama et al., 
2006). Alsayed et al (2007) showed CXCR4 expressed on MM cells are responsible for 
migration and homing of the MM to BM in response to high levels of SDF-1 
(CXCL12). Targeting CXCR4 by specific inhibitor (AMD3100) and anti-CXCR4 
antibody (MAB171) have been shown to inhibit MM cells migration in vitro (Alsayed 
et al., 2007). Ding et al (2012) showed that Stem cell factor (SCF) was primarily 
expressed by perivascular cells throughout the BM. knock-out SCF from both 
endothelial and receptor-expressing perivascular cells resulting in HSCs lost from BM 
suggesting that HSCs reside in a perivascular niche (Ding et al., 2012). More recently, 
Ding et al (2013) showed that showed that CXCL12 was primarily expressed by 
perivascular stromal cells. Deletion of CXCL12 from endothelial cells and/or from 
perivascular stromal cells, but not from osteoblasts depleted HSCs from BM and 
mobilized these cells into circulation (Ding and Morrison, 2013).  
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1.4.2 Cellular and molecular crosstalk in the HSC niche 
The cellular interactions in the HSC niche occur between HSCs and osteoblasts at 
endosteal surfaces to maintain HSCs quiescence. The endosteal surface is enriched for 
primary HSCs indicating a potential important role of the osteoblastic niche to support 
hematopoiesis and regulate HSC niche (Calvi et al., 2003, Zhang et al., 2003, Wu et al., 
2009). Passegué et al (2005) demonstrated that LT-HSCs are maintained as quiescent or 
slowly cycling cells comparing with ST-HSCs, which are maintained as active cycling 
cells. This result suggests that LT-HSCs require osteoblasts to remain quiescent in the 
niche (Passegue et al., 2005). In contrast, in response to higher levels of stromal cell-
derived factor 1 (SDF-1) and fibroblast growth  factor-4 (FGF-4) LT-HSCs exit the 
osteoblastic niche and migrate towards the central marrow or toward the vascular niche 
(Zhang et al., 2003, Xie et al., 2009, Askmyr et al., 2009, Lo Celso et al., 2009).  
Figure 1.6: N-cadherin
+
 osteoblasts are required to maintain quiescent 
hematopoietic stem cells. Hematopoietic stem cells (HSCs) line the endosteal bone 
surfaces. Spindle-shaped N-cadherin
+
 osteoblasts serve as HSC docking sites, which 
maintain quiescent cells and prevent their differentiation (Zhang et al., 2003). In 
response to injury, HSCs leave the osteoblastic niche and are recruited to the vascular 
niche. HSCs outside their niche become active and differentiate to large numbers of 
cell progeny as well as to other cell types and ultimately produce mature blood cells. 
Picture adapted from (Yin and Li, 2006). 
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Several molecules are expressed and secreted by HSCs and osteoblasts that have been 
identified in their interactions. These molecular interactions appear to maintain the 
HSCs quiescent in the niche. Interacting molecular pairs include Notch/jagged 1 (Jag1), 
angiopoietin-1 (Ang-1)/tyrosine kinase receptor 2 (Tie2), osteopontin (OPN)/CD44,   
N-cadherin/N-cadherin and CXCR4/CXCL12 (Figure 1.7). It is possible that colonizing 
myeloma cells may retain the molecular machinery present in HSCs to hijack the HSC 
niche (Calvi et al., 2003, Arai et al., 2004, Nilsson et al., 2005, Stier et al., 2005, Zhang 
et al., 2003, Xie et al., 2009). This would allow a subpopulation of myeloma cells to 
remain quiescent or dormant and escape the effect of the potent agents directed at 
cycling cells.  
 
Notch signalling has an essential supporting role in HSC proliferation and expansion. It 
was found that activating PTH/PTHrP receptors (PPRs) stimulated the production of 
high levels of Notch ligand, jagged 1 (Jag1) resulting in an increase in the number of 
HSCs in vivo. This study suggested that Notch/Jag1 signalling supports the HSC niche 
(Calvi et al., 2003). Jundt et al (2004) demonstrated the expression of Notch1 and 
Notch2 proteins as well as their ligand, Jag1 in MM cells (Jundt et al., 2004). Together 
these studies suggest that Notch/Jag1 mediated cell-cell interactions between MM cells 
and their microenvironment inducing proliferation of multiple myeloma cells.  
 
Osteoblasts express Ang-1 that binds to tyrosine kinase receptor 2 (Tie-2), which is 
expressed in HSCs. Ang-1/Tie-2 activity plays an important role for HSCs in 
maintaining quiescence in the niche as well as inducing adhesion between HSCs and 
osteoblastic cells (Arai et al., 2004). Giuliani et al (2003) demonstrated that human 
myeloma cell lines; RPMI 8226, U266, OPM-2, XG-1 and XG-6 expressed Ang-1. In 
addition, human myeloma cell lines; XG-1 and XG-6 also expressed Tie-2. Moreover, it 
was found that Ang-1 and Tie-2 was expressed in patients with MM, suggesting a 
possible role in inducing angiogenesis in MM (Giuliani et al., 2003). On the other hand, 
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expression of Tie-2 by MM cells is a potential mechanism to establish colonies in the 
HSC niche via interactions with Ang-1 expressed by osteoblast cells.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
One mechanism by which HSCs are regulated in the HSC niche is via OPN, an acidic 
glycoprotein, expressed by osteoblasts. It was shown that OPN expression on the 
endosteal surface resulted in migration of HSCs toward the endosteal region (Nilsson et 
al., 2005). In addition, data from OPN-deficient mice demonstrated an increase in the 
number of HSCs in bone marrow microenvironment and a reduction in their apoptosis. 
Figure 1.7: Opportunities of multiple myeloma cells to colonise the hematopoietic 
stem cell niche. (A) Interactions between HSCs and osteoblasts are mediated by 
several secreted factors and receptors expressed on both cells types including; 
Notch/jagged 1 (Jag1), angiopoietin-1 (Ang-1)/tyrosine kinase receptor 2 (Tie2), 
osteopontin (OPN)/CD44 N-cadherin/N-cadherin and C-X-C chemokine receptor type 
4 (CXCR4)/ C-X-C chemokine ligand 12 (CXCL12). HSCs require osteoblasts to be 
quiescent in the niche. Interactions between osteoblasts and colonising MM cell in the 
putative MM niche are unknown. (B) Potential interactions between MM cells and 
osteoblasts to establish the colonization of MM cells into the bone. Picture adapted 
from (Wilson and Trumpp, 2006). 
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Therefore, this data provides evidence that OPN is a negative regulator for HSC 
proliferation in the HSC niche (Stier et al., 2005). Asosingh et al (2000) showed CD44 
is expressed in the 5T33MM cell line and contributes to adherence of myeloma cells to 
BM stromal cells (Asosingh et al., 2000a). Vincent and Mechti (2004) showed CD44 
has an important role in MM cell survival (Vincent and Mechti, 2004). In relation to 
early stage MM disease, CD44 may be exploited to establish MM cells in the HSC 
niche via interactions with OPN expressed by osteoblast cells.  
 
HSCs express CXCR4 which binds to CXCL12 for the maintenance and migration of 
HSCs in the BM. It was reported that CXCR4-CXCL12 signaling play an important role 
in the regulation of HSCs in both vascular and endosteal niches. Sugiyama et al (2006) 
demonstrated that HSCs contact with the cells that express high amounts of CXCL12 
called CXCL12-abundant reticular in vascular niche as well as in at the endosteum 
(Sugiyama et al., 2006). Broxmeyer et al (2010) demonstrated that blocking the 
interaction of CXCL12 and CXCR4 by AMD3100, a CXCR4 antagonist results in a 
rapid mobilization of HSCs from the BM into the peripheral blood. This result showed 
that CXCR4-CXCL12 signaling retains HSCs in the BM microenvironment (Broxmeyer 
et al., 2005). In relation to MM, Azab et al (2009) showed that using AMD3100 
inhibited the migration of MM cells in vitro and inhibited the homing of MM cells to 
the BM in vivo (Azab et al., 2009).  
 
N-cadherin is an adhesion molecule expressed by both HSCs and osteoblasts. Puch et al 
(2001) showed human CD34
+
 HSCs express N-cadherin. Treatment of these cells with 
monoclonal anti-N-cadherin antibodies resulted in a reduction in the colony formation, 
which suggested a direct interaction between osteoblasts and HSCs via N-cadherin 
(Puch et al., 2001). In vitro, Aria and Suda showed enhancements of both HSCs and 
stromal cell adhesion and inhibition of cell division of HSCs by enforced N-cadherin 
expression suggesting a key role of N-cadherin-mediated adhesion and maintaining 
HSCs quiescence in the osteoblastic niche (Arai and Suda, 2007). Using gene array 
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studies Dring et al (2004) showed N-cadherin is expressed in t(4;14) MM cases (Dring 
et al., 2004). However, no publication has addressed the blocking of N-cadherin in 
myeloma cells. In addition, it was found that N-cadherin allows HSCs to localize to 
osteoblasts on endosteal bone surfaces in the HSC niche (Zhang et al., 2003, Xie et al., 
2009). Expression of N-cadherin may be exploited by myeloma cells to establish the 
HSC niche via interactions with N-cadherin expressed by osteoblasts.  
 
1.5 N-cadherin  
1.5.1 Structure of N-cadherin cell-cell adhesion molecule  
N-cadherin is a member of a Ca
2+
-dependent cell-cell adhesion receptor family known 
as cadherin 2, containing extracellular domain, transmembrane domain and cytoplasmic 
domain (Figure 1.8). The extracellular domain of N-cadherin contains five extracellular 
repeats of ~110 amino acids each. The cytoplasmic domain directly binds to p120 
catenin, β-catenin and α-catenin cleaved by γ-secretase protein and translocate the 
carboxy-terminal fragment of N-cadherin with β-catenin to the nucleus (Figure 1.9). 
Cleaved N-cadherin mediates signalling pathway following cell-cell adhesion (Miyatani 
et al., 1992, Gumbiner, 2005).  
 
 
 
 
 
 
 
Figure 1.8: The structure of 
N-cadherin. N-cadherin is a 
member of the Ca
2+
-dependent 
cell-cell adhesion receptor 
family containing extracellular 
domain, transmembrane 
domain and cytoplasmic 
domain. The extracellular 
domain of N-cadherin contains 
five extracellular repeats of 
~110 amino acids each. Picture 
adapted from (Gumbiner, 
2005). 
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1.5.2 N-cadherin expression in bone cells  
Within the skeleton there are four basic types of bone cells; osteoclasts, osteoblast, bone 
lining cells and osteocytes. Mbalaviele et al (1995) showed that E-cadherin was 
expressed by osteoclasts, but no expression of N-cadherin was detected in these cells 
(Mbalaviele et al., 1995). In osteoblasts, Ferrari et al (2000) demonstrated that             
N-cadherin was expressed and this was increased during osteoblastogenesis. This study 
suggested a role for N-cadherin in the late stage of osteoblast differentiation (Ferretti et 
al., 2002). Kawaguchi et al (2001) also showed that N-cadherin was expressed by 
osteoblasts and this expression was increased during osteoblastogenesis (Kawaguchi et 
al., 2001). Marie (2002) demonstrated that the marked increases in expression of         
N-cadherin during osteoblast differentiation was correlated with increased cell-cell 
interactions in mature osteoblasts (Marie, 2002). In bone lining cells, Zhange et al 
(2003) demonstrated that N-cadherin was expressed by spindle-shaped osteoblasts 
(bone lining cells) and has an important role in maintaining HSCs quiescence in the 
HSC niche (Zhang et al., 2003). Ferrari et al (2000) demonstrated that N-cadherin was 
not expressed by osteocytes (Ferrari et al., 2000). Kawaguchi et al (2001) also showed 
that N-cadherin was not expressed by the osteocyte-like cell line MLO-Y4 (Kawaguchi 
et al., 2001). There studies showed that osteoblasts and bone lining cells, but not 
osteoclasts and osteocytes express N-cadherin.  
 
1.5.3 N-cadherin interacts with FGFR mediating signalling 
Fibroblast growth factor receptor (FGFR) has an important role in neurogenesis, cell 
migration and cell differentiation. Recent evidence has pointed to an interaction 
between N-cadherin and FGFR that might be able to serve as replacement ligands 
and/or receptor-binding partners that modulate signalling by the conventional ligands. 
Williams et al (2001) demonstrated that N-cadherin interacted with FGFR and was 
required for axonal growth. Blocking N-cadherin by antibody inhibited the neurite 
outgrowth response stimulated by N-cadherin (Williams et al., 2001). Suyama et al 
(2002) demonstrated that N-cadherin binds to FGFR-2 in breast cancer cells and this 
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binding increase migration, invasion, and secretion of extracellular proteases in breast 
cancer cells (Suyama et al., 2002). Sanchez-Heras et al (2006) showed that N-cadherin 
interacts with FGFR and this interaction is dependent on the presence of the acid box 
motif that can be found in the linker region between D1 and D2 (Sanchez-Heras et al., 
2006). These studies produced some evidence for the possibility that N-cadherin binds 
to FGFR and mediates signalling.  
 
1.5.4 N-cadherin mediates the interaction of HSCs with osteoblasts or bone lining 
cells in the niche  
As stated previously in this chapter, Zhang et al (2003) demonstrated that HSCs home 
into the endosteal surfaces and attach to N-cadherin
+
 osteoblasts. This attachment 
maintains the HSCs in a quiescent state in the HSC niche (Zhang et al., 2003). In 
addition, Xie et al (2009) tracked the HSCs by using high resolution microscopy and 
demonstrated that HSCs home to an osteoblastic niche and attach to N-cadherin
+
 
osteoblasts (Xie et al., 2009). Hosokawa et al (2010) showed that overexpression of    
N-cadherin inhibited the division of HSCs. In addition, knockdown of N-cadherin in 
HSCs reduced the long-term engraftment of HSCs in vivo and reduced the adhesion of 
HSCs onto the bone surfaces (Hosokawa et al., 2010). These studies showed that         
N-cadherin has an important role as N-cadherin is utilized in the location of HSCs to 
healthy bone.  
 
1.5.5 N-cadherin interacts with Axin and LRP5a and negatively regulate Wnt/β-
catenin signalling and bone formation  
Canonical Wnt signalling plays an important regulatory role in the maintenance of bone 
mass and in bone formation. The canonical wnt signalling pathway is mediated by 
binding of wnt3a to LRP5 and frizzled. This binding activates dishevelled family 
proteins; axin, adenomatous polyposis coli protein (APC), Frat1, glycogen synthase 
kinase 3β (GSK3β) and ultimately β-catenin to reach the nucleus, promoting 
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osteoblastogenesis (Rawadi and Roman-Roman, 2005). Current evidence indicated 
some extracellular natural antagonists; SFRPs, connective tissue growth factor (CTGF), 
Wnt-inhibitory factor 1 (WIF1), Cerberus, Wise, Dkk and sclerostin that regulate the 
Wnt canonical signalling pathway (Kawano and Kypta, 2003, Rawadi and Roman-
Roman, 2005). Hay et al (2009) demonstrated that N-cadherin interacts with LRP5 and 
axin in addition to directly binding with β-catenin to regulate osteoblastogenesis. The 
data showed N-cadherin-axin-LRP5 interactions increased β-catenin degradation 
resulting in negatively regulation of wnt signalling and decreased osteoblast 
differentiation (Hay et al., 2009a). Moreover, data from murine MC3T3-E1 osteoblastic 
cells and N-cadherin transgenic mice, demonstrated that over-expression of N-cadherin 
inhibited osteoblast proliferation and survival through increasing β-catenin degradation 
by N-cadherin-axin-LRP5 interactions in vitro and in vivo (Hay et al., 2009b).  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.9: The N-cadherin signalling pathways. During cells-cell interactions,             
N-cadherin associates with N-cadherin and/or FGF receptors family. The cytoplasmic 
domain is cleaved and translocate the carboxy-terminal fragment of N-cadherin with 
β-catenin to the nucleus mediates the signalling following cell-cell adhesion. Picture 
adapted from (Christofori, 2006). 
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1.5.6 N-cadherin may established the colonisation of MM cell in the HSC niche 
N-cadherin is a key component promoting quiescent HSCs and is expressed during 
osteoblast differentiation. Blaschuk et al (1990) reported that extracellular-1 of 
extracellular domain contain His-Ala-Val (HAV) motif sequence (Figure 1.10), which 
play an important role in N-cadherin functions (Blaschuk et al., 1990). ADH-1, N-Ac-
CHAVC-NH2, is an agent targeting the HAV motif on extracellular-1 of N-cadherin 
was recently used as an anticancer agent (Shintani et al., 2008). During tumour 
progression, the invasion and metastatic properties acquired by cancer cells are initially 
linked to expression of adhesion molecules. Changes in expression of adhesion 
molecules mediate the interaction of cancer cells from their primary site to establish 
new interactions with the surrounding microenvironment. N-cadherin is expressed in 
several type of cancer including melanoma, breast cancer, prostatic cancer, gastric 
carcinoma, bladder carcinoma, overian carcinoma and pancreatic cancer mediating 
tumour cell invasion and metastasis (Li et al., 2001, Augustine et al., 2008, Hazan et al., 
2004, Tanaka et al., 2010, Yanagimoto et al., 2001, Lascombe et al., 2006, Sarrio et al., 
2006, Shintani et al., 2008).  
 
 
 
 
 
 
 
 
 
Figure 1.10: Schematic of Mus musculus N-cadherin. N-cadherin consists of 16 
exons. The extracellular (EC) domain is encoded from exon 1 to exon 13 whereas the 
transmembrane domain (TMD) and cytoplasmic domain (CD) are encoded with exon 
14 to exon 16. EC1 of cadherin contains His-Ala-Val (HAV) motif sequence, which 
play an important role in cadherin functions. C is carboxy-terminal; N is amino-
terminal; PRO is propeptide; S is signal peptide; UTR is untranslated region.  
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1.6 Aim of the study  
Multiple myeloma is a plasma cell malignancy that causes extensive osteolytic bone 
disease. Present treatments target end stage disease but understanding how tumours in 
bone are initiated may offer new approaches to prevent/suppress colonization. It is clear 
that myeloma cells form specific interactions with the bone microenvironment, where 
they can remain dormant and protected from current therapy to eventually proliferate 
and cause disease progression (Roodman, 2007). N-cadherin is an adhesion molecule 
that allows HSCs to localize to osteoblasts on endosteal bone surfaces in the HSC niche 
(Zhang et al., 2003, Xie et al., 2009). During tumour progression in solid tumours, the 
invasion and metastatic properties acquired by cancer cells have been linked to 
expression of N-adhesion molecules and cadherin switching from E-cadherin to          
N-cadherin (Li et al., 2001, Lascombe et al., 2006, Gravdal et al., 2007). Little was 
known at the start of my studies about N-cadherin expression, cell surface distribution 
or formation in MM. The hypothesis is that myeloma cells locate close to bone surfaces 
which is where the various bone cells are found. In addition, as N-cadherin is expressed 
by osteoblasts, but not by osteoclasts or osteocytes (Mbalaviele et al., 1995, Ferrari et 
al., 2000, Kawaguchi et al., 2001), the hypothesis that “myeloma cells utilise              
N-cadherin to adhere to osteoblasts in vitro and in vivo during colonization of 
bone” has been tested in this study.  
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The hypothesis of my study was addressed through four objectives.  
1. Determine whether the stem cell marker N-cadherin is expressed by myeloma 
cells and osteoblasts (chapter 3).  
 
2. Determine whether the expression of N-cadherin mediates attachment of 
osteoblasts/myeloma cells in vitro (chapter 4).  
 
3. Determine whether different calvarial bones; frontal, parietal and interparietal 
contain different bone microenvironments (chapter 5).  
 
4. Determine whether the expression of N-cadherin is important in the attachment 
of osteoblasts/myeloma cells in vivo (chapter 6).  
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2 Chapter 2: Materials and Methods  
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2.1 Materials  
2.1.1 General chemicals and reagents  
All chemicals, reagents and buffers used in this project were purchased from Sigma
®
 
Chemical company Ltd (UK), unless otherwise stated. Trizol
®
, chloroform and 
isopropanol were purchased from Invitrogen (UK). Oligonucleotides were purchased 
from Invitrogen (UK). Deoxynucleoside triphosphates (dNTPs) were purchased from 
Promega (UK). Agarose and ethidium bromide used for gel electrophoresis were 
purchased from Invitrogen (UK).  
 
A 100-1500 bp DNA Ladder was purchased from Invitrogen (UK). The TaqMan 
Universal master Mix II and TaqMan
®
 gene expression assays were purchased from 
Applied Biosystems (UK). QIAquick Gel Extraction Kit was purchased from QIAGEN 
Ltd (UK). UltraPure™ DNase/RNase-free distilled water was purchased from 
Invitrogen (UK). Quant-iT™ PicoGreen ® dsDNA Reagent and Kits used to normalise 
ALP activity with DNA content were purchased from Invitrogen (UK).  
 
2.1.2 Immunofluorescence reagents and antibodies  
Rabbit monoclonal anti-N-cadherin antibody (Catalogue No. 04-1126) used as a 
primary antibody (C-terminus of mouse N-cadherin) was purchased from Millipore 
(UK). Normal rabbit IgG was used as an isotype negative control (Catalogue No. AB-
105-C) and Northern Lights™ donkey anti-rabbit IgG-NL637 used as secondary 
antibody (Catalogue No. NL005) were purchased from R&D systems (UK). ProLong® 
Gold reagent contains DAPI nuclear stain (Catalogue No. P-36931) was purchased from 
Invitrogen (UK).  
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2.1.3 Immunohistochemistry reagents and antibodies  
A rabbit monoclonal anti-N-cadherin antibody (Catalogue No. 04-1126) used as a 
primary antibody (C-terminus of mouse N-cadherin) was purchased from Millipore 
(UK). Normal rabbit IgG was used as an isotype negative control (Catalogue No. AB-
105-C) was purchased from R&D systems (UK). VECTASTAIN Elite ABC kit 
(Catalogue No. PK-6101) containing; normal rabbit serum, biotinylated anti-rabbit 
secondary antibody and VECTASTAIN
®
 Elite
®
 ABC reagent was purchased from 
Vector laboratories (UK). ImmPACT
TM
 DAB kit (Catalogue No. SK-4105) was 
purchased from Vector laboratories (UK).  
 
2.1.4 Flow cytometry reagents and antibodies  
A mouse monoclonal anti-N-cadherin antibody (Catalogue No. 04-1126) was used as a 
primary antibody (N-terminus of mouse N-cadherin) was purchased from Sigma (UK). 
Mouse IgG antibody (Catalogue No. I-2000) used as an isotype negative control was 
purchased from Vector Laboratories (UK). Lightning-Link
TM
 Atto637 conjugation kit 
(Catalogue No. 746-0010) used to label both mouse monoclonal anti-N-cadherin 
antibody and mouse IgG antibody was purchased from Innova Biosciences (UK).  
 
2.1.5 Enzymes  
DNase I was purchased from Invitrogen (UK). SuperScript™ III reverse transcriptase 
kit and Platinum Taq DNA polymerase kit and Collagenase II were purchased from 
Invitrogen (UK).  
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2.1.6 Tissue culture materials  
Tissue culture media; RPMI1640 medium and Minimum Essential Medium (MEM) 
alpha were purchased from Invitrogen (UK). Fetal calf serum (FCS) was purchased 
from Invitrogen (UK). Penicillin/Streptomycin, amphotericin B, sodium pyruvate 
(Na2PO3) and non-essential amino acids (NEAA) were purchase from Invitrogen (UK). 
β-glycerophosphate, ascorbic acid and dexamethasone were purchased from Sigma 
(UK).  
 
2.1.7 Cell lines  
2.1.7.1 5T33 myeloma cell line  
5T33MM model originates from a spontaneously developed myeloma in aging mice. 
These cells can grow in vitro as well as in vivo. In culture, 5T33MM cells grow as non-
adherent single cells or in small loosely adherent clusters. 5T33MM is a highly 
aggressive form of MM with rapid tumour growth in C57BL/KaLwRij mice and is 
mainly localised in the BM in addition to spleen and liver. 5T33MM cells cause 
myeloma in inoculated C57BL/KaLwRij mice after 5-8 weeks of injection with 10
5
 of 
5T33MM cells isolated from mice bone marrow. C57BL/KalwRij mice post injected 
with 5T33MM cells develop high levels of tumour-related monoclonal 
immunoglobulins in their serum with reduction in the level of normal polyclonal 
immunoglobulins similar to 5T2MM cells. In contrast to human disease, radiography 
and histology show 5T33MM cells do not induce osteolytic bone lesions (Manning et 
al., 1992, Vanderkerken et al., 1997, Asosingh et al., 2000b).  
 
 
 
 
Determining the role of N-cadherin in the formation of the myeloma niche 
  
 Page 43 
 
2.1.7.2 5TGM1 myeloma cell line  
The 5TGM1 model was derived from the 5T33 model. 5T33MM cells were passaged in 
mice, and then obtained from the marrow of 5T33MM-bearing mice cultured and 
cloned. 5TGM1 cells have all the features of human disease including the production of 
characteristic osteolytic bone lesions in mice, in contrast to 5T33MM cells that do not 
induce osteolytic bone lesions in mice. 5TGM1 cells grow rapidly in vitro as well as in 
vivo. In culture, 5TGM1 cells grow as non-adherent single cells or in small loosely 
adherent clusters. C57BL/KalwRij mice after injection with 5TGM1 cells develop high 
levels of tumour-related monoclonal immunoglobulins in their serum similar to 5T2MM 
cells and 5T33MM cells. Radiography and histology show 5TGM1 cells induce 
osteolytic bone lesion similar to the human disease. Use of the bisphosphonate, 
ibandronate, demonstrated significantly reduced osteolytic bone lesions in 5TGM1-
bearing mice (Garrett et al., 1997, Dallas et al., 1999).  
 
2.1.8 Cell culture  
All cell culture was performed using sterile equipment in a microbiological class II 
safety cabinet (Walker, UK) and cultures were incubated in a humidified atmosphere at 
37 °C and 5% CO2. All media were warmed in a water bath (37 °C) and filtered through 
a 0.2µM membrane before use. 5T33MM cells were a kind gift from Dr. Karin 
Vanderkerken (Free University Brussels, Belgium). 5TGM1 cells were a kind gift from 
Dr. Claire Edwards (University of Oxford, UK). These myeloma cells were cultured 
separately in vitro in RPMI1640 medium (Invitrogen, UK) containing 10% FCS, 100 
units/ml Penicillin / 100 μg/ml of Streptomycin, 1% Na2PO3 and 1% non-essential 
amino acids (NEAA). Medium was changed every 2 days (Manning et al., 1992).   
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2.1.9 Mouse primary osteoblast preparation and culture  
As N-cadherin is expressed by osteoblasts, but not by osteoclasts or osteocytes 
(Mbalaviele et al., 1995, Ferrari et al., 2000, Kawaguchi et al., 2001), osteoblasts were 
extracted as in previous standard published methods (Garcia et al., 2002, Hay et al., 
2009a). Calvarial bones were obtained from 2-4 day old C57Bl/6J mice to extract 
mouse primary osteoblasts. Calvariae were dissected into small pieces and then digested 
with trypsin-ethylene-diaminetetraacetic acid (EDTA) for 10 minutes at 37°C with 
shaking then centrifuged at 1100 rpm for 1 min after which the supernatant was 
discarded. Tissues were incubated with 0.5% of 280 units/mg collagenase II in PBS, 
0.15g of collagenase II was added into 30ml of PBS containing 100 units/ml Penicillin / 
100 µg/ml of Streptomycin and 1.36 μg/mL of amphotericin B, for 10 minutes then 
centrifuged at 1100 rpm for 1 min after which the supernatant was discarded. Tissues 
were incubated with 0.5% of 280 units/mg collagenase II in PBS for 10 minutes then 
centrifuged at 1100 rpm for 1 min after which the supernatant was collected. This step 
was repeated 4 times and then the cells were pooled and re-suspended in MEM alpha 
containing 10% FCS, 100 units/ml Penicillin / 100 µg/ml of Streptomycin and 
1.36 μg/mL of amphotericin B. After 6 hours, osteoblasts adhered to the bottom of the 
flasks while other cells floated in the medium. In addition, 10 mM of                            
β-glycerophosphate and 50 µg/ml of ascorbic acid were added into the medium to 
promote cells to differentiate into osteoblasts, other cells (being dead) floated in the 
medium during the time. Medium with floated cells were discarded and replaced with 
new medium. Alkaline phosphatase activity and alizarin red staining were used as 
osteoblastogenesis markers.  
 
2.1.10 Animals  
Male C57BL/KalwRiJHsD mice, aged 5 weeks, were purchased from Harlan, 
Netherlands and from University of Leeds, UK. Mice were housed by University of 
Sheffield biological services laboratory. All animals were provided with food and water 
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ad libitum, light and all procedures were carried out under project license (402901). 
Live animals were by me, personal license (40/10118).  
 
2.2 Methods  
2.2.1 Cell counting using haemocytometer  
Using a haemocytometer is a practical method to determine cell numbers. The 
Hemacytometer consists of two chambers, each of which consists of nine large, 1 x 
1 mm (1 mm
2
) squares (Figure 2.1). To count cells 15 μl of cell suspension was mixed 
with 15 μl of 0.4% w/v trypan blue. 10 μl of mix was loaded to each chamber of the 
Hemacytometer. To determine cell numbers, cells were counted in four 1mm
2
 areas of 
the counting chamber. Each 1 mm
2
 contains 1X10
-4
 ml. Therefore, to obtain cells/ml the 
final multiplication factors is 10
4
. A light microscope was used to count cells. The 
number of cells was calculated as following example (Table 2.1):  
 
Table 2.1: Counting cell number: Example calculation  
Total cells counted 
in 4 X 1 mm
2
 
Divided by 4 = 
cells/mm
2
 
Multiply dilution factor 
(x2) (trypan blue) 
= cells/ml 
100 25 50 50 x 10
4
  
 
2.2.2 Passaging the cells  
Primary osteoblasts are adherent cells that attach to the bottom of flasks. 6x10
3
 
cells/cm
2
 cells were seeded into T75 flasks containing 10 ml of MEM alpha (Invitrogen, 
UK) with 10% FCS, 100 units/ml Penicillin / 100 µg/ml of Streptomycin and 
1.36 μg/mL of amphotericin B to grow. 3 days later flasks were sub-confluent. Medium 
was discarded and cells washed twice with PBS. Cells were incubated with 2 ml of 
0.25% trypsin-EDTA at °C for 2 minutes and floating cells were observed under the 
microscope. 5 ml of MEM alpha (Invitrogen, UK) was added to cells and transferred 
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into 50 ml tube. Cells were centrifuged at 1000 rpm for 5 minutes at room temperature. 
Cells were re-suspended in 10 ml of MEM alpha (Invitrogen, UK) with 10% FCS, 100 
units/ml Penicillin / 100 µg/ml of Streptomycin and 1.36 μg/mL of amphotericin B and 
seeded into several new T75 flasks in 6000 cells/m
2
 density.  
 
Myeloma cells, 5T33MM and 5TGM1 cells grow as non-adherent single cells or in 
small loosely adherent clusters. 10
5
 of myeloma cells were seeded into T75 flasks 
containing 10 ml of RPMI1640 medium (Invitrogen, UK) with 10% FCS, 100 units/ml 
Penicillin / 100 μg/ml of Streptomycin, 1% Na2PO3 and 1% NEAA. 3 days later flasks 
were sub-confluent. Medium containing myeloma cells was transferred into a 50 ml 
tube and centrifuge at 1000 rpm for 5 minutes at room temperature. Cells were            
re-suspended in 10 ml of MEM alpha (Invitrogen, UK) with 10% FCS, 100 units/ml 
Penicillin / 100 μg/ml of Streptomycin, 1% Na2PO3 and 1% NEAA and seeded into 5 
new T75 flasks at 10
5
 cells/flask density. Medium was changed every 2 days.  
 
 
 
 
 
 
 
 
 
 
Figure 2.1: Schematic overview of a haemocytometer under the microscope to 
count the cells. The Haemocytometer consists of nine large, 1mm
2
 squares. Cells 
were counted in four corners 1mm
2
 squares and divided by four. Cell numbers were 
determined as described in table1. Yellow square = 1 mm
2
, blue square = 0.0625 mm
2
, 
red square = 0.0025 mm
2
.  
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2.2.3 Cell viability tests using Trypan Blue  
Cell viability was assessed by staining cells with Trypan Blue: live cells possess intact 
cell membranes and exclude the Trypan Blue dye, dead cells do not exclude Trypan 
Blue dye and stain blue. 15 µl of cell suspension was mixed with 15 μl of 0.4% w/v 
trypan blue. Cells were examined and counted as described in section 2.2.1. The 
percentages of viable and non-viable cells present in the samples were determined using 
Phase contrast microscopy.  
 
2.2.4 Osteoblast differentiation  
Osteoblasts were differentiated into mature functional osteoblasts, mineralised 
osteoblasts, to study the differences between immature osteoblasts and mature 
functional osteoblasts (Bancroft et al., 2002, Xiao et al., 2006, Garcia et al., 2002). 
6x10
3
 cells/cm
2
 of mouse primary osteoblasts was seeded in vitro into flasks for 2 days. 
When confluent after 2 days osteogenic media were added and osteoblasts were 
differentiated for 4 weeks into mature functional osteoblasts using osteogenic media; 
MEM alpha (Invitrogen, UK) containing 10 mM of β-glycerophosphate, 50 µg/ml of 
ascorbic acid and 10
-8
 M of dexamethasone in addition to 10% FCS, 100 units/ml 
Penicillin / 100 µg/ml of Streptomycin and 1.36 μg/mL of amphotericin B. Medium was 
changed every 2 days. Alkaline phosphatase [ALP] activity and alizarin red staining 
were used to analyse osteoblast differentiation. 2000 cells/well were seeded in 96 well 
plates for ALP activity assay. 12,000 cells/well were seeded in 24 well plates for the 
alizarin red staining assay. 150,000 cells/well were seeded in T25 for molecular biology 
assays. 4400 cells/well were seeded in 8 chamber slides for immuno-staining.  
 
2.2.4.1 Alkaline phosphatase activity assay  
p-Nitrophenyl phosphate (pNPP) (Sigma, UK) is a soluble substrate used for the 
detection of alkaline phosphatase activity (Xiao et al., 2006). 6x10
3
 cells/cm
2
 of primary 
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osteoblasts were seeded in 96 well plates in MEM alpha containing 10% FCS, 100 
units/ml Penicillin / 100 µg/ml of Streptomycin and 1.36 μg/mL of amphotericin B. 
Cells were washed twice with ice cold phosphate buffered saline (PBS) and 
permeabilised with 20 μl of 0.1% triton with agitating for 20 minutes at room 
temperature. One pNPP tablet and one tris buffer tablet were dissolved in 20 ml of 
water and 200 μl was carefully added to cells. ALP activity was determined by reading 
the absorbance at A405 every 5 minutes for 90 minutes (Figure 2.2) and using the 
following formula; OD(t1), last optical density; OD(t0), start optical density; ε, constant; 
path length, length of 200 volume of sample in 96 well plate.  
 
     (OD(t1) – OD(t0)) X 1000 X Total volume 
ALP activity = 
  Time X ε (18.75) X Path length (0.639) X Sample volume  
 
 
 
 
 
 
 
 
 
 
 
Figure 2.2: Determining alkaline phosphatase activity during osteoblast 
differentiation. p-Nitrophenyl phosphate was used as a soluble substrate to detect 
alkaline phosphatase activity. One pNPP tablet and one Tris Buffer tablet were 
dissolved in 25ml tap water. ALP hydrolyses colourless pNPP to a coloured product. 
The colour intensity was determined by reading the absorbance at A405. The more ALP 
activity correlates with more yellow product. Panel A shows a yellow product is 
formed in the presence of ALP. Panel B shows no yellow product was formed in the 
absence of ALP. ALP activity is expressed as U/ml/min/ug DNA.  
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2.2.4.2 PicoGreen assay  
ALP activity was normalised with osteoblast DNA concentration using the picogreen 
assay. PicoGreen
®
 double-stranded DNA (dsDNA) quantitation reagent (Invitrogen, 
UK) is a fluorescent nucleic acid stain used to quantify dsDNA (Xiao et al., 2006). 
100µl of 1X TE buffer (10 mM Tris-HCl, 1 mM EDTA, pH 7.5) was added to standards 
and unknown DNA concentration of the osteoblasts in a 96 well plate. 100 µl of 1:200 
dilutions of PicoGreen reagent was added to each standard and unknown sample, and 
incubated in the dark at room temperature for 5 minutes. Quantitation of DNA was 
determined by exciting samples at 485 nm and detecting fluorescence emission intensity 
at 530 nm.  
 
2.2.4.3 Alizarin red staining  
Alizarin red staining is a dye used as an in vitro mineralisation marker, in which alizarin 
red dye binds to calcium in matrix deposited by osteoblasts (Xiao et al., 2006). 6x10
3
 
cells/cm
2
 of primary mouse osteoblasts were seeded in 24 well plates in MEM alpha 
containing 10% FCS, 100 units/ml penicillin / 100 µg/ml of streptomycin and 
1.36 μg/mL of amphotericin B. Cells were washed twice with ice cold PBS and fixed 
with 1 ml of ice cold 70% ethanol for 1 hour at 4°C. Cells were rehydrated with water 
for 5 minutes before 1 ml of 1% alizarin red (pH 4.2) was added to each well for 10 
minutes, washed 5 times with water and dried overnight to at 25°C. ImageJ software 
was used to quantify the red colour of alizarin red staining. Colour images were 
converted into 8 bit images (255 grey levels) and the intensity of objects and pixel value 
of white/black was calculated (Figure 2.3).  
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2.2.5 Molecular biology  
2.2.5.1 RNA extraction  
RNA was extracted from 5T33MM cells, 5TGM1 cells and mouse calvarial primary 
osteoblasts. According to manufacturer’s instructions homogenised tissues/cells were 
washed in phosphate buffered saline (PBS) and Trizol
®
 (Invitrogen, UK) and 
chloroform was added. The solution was centrifuged for 12000rpm at 4°C for 10 
minutes. RNA in aqueous phase was removed, and 2 volumes of isopropanol added to 
precipitate the RNA in -20ºC for 24 hour. The solution was thawed and centrifuged for 
12000rpm at 4°C for 10 minutes. The resultant RNA pellet was re-suspended in RNase 
and DNase free H2O and stored at -20°C. Samples were stored for no more than 6 
weeks.  
 
Figure 2.3: Determining alizarin red staining as a marker of osteoblast activity. 
Wells containing alizarin red stained osteoblasts from 24 well plates were digitally 
scanned to capture alizarin red staining (A). Captured colour digital images were 
processed using imageJ software to generate 8 bit images (B) with 0-255 gray levels. 
8 bit images were converted into binary images (C). The pixel value of equal binary 
areas osteoblasts in each stained well was derived. Results were expressed by 
intensity 0-255. Pixel values of 0 = white represented minimum intensity alizarin red 
staining whereas pixel values of 255 were maximum intensity alizarin red staining.  
Determining the role of N-cadherin in the formation of the myeloma niche 
  
 Page 51 
 
2.2.5.2 RNA and DNA quantitation  
NanoDrop ND 1000 Spectrophotometer (NanoDrop Technologies, USA) was used to 
quantify total RNA and DNA in the solution. RNA and/or DNA solutions were 
centrifuged for 12000rpm at 4°C for 10 minutes and pellets washed twice in 70% 
ethanol to precipitate RNA and/or DNA. The resultant RNA and/or DNA pellet was re-
suspended in 10 μl of DNase/RNase-free distilled water. The purity of the RNA and/or 
DNA with respect to protein contamination was estimated by 280 nm and 260/280 nm 
ratio.  
 
2.2.5.3 RNA agarose gel electrophoresis  
The quality of the purified RNA was verified with 1% Agarose gel electrophoresis of 
RNA samples. 2g agarose (Invitrogen, UK) was dissolved in 200 ml 1X Tris-Borate-
EDTA buffer (TBE) preparing 1% (w/v) agarose gels. The gel mixture was boiled and 
allowed to cool to ambient temperature. 2 µl of ethidium bromide (Fluka, Switzerland), 
a fluorescent tag that permits visualisation of bands under ultraviolet light was added. 
Agarose was poured into a casting tray containing a multi-well comb. RNA samples 
were added and mixed with 3 µl of loading buffer (X2 TBE, 0.25% bromophenol blue 
(BPB)/ 30% glycerol) and loaded into wells for electrophoresis and run in 1X TBE 
buffer with BIO-RAD Power PAC300 at 120 volts (constant voltage) for 40 minutes. 
After electrophoresis, bands were visualized under UV light using ultraviolet 
transilluminator (Bio-Rad Gel Doc 2000 using Quantity One v4.5.1 software). Images 
were saved as tiff files. Good quality RNA was judged to have clean 28S and 18S 
ribosomal RNA bands, little or no fluorescence at the bottom of the gel and a smear or 
fluorescent fragments above the 28S and 18S ribosomal bands.  
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2.2.5.4 cDNA synthesis  
According to manufacturer's instructions (Invitrogen, UK), a known concentration of 
RNA was treated with DNase I to remove any genomic DNA contamination. 
SuperScript™ II reverse transcriptase (Invitrogen, UK) was used to reverse transcribes 
mRNA to cDNA. The resultant solution was incubated at 50°C for an hour and made up 
to 50 μl, with DNase/RNase-free distilled water, as a cDNA template for amplification 
in PCR. Control samples (water only) were used to ensure there is no false positives or 
negative in subsequent RT-PCR (Figure 2.4).  
 
2.2.5.5 Bioinformatics and primer design  
National Center for Biotechnology Information (NCBI), UCSC (University of 
California Santa Cruz) and Ensemble were searched against N-cadherin, NM_007664.4 
mouse RefSeq gene and GAPDH (control), NM_008084.2 mouse RefSeq gene. Exon 
spanning primers, on separate exons, were designed (Table 2.2) with PCR product sizes 
of approximately 560 bp and 354 bp to cover coding region of N-cadherin and GAPDH, 
respectively (Figure 2.5). All primers were manually designed with 20 bases in length, 
melting temperatures of 60ºC (annealing at 55ºC), containing 50% G or C, and 
containing GC clamp at the 3’ end. BLAST software was used to determine the 
specificity of PCR primers.  
 
2.2.5.6 Polymerase chain reaction  
Platinum Taq DNA polymerase kit (Invitrogen, UK) was used to amplify N-cadherin 
using 1μl of cDNA template according to manufacturer's instructions (Invitrogen, UK). 
16.05 µl of water was mixed with 2.5 µl of 10X PCR buffer, 0.75 µl of 1.5 mM MgCl2,  
1 µl of  10 mM deoxynucleoside triphosphates (dNTPs), 0.5 μl of each primer (final 
concentration = 0.2 μM), and 0.2 μl Platinum Taq polymerase (5 U/μl stock). Using 
DNA Engine (MJ Research PTC200 Thermo Cycler (BC-MJPC200)) PCR reaction was 
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started with heating at 94ºC for 3 minutes followed by cycles of denaturation at 94 ºC 
for 30 seconds, annealing at 55ºC for 30 seconds, and extension at 72ºC for 30 seconds, 
performed for 30 cycles for N-cadherin and 20 cycles for GAPDH. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.4: Gene expression analysis using reverse transcriptase-polymerase 
chain reaction (RT-PCR) to synthesise cDNA from RNA and amplify specific 
gene transcripts using PCR. Total RNA was treated with DNase I to remove 
genomic DNA prior to reverse transcription. PCR was performed using 1µl cDNA 
template (A) and 1µl no cDNA template (B). Housekeeping gene GAPDH primers 
were used as an internal control for each sample showing successful cDNA synthesis. 
PCR products were electrophoretically separated by size using ethidium 
bromide/agarose gel demonstrating no genomic contamination in the RT-ve samples. 
Expected size of GAPDH products = 354 bp.  
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Table 2.2: Primers designed and used to amplify target genes  
Gene  Accession 
number 
Forward                               
5`- 3` 
Reverse                               
5`- 3` 
Expected 
size 
N-cad NM_007664.4 CAGGTAGCTGTAAACCTGAG CCATTCAGGGCATTTGGATC 560 bp 
GAPDH NM_008084.2 TTGTCAGCAATGCATCCTGC GCTTCACCACCTTCTTGATG 354 bp 
 
 
2.2.5.7 cDNA agarose gel electrophoresis  
Agarose gel electrophoresis was used to separate the amplified nucleic acids by length. 
2g agarose (Invitrogen, UK) was dissolved in 200 ml 1X Tris-Borate-EDTA buffer 
(TBE) preparing 1% (w/v) agarose gels. The gel mixture was boiled and allowed to cool 
to ambient temperature. 2 µl of ethidium bromide (Fluka, Switzerland), a fluorescent tag 
that binds to dsDNA permits visualisation of bands under ultraviolet light. Agarose was 
poured into a casting tray containing a multi-well comb. PCR samples were added and 
mixed with 3 µl of loading buffer (X2 TBE, 0.25% bromophenol blue (BPB)/ 30% 
glycerol) and loaded into wells for electrophoresis and run in 1X TBE buffer with BIO-
RAD Power PAC300 at 120 volts (constant voltage) for 40 minutes. After 
electrophoresis, bands were visualised under UV light using ultraviolet transilluminator 
(Bio-Rad Gel Doc 2000 using Quantity One v4.5.1 software).  
 
2.2.5.8 DNA extraction from the gel using Qiaquick gel extraction Kit  
This QIAquick Gel Extraction kit was used according to manufacturer's instructions 
(QIAGEN Ltd, UK) to extract and purify DNA fragments from agarose gels. PCR 
samples were added and mixed with 3 µl of loading buffer (0.25% bromophenol blue 
(BPB)/ 30% glycerol) and loaded into wells for electrophoresis and run in 1X TBE 
buffer with BIO-RAD Power PAC300 at 120 volts (constant voltage) for 40 minutes. 
The position of the fragment of interest was excised from the agarose gel with a clean, 
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sharp scalpel under the UV light and placed in a 1.5 ml Eppendorf tube. 600 µl of buffer 
QC (contains guanidine thiocyanate, buffer composition is proprietary, pH ≤7.5) was 
added to the gel in the tube. Samples were incubated at 50°C until the gel slice had 
completely dissolved and the colour of buffer changed to yellow. Samples were mixed 
every 2 minutes to help the gel to dissolve. The products were transferred into a 
QIAquick spin column and centrifuged at 13,000 rpm for 1 minute. The flow-through 
was discarded to remove all traces of agarose. 0.5 ml of buffer QC was added to the 
membrane of QIAquick spin column and centrifuged at 13,000 rpm for 1 minute. The 
flow-through was discarded and 0.7 ml of buffer PE (containing 80% (v/v) ethanol, 
while the composition of the buffer was proprietary) was added to the membrane of 
QIAquick spin column to wash the column. Samples were centrifuged at 13,000 rpm for 
1 minute and the flow-through was discarded. The column was then transferred to a 
clean 1.5 ml Eppendorf tube and 50 µl of DNase/RNase-free distilled water was added 
to the QIAquick spin column membrane and allowing the column to stand for 1 minute 
in room temperature. DNA was recovered by centrifugation the QIAquick spin column 
at 13,000 rpm for 1 minute and quantitated as described in section 2.2.5.2.  
 
2.2.5.9 Sequencing  
DNA samples were sequenced in the DNA Sequencing Core Facility housed within the 
University of Sheffield Medical School (http://genetics.group.shef.ac.uk/dna-
sequencing.html). 10 µl of purified PCR product (50 ng/µl) was supplied to the core 
facility for sequencing along with the appropriate primers for N-cadherin (1 pmol/µl) 
(Table 2.2). Samples were sequenced in both directions using an ABI 3730 DNA 
capillary sequencer (Applied Biosystems). FinchTV software was used in analysing the 
output sequence after receiving from the Sequencing Core Facility.  
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2.2.5.10 TaqMan analysis  
TaqMan is a method used to quantify gene expression (Holland et al., 1991). According 
to manufacturer's instructions (Invitrogen, UK) TaqMan Universal master Mix II 
(Applied biosystems, UK) was mixed with cDNA templates. According to 
manufacturer's instructions (Applied Biosystems, UK) 10 µl of TaqMan Universal 
Master Mix II was mixed with 1 µl of TaqMan assay and 9 µl of cDNA. Runx2 
(Mm00501580_m1), COL1A2 (Mm00483888_m1), osteocalcin (Mm03413826_mH), 
N-cadherin (Mm01162497_m1) and β-actin (Mm00607939_s1) assays were used. ABI 
PRISM > 900 sequence detector was used to quantify gene expression. Expression was 
normalised with housekeeping genes.  
 
2.2.6 Immuno-detection of N-cadherin  
2.2.6.1 Immunofluorescence detection of N-cadherin in osteoblasts  
Immunofluorescence is a technique used to detect specific antigens using specific 
antibodies. Rabbit monoclonal anti-N-cadherin antibody (Millipore, UK) and donkey 
anti-rabbit IgG antibodies (R&D systems, UK) were used as primary and secondary 
antibodies. 6x10
3
 cells/cm
2
 of osteoblasts were seeded in chamber slides (BD, UK) and 
cultured in MEM alpha containing 10% FCS, 100 units/ml penicillin / 100 µg/ml of 
streptomycin and 1.36 μg/mL of amphotericin B. Cells were washed twice with ice cold 
PBS and fixed with 300 µl of 4% fresh paraformaldehyde in PBS for 10 minutes in 4°C. 
Cells were permeablized with 0.1% triton in PBS for 10 minutes at room temperature. 
Osteoblasts were washed twice with room temperature PBS, blocked with 1% normal 
donkey serum for 30 minutes at room temperature.  
 
In optimising antibody concentration, osteoblast were incubated overnight at 4°C with 
300 µl of 25-125 µg/ml anti-N-cadherin antibody (Millipore, UK) in different dilutions 
in PBS (1:50), (1:100), and (1:500). 300 µl of 100 µg/ml normal rabbit IgG antibody 
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(R&D systems, UK) was used with (1:50), (1:100), and (1:500) dilution of isotype in 
PBS as a negative controls. Cells were washed twice with 300 µl of PBS and incubated 
with 300 µl of donkey anti-rabbit IgG secondary antibody, (1:200) (R&D systems, UK) 
for 1 hour at room temperature, then washed twice with 300 µl of PBS. to remove 
unbound antibody, and incubated with 300 µl of donkey anti-rabbit IgG secondary 
antibody, (1:200), labelled with fluorochrome northern light (NL637) (R&D systems, 
UK) for 1 hour at room temperature, then washed twice with PBS. Slides were mounted 
using prolong mounting medium containing DAPI stain (Invitrogen, UK), DAPI stain 
was used to stain nuclei. Images were acquired using a Zeiss 510 microscope.  
 
After optimal concentration of antibody determined, osteoblasts incubated overnight at 
4°C with 300 µl of 25-125 µg/ml anti-N-cadherin antibody (Millipore, UK) using 1:50 
dilution. 300 µl of 100 µg/ml normal rabbit IgG antibody (R&D systems, UK) was used 
with 1:50 dilution as a negative control. Cells were washed twice with PBS to remove 
unbound antibody, and incubated with 300 µl of donkey anti-rabbit IgG secondary 
antibody, (1:200), labelled with fluorochrome northern light (NL637) (R&D systems, 
UK) for 1 hour at room temperature, then washed twice with PBS. Slides were mounted 
using prolong mounting medium containing DAPI stain (Invitrogen, UK), DAPI stain 
was used to stain nuclei. Images were acquired using a Zeiss 510 microscope.  
 
2.2.6.2 Immunofluorescence detection of N-cadherin in 5T33MM cell line  
1x10
6
 cells/ml were re-suspended in 4% paraformaldehyde and fixed for 10 minutes. 
250 μl of this suspension was added to the funnel in assembled cytospin cassette and 
centrifuged in cytospin for 5 minutes at 500 rpm. Slides were removed from cytospin 
cassette. Cells were permeablized with 0.1% triton in PBS for 10 minutes at room 
temperature, washed twice with PBS, blocked with 1% normal donkey serum for 30 
minutes at room temperature and incubated overnight at 4°C with 300 µl of 25-125 
µg/ml anti-N-cadherin antibody (Millipore, UK), 1:50 dilutions. 300 µl of 100 µg/ml 
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normal rabbit IgG antibody (R&D systems, UK) was used with 1:50 dilution as a 
negative control. Cells were washed twice with room temperature PBS to remove 
unbound antibody, and incubated with 300 µl of donkey anti-rabbit IgG secondary 
antibody, (1:200 dilution), labelled with fluorochrome northern light (NL637) (R&D 
systems, UK) for 1 hour at room temperature, then washed twice with PBS. Slides were 
mounted using Prolong mounting medium containing DAPI stain (Invitrogen, UK), 
DAPI stain was used to stain nuclei. Images were acquired using a Zeiss 510 
microscope.  
 
2.2.6.3 Immunocytochemistry detection of N-cadherin in 5T33MM and 5TGM1MM 
cell lines  
1x10
6
 cells/ml were re-suspended in 4% paraformaldehyde and fixed for 10 minutes. 
250 μl of this stock was added to funnel in assembled cytospin cassette and centrifuged 
in cytospin for 5 minutes at 500 rpm. Slides were removed from cytospin cassette. Cells 
were permeablized with 0.1% triton in PBS for 10 minutes at room temperature, washed 
twice with PBS, blocked with 1% normal donkey serum for 30 minutes at room 
temperature and incubated overnight at 4°C with 300 µl of 25-125 µg/ml anti-N-
cadherin antibody (Millipore, UK), 1:50 dilutions in PBS. 300 µl of 100 µg/ml normal 
rabbit IgG antibody (R&D systems, UK) was used with 1:50 dilution of isotype in PBS 
as a negative control. Cells were washed twice with 300 µl of PBS to remove unbound 
antibody, and incubated with 300 µl of biotinylated anti rabbit IgG secondary antibody, 
(1:200 dilution), for 30 minutes at room temperature. Cells were washed twice again 
with PBS, and incubated with 300 µl of avidin-biotin complex (ABC) for 30 minutes at 
room temperature. Cells were washed twice again with PBS, and incubated with 300 µl 
of DAB for 5 minutes at room temperature. Cells were washed with water for                
5 minutes, and counter stained with haematoxyline for 20 seconds to stain nuclei. Slides 
were mounted and covered using cover slip. Images were acquired using an 
Osteomeasure software version 4.10 (Osteomerics Incorporated, Atlanta, USA).  
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2.2.7 Flow cytometry  
2.2.7.1 Antibody labelling  
Lightning-Link
TM
 Atto637 conjugation kit (Innova Biosciences, UK) was used for 
labelling the anti-N-cadherin antibody, GC-4 (Sigma, UK) and the mouse IgG antibody 
(Vector laboratories, UK). The kit contains 3 glass vials of Lightning-Link
TM
 mix, each 
suitable to label 100-200 μg of antibody. 10 μl of LL-Modifier reagent was added to 
100 μl of 2 mg/ml anti-N-cadherin, GC-4, antibody (Sigma, UK) and added to 100 μl of 
2 mg/ml mouse IgG antibody (Vector laboratories, UK). Each antibody was added to 
separate glass vial of Lightning-Link
TM
 mix and incubated overnight at 4°C before used.  
 
2.2.7.2 Cell preparation  
Mouse primary osteoblasts adhere to the bottom of flasks. Medium was discarded and 
cells were washed twice with room temperature PBS. Four different methods were used 
to harvest cells to determine the expression of N-cadherin protein by flow cytometry 
including; 0.25% trypsin-EDTA, scrape cells gently using cell scrapers (Thermo 
Scientific, UK), 1X sodium citrate (Sigma, UK) and 1% of 280 units/mg collagenase II 
(Invitrogen, UK) in 1X sodium citrate (Sigma, UK).  
 
2.2.7.3 Detection of N-cadherin protein in osteoblasts and myeloma cell lines; 
5T33MM and 5TGM1  
Flow cytometry is a technique used to separate and detect sub-population of cells or 
particles, such as cell surface antigens, protein expression and enzymatic activity based 
on fluorescence detection and/or bio-physiology, such as size and granularity of cells. 
Flow cytometry is routinely used in basic research, clinical practice and the diagnosis of 
health disorders, such as blood cancers (Barlogie et al., 1983). In this study, flow 
cytometry was used to detect the specific cell surface antigen, N-cadherin, using 
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specific fluorescent antibodies. Mouse monoclonal anti-N-cadherin, GC-4 antibody 
(Sigma, UK) was used as primary antibody. Mouse IgG (Vector Laboratory, UK) was 
used as a negative control. 5x10
5
 of mouse primary osteoblasts, 5T33MM cells and 
5TGM1 cells were re-suspended in 1 ml of 4% paraformaldehyde and fixed at 4°C for 
10 minutes. Cells were washed twice with PBS, blocked with 1 ml of 1% normal FCS 
for 30 minutes at room temperature. Cells were incubated with 1 ml of 2 mg/ml anti-N-
cadherin GC-4 antibody labeled by Lightning-Link
TM
 Atto637 (1:200 dilution in 1% 
normal FCS) for 30 minutes at 4°C in dark. 1 ml of 2 mg/ml mouse IgG antibody 
labeled by Lightning-Link
TM
 Atto637 was used (1:200 dilution in 1% normal FCS) for 
30 minutes at 4°C in dark as a negative control. Cells were washed twice with room 
temperature PBS to remove unbound antibody and resuspended in 300 μl in 1% normal 
FCS. Results were acquired using FACSCalibur.  
 
2.2.8 Western blot  
2.2.8.1 Protein extraction using NP40 buffer  
Proteins were extracted from cells using Nonylphenoxypolyethoxylethanol (NP40) 
reagent (Fluka). 1mL of NP40 buffer (1.0%NP40 reagent (Fluka) +150 mM sodium 
chloride +50 mM Tris, pH 8.0) was added to the ~80% confluent of pre-osteoblasts and 
mature osteoblasts and to 1x10
6
 of 5T33MM cells and 5TGM1 cells. Then, 1X of 
Protease Inhibitor Cocktail set 1 (CALBIOCHEM) was added to prevent protein 
degradation.  
 
2.2.8.2 Bicinchoninic acid (BCA) protein assay  
BCA protein assay is a biochemical assay for determining the total concentration of 
protein in a solution (Smith et al., 1985). Peptide bonds in the proteins reduced the 
copper sulphate(II) to copper sulphate(I). The amount of copper sulphate(II) reduced is 
propotional to the amount of proteins in the sample. The BCA protein assay detects the 
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copper sulphate(I). In this study, 10μl of each standard protein concentration, 1000 
µg/ml, 800 µg/ml, 600 µg/ml, 400 µg/ml, 200 µg/ml, 100 µg/ml and 0 µg/ml was added 
into 96 well plates. 10μl of the un-known sample was added in duplicate in the same 96 
well plate. 200 µl of BCA working reagent (50 part of BCA reagent A : 1 part of BCA 
reagent B) was added into each standard and samples. Plates were read on a plate reader 
(DYNEX technologies, MRX II) at 562nm.  
 
2.2.8.3 Sodium-Dodecyl-Sulphate Poly-Acrylamide Gel Electrophoresis            
(SDS-PAGE)   
This technique allows the separation of proteins based on their size. SDS is applied to 
denature the protein and imparts a uniform negative charge to linearized proteins. The 
separation of proteins is done by the acrylamide/bis-acrylamide matrix on the basis of 
molecular weight. 12% resolving gel was prepared by a mixture of 4 ml of Acrylamide 
30% (Total), 2.5 ml of resolving gel buffer (1.5 M Tris), 3.3 ml of water, 100 μl of 10% 
SDS, 100 μl of 10% ammonium persulphate (APS) and 4 μl of 
Tetramethylethylenediamine (TEMED) (BIORAD). This was loaded between the 
spacer plates 1.5 mm apart and kept for 30 – 40 minutes to polymerise. 15% resolving 
gel was prepared by a mixture of 5 ml of Acrylamide 30% (Total), 2.5 ml of resolving 
gel buffer (1.5 M Tris), 2.3 ml of water, 100 μl of 10% SDS, 100 μl of 10% APS and 4 
μl of Tetramethylethylenediamine (TEMED) (BIORAD). This was loaded between the 
spacer plates 1.5 mm apart and kept for 30 – 40 minutes to polymerise. 3% stacking gel 
was prepared by mixing of 180 μl of Acrylamide 30% (Total), 600 μl of stacking gel 
buffer 0.5 M Tris, 1.57 ml of water, 24 μl of 10% SDS, 24 μl of 10% APS and 2.4 μl of 
TEMED. These were loaded onto the resolving gel after it had polymerised.  
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Sample buffer was prepared by diluted 250 μl of 4X SDS in 750 μl water that gave a 1X 
SDS solution. 25 mg of DTT was then dissolved in 1X SDS and used as sample buffer. 
1X SDS running buffer was prepared by diluted 100 ml of 10X Tris/Glycine/SDS 
running buffer in 900 ml water that gave a 1X SDS running buffer (pH 8.3).  
 
In this procedure, SDS/polyacrylamide-gel electrophoresis was done in slab gels 
containing 12% (w/v) total acrylamide and 3% stacking gels for N-cadherin and 15% 
(w/v) total acrylamide and 3% stacking gels for β-actin, where proteins were separated 
by molecular mass. 25 µl of degraded proteins was mixed with 25 μl of the sample 
buffer. The samples were then boiled for 5 minutes at 100 °C and allowed to cool to 
ambient temperature for 5 minutes. 40 μl of each sample were then loaded into the gel 
slots for electrophoresis and run in 1X running buffer at 200 volts (constant voltage) for 
1 hour surrounded by ice.  
 
2.2.8.4 Proteins transfer  
The SDS-PAGE gels were placed into a transfer manifold. The transfer apparatus was 
purchased from BioRad (Mini Trans-Blot Electrophoretic Transfer Cell). 
Polyvinylidene fluoride (PVDF) membrane was re-hydrated by successive washing in 
MeOH, dH2O and transfer buffer. The transfer apparatus was assembled as described in 
figure 2.5 and the cassette placed in the transfer cell filled with cooled transfer buffer. 
For keeping the buffer cold during the horizontal protein transfer to the PVDF 
membrane, a stirrer and an ice container were placed in the transfer cell. 
Electrophoresed gel was placed on the top of PVDF membrane, which was kept on the 
cathode side. The transfer manifold allowed transfer at 100V for 600 min in a tank 
containing transfer buffer (25mM Tris base, 200mM glycine, 20% (v/v) methanol) and 
was cooled using an ice block.  
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Figure 2.5: A diagram showing the transfer apparatus for western blotting. The 
transfer apparatus (Mini Trans-Blot Electrophoretic Transfer Cell, Bio Rad) is 
assembled in following order: cassette (red/anode), scouring pad (sponge), 2X filter 
paper, PVDF membrane, acrylamide gel, 2X filter paper, scouring pad, cassette 
(black/cathode). When the electric field is applied, proteins, which are negatively 
charged with SDS, migrate to the positive pole and are captured by the PVDF 
membrane at 100V for 600 min in a tank containing transfer buffer.  
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2.2.8.5 Immuno-detection of N-cadherin on western blot  
After the transfer, the membrane was blocked using 5% non-fat powder milk (Marvel) 
in TBS (0.136M NaCl, 2.68mM KCl, 24.7mM Tris base, adjusted to pH 7.4 using HCl) 
for 1 hour. After the blocking, the membrane was incubated on a rotary shaker 
overnight at 4˚C with 10 ml of anti-N-cadherin antibody (Millipore, UK) (1:1000 
dilution) in 1% milk solution. Membranes were washed 4 times for 10 minutes in PBS-
T on a rotary shaker and incubated with anti-rabbit IgG, horseradish peroxidase-linked 
species-specific (GE Healthcare, UK) at a 1:2000 dilution in 1% milk solution for 1 
hour on a rotary shaker. Membranes were washed 3 times for 10-15 minutes in PBS-T 
on a rotary shaker followed by 3 times washes with distilled water for 10-15 minutes. 
Membranes were dipped in enhanced chemiluminescent substrate (SuperSignal®West 
Dura Extended Duration Substrate, Thermo Scientific) for 15-30 seconds for detecting 
horseradish peroxidase, in which horseradish peroxidase cleave the chemiluminescent 
and produces luminescence in proportion to amount of protein. Films (Hyperfilm™, 
Amersham) were developed using AGFA Curix 60 in the dark room.  
 
2.2.9 Cell adhesion assay  
2.2.9.1 Determining the incubation time and concentration of recombinant            
N-cadherin for adherence of myeloma cells  
96 well plates were coated overnight at 4°C with different concentrations of 
recombinant N-cadherin/Fc chimera (R&D Systems). Optimal incubation period was 
determined by incubating 1x10
5
 cells/ml of myeloma cells with 1 µg/ml of recombinant 
N-cadherin/Fc chimera at 37°C for different times; 0, 4, 8, 10, 15, 20, 30 and 60 
minutes. Optimal N-cadherin concentration was detected by incubating 1x10
5
 cells/ml 
of myeloma cells with 0, 0.1, 0.5, 1, 2, 5, 10 µg/ml of recombinant N-cadherin/Fc 
chimera (R&D Systems) at 37°C for 20 minutes. Plates were washed 5 times using 
PBS. Adherent cells were fixed with 4% PFA and counted. Results were presented as 
percentage of adhered myeloma cells out of the total number of myeloma cells.  
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2.2.9.2 Blocking N-cadherin using anti-N-cadherin (GC-4) antibody: blocking 
myeloma interaction with recombinant N-cadherin/Fc chimera  
To block N-cadherin, myeloma cells, 5T33MM and 5TGM1, were incubated with anti-
N-cadherin antibody (10 µg/ml) (Sigma, UK) at 37°C for 30 minutes (Figure 2.6). 
Mouse IgG1 antibody (Dako, Denmark) (10 μg/ml) was used as a negative control. 
Cells were mixed every 5 minutes. After 30 minutes, myeloma cells were centrifuged at 
1000 rpm for 4 minutes, washed twice with PBS to remove non-binding antibody and 
re-suspended in MEM alpha media (Groen et al., 2011). After blocking, 1x10
5
 cells/ml 
of myeloma cells were plated and incubated with recombinant N-cadherin/Fc chimera at 
37°C for 20 minutes. Plates were washed 5 times using PBS. Adherent cells were fixed 
with 4% PFA and counted using phase contrast microscopy. Results were presented as 
percentage of adhered myeloma cells out of the total number of myeloma cells.  
 
 
 
 
 
 
 
 
 
 
 
Figure 2.6: A diagram showing the process of an adhesion assay of myeloma cells 
on N-cadherin-coated wells. 96 well plates were coated overnight at 4°C with 
different concentrations of recombinant N-cadherin/Fc chimera (R&D Systems). 
1x10
5
 cells/ml of myeloma cells were pre-treated with anti-N-cadherin antibody or 
isotype control for 30 minutes at 4ºC. Myeloma cells were plated and incubated with 1 
µg/ml recombinant N-cadherin/Fc chimera at 37°C for 20 minutes. Plates were 
washed 5 times using PBS. Adherent cells were counted using phase contrast 
microscopy. Results were presented as percentage of adhesion out of the total number 
of cells.  
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2.2.10 Co-culture myeloma cells with osteoblasts  
6x10
3
 cells/cm
2
 of primary osteoblasts were seeded in 24 well plates for 2 days in MEM 
alpha media (Invitrogen, UK) containing 10% FCS. When confluent, after 2 days, 
osteogenic media was added and osteoblasts were differentiated for 4 weeks to mature 
functional osteoblasts using osteogenic media; MEM alpha (Invitrogen, UK) containing 
10 mM of β-glycerophosphate, 50 µg/ml of ascorbic acid and 10-8 M of dexamethasone 
(day 15 – day 28) in addition to 10% FCS, 100 units/ml Penicillin / 100 µg/ml of 
Streptomycin and 1.36 μg/mL of amphotericin B. Medium was changed every 2 days. 
Non-adherent 5T33MM and 5TGM1MM cells were cultured separately in RPMI1640 
medium (Invitrogen, UK) containing 10% FCS, 100 units/ml Penicillin / 100 µg/ml of 
Streptomycin, 1% Na2PO3 and 1% non-essential amino acids (NEAA) and incubated in 
a humidified atmosphere at 37°C and 5% CO2. Medium was changed every 2 days.  
 
6x10
3
 cells/cm
2
 of mouse primary osteoblasts were seeded in 35mm glass bottom 
dishes. 5x10
4
 cells/ml of myeloma cells, 5T33MM-GFP and 5TGM1-GFP, were plated 
and incubated with osteoblasts at 37°C for 20 minutes. Plates were washed 5 times with 
1ml of PBS and fixed with 300 µl of 4% fresh paraformaldehyde in PBS for 10 minutes 
in 4°C. Cells were permeablized with 0.1% triton in PBS for 10 minutes at room 
temperature and washed twice using PBS. Rabbit monoclonal anti-N-cadherin antibody 
(Millipore, UK) (1:50 dilution) was used. Cells were washed twice with 1ml of PBS to 
remove unbound antibody, and incubated with 300 µl of donkey anti-rabbit IgG 
secondary antibody, (1:200), labelled with fluorochrome northern light (NL637) (R&D 
systems, UK) for 1 hour at room temperature, then washed twice with PBS. Slides were 
mounted using Prolong mounting medium containing DAPI stain (Invitrogen, UK), 
DAPI stain was used to stain nuclei. Images were acquired using a Zeiss 510 
microscope. Myeloma cells can be clearly identified in these cultures, as they are GFP
+
 
(green fluorescence) cells.  
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To block N-cadherin, myeloma cells, 5T33MM and 5TGM1, were incubated with anti-
N-cadherin antibody (10 µg/ml) (Sigma, UK) at 37°C for 30 minutes (Figure 2.7). 
Mouse IgG1 antibody (Dako, Denmark) (10 μg/ml) was used as a negative control. 
Cells were mixed every 5 minutes. After 30 minutes, myeloma cells were centrifuged at 
1000 rpm for 4 minutes, washed twice with PBS to remove non-binding antibody and 
re-suspended in MEM alpha (Groen et al., 2011). After blocking, 1x10
6
 cells/ml of 
myeloma cells were plated and incubated with immature osteoblasts (day 7) and mature 
functional osteoblasts (day 28) at 37°C for 20 minutes (Figure 2.6). Plates were washed 
5 times using PBS. Adherent cells were fixed with 4% PFA and counted using phase 
contrast microscopy. Results were presented as percentage of adhered myeloma cells 
out of the total number of myeloma cells.  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.7: A diagram showing the process of a co-culture of myeloma cells with 
osteoblasts. Primary osteoblasts were seeded in 24 well plates and differentiated for 4 
weeks from pre-osteoblasts to mature osteoblasts. 1x10
6
 cells/ml of myeloma cells 
were pre-treated with anti-N-cadherin antibody or isotype control for 30 minutes at 
4ºC. Myeloma cells were plated and incubated with osteoblasts at 37°C for 20 
minutes. Plates were washed 5 times using PBS. Adherent cells were counted using 
phase contrast microscopy. Results were presented as percentage of adhesion out of 
the total number of cells.  
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2.2.11 Cell labelling with DiD and blocking using anti-N-cadherin antibody 
Myeloma cells (1x10
6
 cells/ml) were re-suspended in RPMI1640 medium (Invitrogen, 
UK) containing 10% FCS. 5 µl of 1 µg/ml DiD (Invitrogen, UK) was added to each 
1x10
6
 cells/ml and incubated at 37°C for 20 minutes. Cells were mixed every 5 minutes. 
After 20 minutes, myeloma cells were centrifuged at 1000 rpm for 4 minutes, washed 
twice with PBS to remove excessed DiD dye and re-constituted in RPMI medium 
containing 10% FCS. Figure 2.8 shows myeloma cells after labelling under the Zeiss 
510 multiphoton laser scanning microscope. To block N-cadherin, myeloma cells, 
5T33MM and 5TGM1, were incubated with anti-N-cadherin 40 µg/ml antibody (Sigma, 
UK) for 30 minutes at 37 °C (Ciolczyk-Wierzbicka et al., 2004). Mouse IgG1 antibody 
(Dako, Denmark) was used as a negative control. Cells were mixed every 5 minutes. 
After 30 minutes, myeloma cells were centrifuged at 1000 rpm for 4 minutes, washed 
twice with PBS to remove the non-adherent antibody and re-suspended in 1 ml PBS. 
Cells were counting (see section 2.2.1) to determine the percentage of dead and live 
cells after blocking.  
 
 
 
 
 
 
 
 
 
 
Figure 2.8: Zeiss 510 multiphoton laser scanning microscope analysis of myeloma 
cells labelled with DiD. 5T33MM-DiD cells (A) and 5TGM1-DiD cells (B) were 
visualised using Zeiss 510 multiphoton laser scanning microscope.  
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2.2.12 Inoculation of MM cells into mice  
4-6 week old male C57BL/KaLwRij mice were used. Mice were handled carefully. 
Mice were put in rodent restrainer, a plastic that hold mice body and keep their tails free 
for induction, and their tails were anesthetized using EMLA
TM
 cream 5% (AstraZeneca, 
UK). After 5 minutes, 200 µl of MM cell lines: 5T33MM and 5TGM1 (2x10
6
 cells/200 
µl) were inoculated into each mouse via their tail veins. Mice were harvested after 
various times according to the aims of each study.  
 
2.2.13 Harvesting calvarial tissues  
2.2.13.1 Excise calvarial tissue  
Bone formation occurs through two unique mechanisms: intramembranous ossification 
and endochondral ossification. Nakashima et al (2003) showed that in calvarial mice, 
MSCs differentiate into osteoprogenitor cells then differentiate into osteoblasts that 
differentiate into osteocytes, which become embedded within the bone matrix in process 
called intramembranous ossification. In this case cells participated in bone formation 
include: MSCs, osteoprogenitor cells, osteoblasts and osteocytes. In contrast, in long 
bone, MSCs differentiate into chondrocytes forming the cartilage anlagen. Cells from 
the perichondrium of cartilage anlagen differentiate into osteoblasts, and the periphery 
of the cartilage anlage becomes hypertrophic. Finally, the matrix surrounding these 
hypertrophic chondrocytes calcifies and longitudinal growth is stimulated as 
cartilaginous matrix. In this case cells that participate in bone formation include: MSCs, 
perichondrium, chondrocytes, periosteum, hypertrophic chondrocytes, osteoclasts 
osteoblasts and osteocytes (Nakashima and de Crombrugghe, 2003). As we were 
interested in osteoblasts, we expected to see more osteoblasts compared to other cells in 
the calvariae. Therefore, we decided to use calvariae in this study.  
 
Determining the role of N-cadherin in the formation of the myeloma niche 
  
 Page 70 
 
The calvariae of mice consists of five bones; two frontal, two parietal and one 
interparietal bone (Figure 2.7). Calvariae of the mice were dipped in dilute embedding 
medium for frozen tissue specimens (Cryo-M-Bed) and snap frozen in liquid nitrogen. 
Samples were transferred and stored at -80 °C for multiphoton microscopy scanning. 
For cellular distribution C57BL/KalwRiJHsD calvariae were excised carefully and 
stored in 10% of neutral buffered formalin (NBF) for a minimum of three days and 
decalcified in EDTA for 14 days (Fisher Scientific, UK). Bones were washed with 
distilled water to remove EDTA and through graded alcohols to remove water. Sections 
of frontal, parietal and interparietal bones were taken for three levels every 200μM 
using a Leica microsystems microtome RM 2265 (Figure 2.8). Sections were floated for 
30 minutes in a 45°C water bath, transferred onto glass slides, dried for 30 minutes on a 
45°C hotplate (Raymond A Lamb Blockmaster II), incubated overnight at 37°C, and 
stored at 4°C until staining. Osteoclasts, osteoblasts and bone lining cells frequency 
were determined from 1.5 mm of both right and left side in the endo-cortical and 
trabecular surfaces of calvariae (Figure 2.9).  
 
 
 
 
 
 
 
 
 
 
Figure 2.7: A three-dimensional microCT reconstruction of a mouse skull 
demonstrating calvariae bones and dissected sections. Calvariae of mice consist of 
five bones; two frontal, two parietal and one interparietal bone (red arrows).  
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Figure 2.8: A microCT three-dimensional reconstruction of C57BL/KaLwRijHsd 
calvariae. Frontal, parietal, and interparietal bones were carefully dissected, as 
denoted by yellow arrows and the sections were taken for 3 levels every 200μM. 
Sections were stained with TRAP for determining the distribution of osteoclasts and 
stained with hematoxylin and eosin for determining the distribution of osteoblasts and 
quiescent bones.   
Figure 2.9: A microCT cross section of calvarial bone. Osteoclasts, osteoblasts and 
bone lining cells were determined in 3 mm from the middle.  
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2.2.13.2 TRAP staining  
Tartrate-resistant acid phosphatase (TRAP) is an isoenzyme of acid phosphatase found 
to be highly expressed by osteoclasts. TRAP is usually detected as a marker of 
osteoclast function (Minkin, 1982, Filgueira, 2004). The enzyme present within the 
tissue reacts with the substrate naphthol AS-BI phosphate to give a primary reaction 
product. This product then reacts with the diazonium salt (hexazotised pararosaniline) to 
form the final reaction product which is seen as a red deposit within the bone osteoclast 
cytoplasm. Bone sections were dipped twice in xylene for 5 minutes to remove wax and 
re-hydrated twice in absolute alcohol, 95% alcohol and 70% alcohol for 5 minutes and 
washed briefly in water. Sections were incubated in solution A, 50ml acetate-tartrate 
buffer (Sigma, UK) in 1ml naphthol/dimethylformamide (Sigma, UK), for 30 minutes at 
37°C. After that, sections were incubated in 2.5ml of hexazotised solution (Sigma, UK), 
2ml pararosaniline stock (Sigma, UK) with 2ml of 4% sodium nitrite solution (Sigma, 
UK), to 50ml acetate-tartrate buffer (VWR, UK) for 15 mins at 37°C. Sections were 
rinse twice gently in running tap water, counterstain for 20 seconds in Gill’s 
haematoxylin (VWR, UK) by washing gently in running tap water. Sections were de-
hydrated through 70% alcohol for 10 seconds, 95% alcohol for 10 seconds and twice in 
absolute alcohol for 30 seconds each. Xylene was used for 1 minute to remove alcohol 
and 3 minutes for clearance. Slides were mounted and covered using coverslips (VWR, 
UK). In endo-cortical and trabecular surfaces of calvariae the nuclei were stained blue 
and osteoclasts stained bright red/pink.  
 
2.2.13.3 Hematoxylin and eosin staining  
Hematoxylin and eosin stain (H&E) is a standard staining method in histological 
studies. Hemalum is formed from aluminium ions and oxidized haematoxylin stains 
nuclei with blue colour whereas eosin stains cytoplasm and extracellular
 
matrix with 
varying degrees of pink staining (Fischer et al., 2008, Llewellyn, 2009). Bone sections 
were dipped twice in xylene for 5 minutes to remove wax and re-hydrated twice in 
absolute alcohol, 95% alcohol and 70% alcohol for 5 minutes and washed briefly in 
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water. Gill’s II haematoxylin (VWR, UK) was used for 120 seconds to stain nuclei. 
Sections were washed in water. 1% aqueous eosin (VWR, UK) with 1% calcium 
carbonate (Sigma, UK) was used for 5 minutes to stain cytoplasm. Sections were de-
hydrated through 70% alcohol for 10 seconds, 95% alcohol for 10 seconds and twice in 
absolute alcohol for 30 seconds each. Xylene was used for 1 minute to remove alcohol 
and 3 minutes for clearance. Slides were mounted and covered using coverslips (VWR, 
UK). In endo-cortical and trabecular surfaces of calvariae the nuclei were stained blue, 
cytoplasm and extracellular
 
matrix stained pink.  
 
2.2.13.4 Immunohistochemistry detection of N-cadherin in calvariae  
Bone sections were dipped twice in xylene for 5 minutes to remove wax and re-hydrated 
twice in absolute alcohol, 95% alcohol and 70% alcohol for 5 minutes and washed 
briefly in water. Sections were incubated in 3% hydrogen peroxide in water for 15 
minutes to block the endogenous peroxidase activity. Sections were washed in water. 
For antigen retrieval sections were incubated with 10 mM of tri-sodium citrate (pH6) 
for 25 minutes at 80 ºC and cooled for 10 minutes. Sections were washed twice with 
PBS-Tween, blocked with 1% normal donkey serum for 30 minutes at room 
temperature, and followed by an incubation overnight at 4°C with 100 µl of 25-125 
µg/ml anti-N-cadherin antibody (Millipore, UK) (1:200 dilution in PBS). 100 µl of 100 
µg/ml normal rabbit IgG antibody (R&D systems, UK) was used as a negative control 
(1:200 dilution in PBS). Cells were washed twice with room temperature to remove 
unbound antibody, and incubated with 100 µl of biotinylated anti rabbit secondary 
antibody, (1:200 dilution), for 30 minutes at room temperature. Cells were washed twice 
again with PBS, and incubated with 300 µl of ABC for 30 minutes at room temperature. 
Cells were washed twice again with PBS, and incubated with 300 µl of Immpact DAB 
for 5 minutes at room temperature. Cells washed with water for 5 minutes, counter 
stained with haematoxyline for 20 seconds to stain nuclei, and washed again with water 
for 5 minutes. Bone sections were de-hydrated in 70% alcohol for 5 minutes, 95% 
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alcohol, twice in absolute alcohol for 5 minutes each and dipped twice in xylene for 5 
minutes to remove alcohol. Slides were mounted and covered using cover slip.  
 
2.2.14 Microscopy  
2.2.14.1 Multiphoton microscopy  
A Zeiss 510 Multiphoton Laser Scanning Microscopy was used to visualise 
fluorescence. Images included 2D X/Y plane, 2D tiled stacks and 3D z stacks to analyze 
imaging in more depth. Zeiss 510 Microscope is connected to the computer were used 
to capture images. The fluorochrome northern light (NL637) of the secondary antibody 
was excited at 633 nM and detected at 658 nM. Blue fluorescence of DAPI stain, which 
stains cells nuclei, is excited at 740 nM and detected at 360 nM. The bone was excited 
at 900 nM and detected at 450 nM. Red fluorescence of DiD stain was excited at 633 
nM and detected at 658 nM. Images included 2D X/Y plane, 2D tiled stacks and 3D z 
stacks to analyze imaging in more depth.  
 
2.2.14.2 Leitz DMRB microscopy  
Osteomeasure software version 4.10 (Osteomerics Incorporated, Atlanta, USA) was 
used with a Leitz DMRB microscope and a drawing tablet, (CalComp Drawing Broad 
III) to quantify the cellular on endo-cortical and trabecular surfaces of calvariae. In 
addition, this microscopy was used to visualized non-florescence cells and sections.  
 
2.2.15 Lightools image analysis system  
All calvariae were analysed using Fluorescence Cheda Lightools Illumatools System 
(LT-9900 Bright Light System) in the University of Sheffield biological services 
laboratory. The Lightools image analysis system used to visualise GFP
+
 tumour in 
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calvarial BM. The GFP-tumour was exited at 470 nm and detected at 515 nm with a 
MagnaFire SP cooled color charge-coupled device (CCD) camera.  
 
2.2.16 High-resolution micro–computed tomography (µCT)  
High resolution µCT scanner (model 1172; Skyscan, Belgium) is a non-destructive 
technique that provides three-dimensional micro-structure of bone (Laib et al., 2000, 
van Lenthe et al., 2007). µCT scanner was used to scan calvarial bones. Image captured 
every 0.35° through a 360° rotation with 4.1 pixel size. Scanned images were 
reconstructed using Skyscan NRecon software (version 1.5.1.3, Skyscan, Belgium) and 
analysed using Skyscan CT analysis software (version 1.8.1.2, Skyscan, Belgium). 
Cortical volume, trabecular volume, trabecular thickness and trabecular number were 
evaluated in a standardized region of interest. All cortical and trabecular bone within 
this region was quantitated.  
 
2.2.17 Study to determine the distribution of osteoclasts, osteoblasts and quiescent 
bone in C57BL/KaLwRijHsd calvariae  
C57BL/KaLwRijHsd calvariae were excised carefully from 5 male mice, 6 weeks of 
age and stored in formalin. Frontal, parietal, and interparietal bones were carefully 
dissected and sections of each calvarial part were cut for 3 levels. Each level cut after 
200μM from previous (Figure 2.8). TRAP staining was used to determine the 
distribution of osteoclasts in the endo-cortical and trabecular surfaces of calvariae as 
described in section 2.2.11.3. Haematoxylin and eosin staining was used to determine 
the frequency of osteoblasts and non-osteoclast/osteoblast lined surfaces, quiescent 
bones in the endo-cortical and trabecular surfaces of calvariae in section 2.2.11.4. 
Osteomeasure software version 4.10 (Osteomerics Incorporated, Atlanta, USA) was 
used to analyse the sections. Osteoclasts, osteoblasts and bone lining cells frequency 
were determined in section 2.2.13.1 (see figure 2.9).  
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2.2.18 Study to determine the distribution of new bone formation in 
C57BL/KaLwRijHsd calvariae  
4 male C57BL/KaLwRijHsd mice, 6 weeks of age, were injected with 200μl of calcein-
GFP (3 mg/ml in PBS) each at day 0 (Figure 2.10). After 3 days, mice were sacrificed 
and calvariae were excised carefully, dipped in 1:2 diluted OCT and stored in -80 ºC. 
Zeiss 510 multiphoton laser scanning microscope was used to determine the new bone 
formation in different part of calvariae bones: frontal, parietal and interparietal.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.10: Experiment design to determine the bone formation rate. 4 x 6 week 
old male, C57BL/KaLwRijHsd mice were injected with 200μl of 3 mg/ml calcein-
GFP each at day 0. At day 3 mice sacrificed and calvarial bone were analysed under 
the Zeiss 510 multiphoton laser scanning microscope.  
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2.2.19 Study to determine if myeloma tumour can grow in C57BL/KaLwRijHsd 
calvarial BM  
9 male C57BL/KaLwRijHsd mice, 6 weeks of age, were used in this experiment and 
separated to 3 groups (Figure 2.11). The first group contained 3 mice used as a control, 
no myeloma injected. The second group contained 3 mice that were inoculated with 
5T33MM-GFP cells (2x10
6
 cells/mouse) at day 0. The third group contained 3 mice that 
were inoculated with 5TGM1-GFP cells (2x10
6
 cells/mouse) at day 0. After 21 days all 
mice were sacrificed. Calvariae were excised carefully and analysed under the Lightools 
system to obtain optical images of fluorescent tumour growth in calvarial BM.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.11: Experiment design to determine the tumour growth in calvarial 
bone marrow. 3 x 6 week old male, C57BL/KaLwRijHsd mice were injected with 
200μl of PBS as control mice at day 0 (group 1). 3 x 6 week old male, 
C57BL/KaLwRijHsd mice were injected with 200μl of 2x106 cells/mouse 5T33MM-
GFP cells at day 0 (group 2). 3 x 6 week old male, C57BL/KaLwRijHsd mice were 
injected with 200μl of 2x106 cells/mouse 5TGM1-GFP cells at day 0 (group 3). At 
day 21 all mice sacrificed and calvarial bone were analysed under the light tool.  
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2.2.20 Study to determine the single cell numbers arriving in C57BL/KaLwRijHsd 
calvarial BM 
12 male C57BL/KaLwRijHsd mice, 6 weeks of age, were used in this experiment and 
separated into 4 groups (Figure 2.12). The first group contained 3 mice were injected 
with 5T33MM-DiD cells (2x10
6
 cells/mouse) at day 0. The second group contained 3 
mice were injected with 5TGM1-DiD cells (2x10
6
 cells/mouse) at day 0. After 3 days 
groups 1 and 2 mice were sacrificed to determine the single cell numbers in calvarial 
BM in the early stage of disease. The third groups contained 3 mice were injected with 
5T33-DiD cells (2x10
6
 cells/mouse) at day 0. The fourth group contained 3 mice were 
injected with 5TGM1-DiD cells (2x10
6
 cells/mouse) at day 0. After 21 days groups 3 
and 4 were sacrificed to determine the quiescent cell numbers in calvarial BM in the late 
stage of disease. Zeiss 510 multiphoton laser scanning microscope was used to 
determine the cell numbers in C57BL/KalwRij calvarial BM.  
 
 
 
 
 
 
 
 
 
 
 
Figure 2.12: Experiment design to determine single cell numbers in calvarial 
bone marrow. 3 x 6 week old male, C57BL/KalwRij mice were injected with 200μl 
of 2x10
6
 cells/mouse 5T33MM-DiD cells at day 0 (group 1). 3 x 6 week old male, 
C57BL/KalwRij mice were injected with 200μl of 2x106 cells/mouse 5TGM1-DiD 
cells at day 0 (group 2). At day 3 groups 1 and 2 mice were sacrificed and calvarial 
bone were analysed under the Zeiss 510 multiphoton laser scanning microscope. 3 x 6 
week old male, C57BL/KalwRij mice were injected with 200μl of 2x106 cells/mouse 
5T33MM-DiD cells at day 0 (group 3). 3 x 6 week old male, C57BL/KalwRij mice 
were injected with 200μl of 2x106 cells/mouse 5TGM1-DiD cells at day 0 (group 4). 
After 21 groups 3 and 4 mice were sacrificed and calvarial bone were analysed under 
the Zeiss 510 multiphoton laser scanning microscope.  
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2.2.21 Assessment of the cellular distribution of N-cadherin in vivo  
9 male C57BL/KaLwRijHsd mice, 6 weeks of age, were used in this experiment and 
separated to 3 groups (Figure 2.13). The first group contained 3 mice and were 
inoculated with PBS at day 0 as a negative control. The second group contained 3 mice 
and were inoculated with 5T33MM cells (2x10
6
 cells/mouse) at day 0. The third group 
contained 3 mice and were inoculated with 5TGM1 cells (2x10
6
 cells/mouse) at day 0. 
After 7 days all mice were sacrificed. Calvariae were excised and sections of 
interparietal bones of calvariae were dissected for immunohistochemistry. Bone sections 
were de-waxed in xylene and re-hydrated twice in absolute alcohol, 95% alcohol and 
70% alcohol. Sections were incubated in 3% hydrogen peroxide in water for 15 minutes 
to block the endogenous peroxidase activity. For antigen retrieval sections were 
incubated with 10 mM of tri-sodium citrate (pH6) for 25 minutes at 80 ºC and cooled 
for 10 minutes. Rabbit monoclonal anti-N-cadherin antibody (Millipore, UK) and 
donkey anti-rabbit IgG antibodies (R&D systems, UK), isotype negative control were 
used as described in section 2.2.11.5.  
 
 
 
 
 
 
 
 
 
Figure 2.13: Experiment design to determine the cellular distribution of               
N-cadherin in vivo. 9 x 6 week old male, C57BL/KaLwRijHsd mice were inoculated 
with 200μl of PBS or myeloma cells (2x106 cells/mouse) at day 0. At day 7 mice 
sacrificed and calvarial bones were carefully dissected for immunohistochemistry.  
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2.2.22 Study to determine the effect of blocking N-cadherin on myeloma 
colonization in bone in vivo  
18 male C57BL/KaLwRijHsd mice, 6 weeks of age, were used in this experiment and 
separated to 3 groups (Figure 2.14). The first group containing 6 mice were inoculated 
with 5T33MM-DiD labelled cells, second group containing 6 mice were inoculated with 
5T33MM-DiD labelled cells pre-treated with isotype control antibody and third group 
containing 6 mice were inoculated with 5T33MM-DiD labelled cells pre-treated with 
anti-N-cadherin antibody (2x10
6
 cells/mouse) at day 0. After 3 days these mice were 
sacrificed to determine the effect of blocking N-cadherin on myeloma arrival and 
colonization in calvariae. Calvariae were excised and sections of frontal, parietal, and 
interparietal bones were dissected (Figure 2.15). Sections were analysed under Zeiss 
510 multiphoton laser scanning microscope to determine the myeloma cell numbers and 
the distance of myeloma cells to bone between different groups in C57BL/KalwRij 
calvarial BM: frontal, parietal and interparietal.  
 
 
 
 
 
 
 
 
 
 
Figure 2.14: Experiment design to determine the effect of blocking N-cadherin on 
myeloma colonisation in bone in vivo. 6 x 6 week old male, C57BL/KalwRij mice 
were inoculated with 200μl of 2x106 cells/mouse 5T33MM-DiD cells, 6 x 6 week old 
male, C57BL/KalwRij mice were inoculated with 200μl of 2x106 cells/mouse 
5T33MM-DiD cells pre-treated with isotype control antibody and 6 x 6 week old 
male, C57BL/KalwRij mice were inoculated with 200μl of 2x106 cells/mouse 
5T33MM-DiD cells pre-treated with anti-N-cadherin antibody at day 0. At day 3 mice 
were sacrificed and calvarial bone were analysed under the Zeiss 510 multiphoton 
laser scanning microscope.  
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2.2.23 Study to determine the effect of blocking N-cadherin on myeloma bone 
disease in vivo  
9 male C57BL/KaLwRijHsd mice, 6 weeks of age, were used in this experiment and 
separated into 3 groups (Figure 2.16). The first group containing 3 mice were inoculated 
with 5TGM1-DiD labelled cells, second group containing 3 mice were inoculated with 
5TGM1-DiD labelled cells pre-treated with isotype control antibody and third group 
containing 3 mice were inoculated with 5TGM-DiD labelled cells pre-treated with anti-
N-cadherin antibody (2x10
6
 cells/mouse) at day 0. After 21 days these mice were 
sacrificed and calvariae examined to determine the effect of blocking N-cadherin on 
myeloma bone disease in vivo. Calvariae were excised and sections of frontal, parietal, 
and interparietal bones were dissected (Figure 2.17). Sections (left side) were analysed 
under Zeiss 510 multiphoton laser scanning microscope to determine the quiescent 
myeloma cell numbers and the distance of quiescent myeloma cells to bone between 
different groups in C57BL/KalwRij calvarial BM. Sections (right side) were analysed 
using the µCT to determine the bone disease.  
Figure 2.15: A microCT three-
dimensional reconstruction of 
C57BL/KaLwRijHsd calvariae 
showing areas selected for 
multiphoton (MP) analysis. Frontal 
(F), parietal (P), and interparietal (IP) 
bones were carefully dissected, as 
denoted by blue oblongs. Section 
were analysed under Zeiss 510 
multiphoton laser scanning 
microscope to determine the myeloma 
cell numbers and the distance of 
myeloma cells to the bone between 
different groups: 5T33MM, 5T33MM 
pre-treated with isotype control 
antibody. 5T33MM pre-treated with 
anti-N-cadherin antibody.  
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Figure 2.16: Experiment design to determine the effect of blocking N-cadherin on 
myeloma bone disease in vivo. 3 x 6 week old male, C57BL/KalwRij mice were 
inoculated with 200μl of 2x106 cells/mouse 5TGM1-DiD cells, 3 x 6 week old male, 
C57BL/KalwRij mice were inoculated with 200μl of 2x106 cells/mouse 5TGM1-DiD 
cells pre-treated with isotype control antibody and 3 x 6 week old male, 
C57BL/KalwRij mice were inoculated with 200μl of 2x106 cells/mouse 5TGM1-DiD 
cells pre-treated with anti-N-cadherin antibody at day 0. At day 21 mice were 
sacrificed and calvarial bone were analysed.  
Figure 2.17: A microCT three-
dimensional reconstruction of 
C57BL/KaLwRijHsd calvariae 
showing areas selected for µCT, 
histology and MP analysis. Frontal 
(F), parietal (P), and interparietal (IP) 
bones were dissected, as denoted by 
blue oblongs. Sections in left side 
were analysed under Zeiss 510 
multiphoton laser scanning 
microscope to determine the quiescent 
myeloma cell numbers and the 
distance of quiescent myeloma cells to 
bone between different groups. 
Sections in right side were analysed 
using the µCT then stained with H&E 
to determine the bone disease and 
tumour burden, respectively, between 
different groups.  
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2.2.24 Statistical analysis  
Statistical analyses were performed with the statistical software package, GraphPad 
Prism 5 version 5.04 for Windows. Firstly the data were checked if they were normally 
distributed or not by using the D'Agostino and Pearson normality test. The data were 
analysed using an ANOVA test (one-way analysis of variance) for more than two group 
comparisons or with t test for two group comparisons if the data was normally 
distributed. Tukey's test was used as post-hoc analysis when ANOVA test was used in 
normal distribution data. When data not normally distributed, ANOVA test (non-
parametric Kruskal-Wallis test) was used for more than two group comparisons or non-
parametric Mann–Whitney test was used for two group comparisons. Dunns test was 
used as post-hoc analysis when ANOVA test was used in not normally distributed data. 
Data were considered statistically significant when a p-value was equal to or less than 
0.05. Results are expressed as mean ± values of standard deviation (SD).  
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3 Chapter 3: The stem cell marker N-cadherin is 
expressed by myeloma cells and osteoblasts  
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3.1 Introduction   
Characterising the putative ‘myeloma niche’ (a myeloma permissive microenvironment) 
may offer novel therapeutic targets to treat patients. The concept of a specialised niche 
“HSC niche” has recently been described for HSCs. In the present project the 
hypothesis that colonising myeloma cells retain the molecular machinery of HSCs and 
modify the HSC niche to establish the myeloma bone disease has been considered. 
Several secreted factors and receptors have been shown to be expressed and may have 
functions in mediating the cellular interactions that occur between osteoblasts and 
HSCs. Notch, Tie2, CD44, N-cadherin and CXCR4 are molecules expressed by HSCs 
and bind with their complimentary ligands, Jag1, Ang-1, OPN, N-cadherin and 
CXCL12, respectively on the osteoblasts. These molecular associations: Notch/Jag1, 
Ang-1/ Tie2, OPN/CD44, N-cadherin/N-cadherin and CXCR4/CXCL12 are thought to 
maintain HSCs in a quiescent state in the HSC niche (Calvi et al., 2003, Arai et al., 
2004, Nilsson et al., 2005, Stier et al., 2005, Zhang et al., 2003, Xie et al., 2009, Burger 
and Kipps, 2006). Colonizing myeloma cells may use one or some of these molecules, 
to bind to their complimentary ligands on the osteoblasts to hijack the HSC niche.  
 
The present study focused on one of these molecules, N-cadherin, that has been 
identified as an important regulatory molecule in the HSC niche expressed by both 
HSCs and osteoblasts (Zhang et al., 2003, Xie et al., 2009) and also during tumour 
progression in solid tumours, in which the invasion and metastatic properties acquired 
by cancer cells have been linked to expression of N-adhesion molecules (Li et al., 2001, 
Lascombe et al., 2006, Gravdal et al., 2007). In addition, there is no current publication 
that addresses blocking of N-cadherin in myeloma cells. As N-cadherin is expressed by 
osteoblasts, but not by osteoclasts or osteocytes (Mbalaviele et al., 1995, Ferrari et al., 
2000, Kawaguchi et al., 2001), this study focused on the expression of N-cadherin in 
myeloma cells and osteoblasts. As we were interested in osteoblasts, more osteoblasts 
compared to other cells were expected to be found in calvariae (Nakashima and de 
Crombrugghe, 2003).  
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Puch et al (2001) showed N-cadherin was expressed on a subpopulation of early 
hematopoietic progenitor cells, human CD34
+
 HSCs using RT-PCR, western blot 
analysis and immunofluorescence staining. During the differentiation of CD34
+
 HSCs, 
N-cadherin expression was lost. Treatment of CD34
+
 HSCs with monoclonal anti-N-
cadherin antibodies, GC-4, inhibited the formation of total (colony-forming unit-
culture) CFU-C count. Furthermore, N-cadherin mediated the adhesion of HSCs within 
the bone marrow, which could be inhibited by using anti-N-cadherin antibodies. 
Together these data suggested a direct interaction of HSCs within the bone marrow 
microenvironment via N-cadherin (Puch et al., 2001). In addition, it was shown that 
HSCs home to and reside in the ‘osteoblast niche’ via attachment to N-cadherin+ 
osteoblasts on the endosteal bone surface. Green fluorescent protein-expressing (GFP
+
) 
HSCs were injected in irradiated mice. GFP
+
 HSCs were monitored using ex vivo real-
time imaging technology and immunoassay. It was found that HSCs tended to home to 
the endosteum near N-cadherin
+
 pre-osteoblasts. In contrast, HSCs in the central 
marrow underwent active division suggesting that the endosteum formed a special zone 
to maintain HSCs quiescent (Xie et al., 2009). It is unclear whether myeloma cells 
attach to sites of bone formation, quiescent bone lining cells or remain close to a 
collagen matrix, a known store of growth factors.  
 
In this chapter, primary mouse osteoblasts and myeloma cell lines, 5T33MM and 
5TGM1 were used. In preliminary studies, the conditions for in vitro osteoblastogenesis 
were established. In addition, the expression of N-cadherin at different stages of 
osteoblastogenesis and in myeloma cell lines; 5T33MM and 5TGM1, was described and 
the potential mechanisms colonising myeloma cells may exploit to establish colonies 
within the BM microenvironment were evaluated.  
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3.2 Hypothesis and objectives of this chapter 
3.2.1 Hypothesis:  
The stem cell marker N-cadherin is expressed by myeloma cells and osteoblasts. 
 
3.2.2 Objectives:  
To test this hypothesis, I have:  
1. Developed a model of mouse osteoblastogenesis.  
2. Determined and quantified the relative expression of N-cadherin mRNA during 
osteoblastogenesis.  
3. Immuno-localized N-cadherin protein in osteoblasts.  
4. Determined the percentage and relative expression of N-cadherin protein during 
osteoblastogenesis.  
5. Determined and quantified the relative expression of N-cadherin mRNA in 
myeloma cell lines, 5T33MM and 5TGM1.  
6. Immuno-localized N-cadherin protein in myeloma cell lines, 5T33MM and 
5TGM1.  
7. Determined the percentage and relative levels of N-cadherin protein in myeloma 
cell lines, 5T33MM and 5TGM1.  
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3.3 Materials and methods  
3.3.1 Cell culture  
Non-adherent 5T33MM cells and 5TGM1 cells were cultured separately in vitro in 
RPMI1640 medium (Invitrogen, UK) containing 10% FCS, 100 units/ml Penicillin / 
100 µg/ml of Streptomycin, 1% Na2PO3 and 1% non-essential amino acids (NEAA) in 
T75 flasks as described in section 2.1.7.1 and section 2.1.7.2. Mouse primary 
osteoblasts were obtained from calvarial bones of 2-4 day old C57Bl/6J mice, (Harlan, 
UK). Mouse primary osteoblasts were prepared and cultured in vitro in T75 flasks as 
described in section 2.1.9.  
 
3.3.2 An in vitro model of mouse osteoblastogenesis 
Osteoblastogenesis is a complex multi-step process, in which osteoblasts derived from 
MSCs, proliferate, maturate and lay down in a matrix which is then mineralised. These 
sequential actions may define unique subsets of osteoblasts residing in discreet pockets 
or niches within bone, depending on functional activity. These niches may maintain 
levels of a specific array of cytokines and growth factors that enable myeloma cell 
colonization. Mouse primary osteoblasts were obtained from calvarial bones of 2-4 day 
old C57Bl/6J mice as in previous published methods (Garcia et al., 2002, Hay et al., 
2009a) and prepared as described in section 2.1.9. In vitro, cells were seeded in T75 
flasks and passaged as described in section 2.2.2 to obtained the required number of 
cells. The cells were transferred to 96 well plates, 24 well plates, 8 chambers slides and 
T25 flasks, and differentiated for 4 weeks (28 days) in osteogenic medium to form 
mature functional osteoblasts (see figure 3.1). ALP activity, alizarin red staining, RT-
PCR, TaqMan, flow cytometry, immuno-staining and western blot experiments were 
used to analysed osteoblastogenesis.  
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3.3.3 Osteoblasts differentiation  
6x10
3
 cells/cm
2
 of mouse primary osteoblasts were seeded and differentiated for to 
mature functional osteoblasts in osteogenic media as described in section 2.2.4. ALP 
activity for mouse primary osteoblasts was analysed as described in section 2.2.4.1. 
Total DNA content of primary osteoblasts was determined with a PicoGreen double-
stranded DNA quantitation reagent as described in section 2.2.4.2 and these 
measurements used to normalise the ALP activity to cell DNA content. Matrix 
deposited by mouse primary osteoblasts was analysed as described in section 2.2.4.3 
during differentiation. ImageJ software was used to quantify the red colour of alizarin 
red staining as described in section 2.2.4.3.  
 
 
Figure 3.1: Experiment design of mouse osteoblastogenesis. Extracted osteoblasts 
from mouse calvariae were seeded in T-75 flasks for expansion of cell numbers. Cells 
were harvested from a nearly confluent flask by trypsinisation. Day 0; 6x10
3
 cells/cm
2
 
of mouse primary osteoblasts was re-suspended in 10% α-MEM medium and seeded 
in 96 well plates, 24 well plates, chamber slides and flasks. Cells were then incubated 
at 37 ˚C with 5% CO2. Osteoblasts were differentiated using osteogenic medium. Day 
2; α-MEM medium was replaced by osteogenic medium to start osteoblastogenesis 
process. Osteoblastogenesis was analyzed at days 7, 14, 21 and 28 using ALP activity, 
alizarin red staining, RT-PCR, TaqMan, flow cytometry, immuno-staining and 
western blot experiments. Medium was changed every 2 days. 
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3.3.4 Determination of the effect of dexamethasone on osteoblastogenesis  
Mouse primary osteoblasts were seeded at day -2, incubated with osteogenic media at 
day 0, and ALP activity and mineralization of primary osteoblasts were analyzed at days 
7, 14, 21 and 28. Gilbert et al (2002) differentiated osteoblasts using α-MEM medium 
containing; 10% FCS, 10 mM of β-glycerophosphate and 50 µg/ml of ascorbic (Gilbert 
et al., 2002). However, Bancroft et al (2002) differentiated osteoblasts using α-MEM 
medium containing; 10% FCS, 10 mM of β-glycerophosphate, 50 µg/ml of ascorbic 
acid and 10
-8
 M of dexamethasone (Bancroft et al., 2002). Therefore, in my study 
different osteogenic medium were used to determine if adding 10
-8
 M of dexamethasone 
promotes the differentiation of osteoblasts. Cells were incubated in different 
formulations and regimens of osteogenic medium as described in the following table 
(Table 3.1).  
 
Table 3.1: Different formulation and regimens of osteogenic medium 
Series 1
st
 formulation and regimens 
(Days 0-14) 
2
nd
 formulation and regimens 
(Days 15-28) 
1 α-MEM medium + 10% FCS + 10 
mM of β-glycerophosphate + 50 
µg/ml of ascorbic acid.  
As 1
st
 formulation  
2 α-MEM medium + 10% FCS + 10 
mM of β-glycerophosphate + 50 
µg/ml of ascorbic acid.  
α-MEM medium + 10% FCS + 10 
mM of β-glycerophosphate + 50 
µg/ml of ascorbic acid + 10
-8
 M 
of dexamethasone.  
3 α-MEM medium + 10% FCS + 10 
mM of β-glycerophosphate + 50 
µg/ml of ascorbic acid + 10
-8
 M 
of dexamethasone.  
As 1
st
 formulation  
4 α-MEM medium + 10% FCS, 10 
mM of β-glycerophosphate, 50 
µg/ml of ascorbic acid + H2O.  
As 1
st
 formulation  
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3.3.5 Molecular biology   
3.3.5.1 RNA isolation and quantitation  
For osteoblasts, nearly confluent T25 flasks were washed twice with PBS and total 
RNA was extracted from primary osteoblasts at different stages of development using 
TriZol. For myeloma cell lines 5T33MM and 5TGM1 cells around 1x10
6
 cells were 
washed twice with PBS and total RNA was extracted using TriZol. Total RNA was 
precipitated using isopropanol and re-suspended in RNase and DNase free H2O as 
described in section 2.2.5.1. NanoDrop ND 1000 Spectrophotometer (NanoDrop 
Technologies, USA) was used to quantify total RNA in the solution as described in 
section 2.2.5.2.  
 
3.3.5.2 cDNA synthesis  
According to the manufacturer's instructions (Invitrogen, UK), known concentrations of 
RNA were treated with DNase I to remove any genomic DNA contamination. RNAs 
were then transcribed to cDNA using SuperScript™ II reverse transcriptase (Invitrogen, 
UK) as described in section 2.2.5.4.  
 
3.3.5.3 RT-PCR and sequencing   
NCBI, UCSC and Ensemble were searched against N-cadherin, NM_007664.4 mouse 
RefSeq gene and GAPDH (control), NM_008084.2 mouse RefSeq gene. PCR primers 
used to amplify N-cadherin and GAPDH (see table 2.2 in materials and methods) in 
mouse primary osteoblasts, 5T33MM cells and 5TGM1 cells were designed as 
described in section 2.2.5.5. According to the manufacturer's instructions (Invitrogen, 
UK), RT-PCR was performed using Platinum Taq DNA polymerase kit (Invitrogen, 
UK) to amplify N-cadherin and GAPDH, a control (Hay et al., 2009b, Arai et al., 2012) 
as described in section 2.2.5.6. PCR products were run in a 1% agarose (Invitrogen, 
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UK) gel and stained with ethidium bromide (Fluka, Switzerland) as described in section 
2.2.5.7. The QIAquick Gel Extraction kit was used according to the manufacturer's 
instructions (QIAGEN Ltd, UK) to extract and purify DNA fragments from agarose gels 
as described in section 2.2.8. DNA samples were sent into the DNA Sequencing Core 
Facility housed within the University of Sheffield, Medical School and sequenced 
(http://genetics.group.shef.ac.uk/dna-sequencing.html).  
 
3.3.5.4 TaqMan analysis   
Nearly confluent T25 flasks were washed twice with PBS and total RNA was extracted 
from primary osteoblasts at different stages of development and from myeloma cells, 
and cDNA was synthesised. N-cadherin mRNA, Runx2 mRNA, COL1A2 mRNA and 
osteocalcin mRNA primers (see table 2-3 in materials and methods) were used to 
quantify the expression of these molecules during mouse primary osteoblast 
differentiation and in myeloma cells using TaqMan. Universal master Mix II (Applied 
biosystems, UK) was used as described in section 2.2.5.10.  
 
3.3.6 Immunofluorescence detection of N-cadherin protein in osteoblasts  
Osteoblasts were seeded and differentiated as described in section 2.2.4. Cells were 
washed twice with PBS then fixed in 4% paraformaldehyde. Rabbit monoclonal anti-N-
cadherin antibody (Millipore, UK) and donkey anti-rabbit IgG antibodies (R&D 
systems, UK), secondary antibody were used as described in section 2.2.6.1. Slides 
were mounted using prolong mounting medium containing DAPI stain (Invitrogen, 
UK), DAPI stain was used to stain nuclei. Images were acquired using a Zeiss 510 
microscope.  
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3.3.7 Immunocytochemistry detection of N-cadherin protein in myeloma cells: 
5T33MM and 5TGM1 cells   
1x10
6
 cells/ml of myeloma cells were re-suspended and fixed in 4% paraformaldehyde 
then spun onto slides using a cytospin cassette. Rabbit monoclonal anti-N-cadherin 
antibody (Millipore, UK) and biotinylated anti-rabbit IgG antibodies (R&D systems, 
UK), secondary antibody were used as described in section 2.2.6.3.  
 
3.3.8 Microscopy  
Osteomeasure software version 4.10 (Osteomerics Incorporated, Atlanta, USA) was 
used with a Leitz DMRB microscope and a drawing tablet, (CalComp Drawing Broad 
III) to determine the N-cadherin when biotinylated anti-rabbit IgG antibodies (R&D 
systems, UK), secondary antibody was used as described in section 2.2.14.2. A Zeiss 
510 Multiphoton Laser Scanning Microscopy was used to visualise fluorescence as 
described in section 2.2.14.1.  
 
3.3.9 Flow cytometry  
Lightning-Link
TM
 Atto637 conjugation kit (Innova Biosciences, UK) was used to label 
the anti-N-cadherin antibody, GC-4 (Sigma, UK) and the mouse IgG antibody (Vector 
laboratories, UK), isotype negative control as described in section 2.2.7.1. To determine 
the expression of N-cadherin protein by flow cytometry, adherent cells were harvested 
as described in section 2.2.7.2. 5x10
5
 of fixed primary osteoblasts, 5T33MM cells and 
5TGM1 cells were stained as described in section 2.2.7.3.  
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3.3.10 Western blot  
Proteins were extracted from ~80% confluent cells and quantified using the BCA 
protein assay. 10 μg of protein samples were separated on 12.5% SDS-PAGE for        
N-cadherin and 15% SDS-PAGE for β-actin, blotted on PVDF membranes and probed 
with anti-N-cadherin antibody and/or with anti-β-actin as housekeeping genes. Rabbit 
monoclonal anti-N-cadherin antibody (Millipore, UK) (1:1000 dilution) and donkey 
anti-rabbit IgG antibodies (R&D systems, UK) (1:1000 dilution), secondary antibody 
were used as described in methods in section 2.2.8.  
 
3.3.11 Statistical analysis  
The data were analysed using an ANOVA test (one-way analysis of variance) for more 
than two group comparisons or with t test for two group comparisons if the data was 
normally distributed. Tukey's test was used as post-hoc analysis when ANOVA test was 
used in normal distribution data. When data not normally distributed, ANOVA test 
(non-parametric Kruskal-Wallis test) was used for more than two group comparisons or 
non-parametric Mann–Whitney test was used for two group comparisons. Dunns test 
was used as post-hoc analysis when ANOVA test was used in not normally distributed 
data. Data were considered statistically significant when a p-value was equal to or less 
than 0.05. Results are expressed as mean ± values of standard deviation (SD).   
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3.4 Results  
3.4.1 Optimising a model of mouse osteoblastogenesis  
3.4.1.1 ALP activity during osteoblast differentiation  
ALP activity was used as an early osteoblast differentiation marker. Figure 3.2 panel A 
shows ALP activity of primary osteoblasts incubated in the first series in which cells 
were incubated in α-MEM medium containing; 10% FCS, 10 mM of                             
β-glycerophosphate and 50 µg/ml of ascorbic acid for 28 days. The result demonstrated 
statistically significant increases in ALP activity on day 14 compared to day 7 
(60.03±8.50 versus 11.48±1.23, p<0.001) then a statistically significant decrease in ALP 
activity on day 21 and day 28.  
 
Figure 3.2 panel B shows ALP activity of primary osteoblast incubated in the second 
series in which cells were incubated in α-MEM medium containing; 10% FCS, 10 mM 
of β-glycerophosphate and 50 µg/ml of ascorbic acid for 14 days and at day 15,   10-8 M 
of dexamethasone was added to the osteogenic medium to promote differentiation. The 
result demonstrated statistically significant increases in ALP activity on day 14 
compared to day 7 (51.55±5.75 versus 12.10±1.07, p<0.001) then a statistically 
significant decrease on day 21 and day 28. Dexamethasone did not increase overall ALP 
activity in series 2.  
 
Figure 3.2 panel C shows ALP activity of primary osteoblast incubated in the third 
series in which cells were incubated in α-MEM medium containing; 10% FCS, 10 mM 
of β-glycerophosphate, 50 µg/ml of ascorbic acid and 10-8 M of dexamethasone for 28 
days. The result demonstrated statistically significant increases in ALP activity on day 
14 compared to day 7 (67.33±8.68 versus 11.71±1.19, p<0.001) then a statistically 
significant decrease on day 21 and day 28. Dexamethasone did not increase overall ALP 
activity in series 3.  
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Figure 3.2 panel D shows ALP activity of primary osteoblast incubated in the fourth 
series in which cells were incubated in α-MEM medium containing; 10% FCS, 10 mM 
of β-glycerophosphate, 50 µg/ml of ascorbic acid and distilled water as a control for 
dexamethasone. The result demonstrated statistically significant increases in ALP 
activity on day 14 compared to day 7 (60.34±7.14 versus 11.05±0.97, p<0.001) then 
statistically significant decreased on day 21 and day 28.  
 
3.4.1.2 Alizarin red staining during osteoblast differentiation  
Alizarin red staining was used as a mineralization marker. Figure 3.3 panel A shows the 
graph of the mineralization marker in the first series in which cells were incubated in   
α-MEM medium containing; 10% FCS, 10 mM of β-glycerophosphate and 50 µg/ml of 
ascorbic acid for 28 days. The result demonstrated statistically significant increases in 
the mineralization marker on day 21 compared to day 7 (30.96±3.92 versus 2.37±1.38, 
p<0.001) and on day 28 compared to day 7 (71.27±2.80 versus 2.37±1.38, p<0.001).  
 
Figure 3.3 panel B shows the graph of the mineralization marker in the second series in 
which cells were incubated in α-MEM medium containing; 10% FCS, 10 mM of          
β-glycerophosphate and 50 µg/ml of ascorbic acid for 14 days and at day 15,   10-8 M of 
dexamethasone was added to the osteogenic medium to promote differentiation. The 
result demonstrated statistically significant increases in the mineralization marker on 
day 21 compared to day 7 (48.35±5.06 versus 5.99±3.80, p<0.001) and on day 28 
compared to day 7 (95.79±4.22 versus 5.99±3.80, p<0.001). Dexamethasone did not 
increase overall mineralization in series 2.  
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Figure 3.3 panel C shows the graph of mineralization marker in the third series in which 
cells were incubated in α-MEM medium containing; 10% FCS, 10 mM of                     
β-glycerophosphate, 50 µg/ml of ascorbic acid and 10-8 M of dexamethasone for 28 
days. The result demonstrated statistically significant increases in the mineralization 
marker on day 14 compared to day 7 (22.91±4.18 versus 4.34±0.53, p<0.001), day 21 
compared to day 7 (69.44±4.55 versus 4.34±0.53, p<0.001) and on day 28 compared to 
day 7 (95.06±4.28 versus 4.34±0.53, p<0.001). Dexamethasone did not increase overall 
mineralization in series 3.  
 
Figure 3.3 panel D shows the graph of mineralization marker in the fourth series in 
which cells were incubated in α-MEM medium containing; 10% FCS, 10 mM of          
β-glycerophosphate, 50 µg/ml of ascorbic acid and distilled water as a control for 
dexamethasone. The result demonstrated statistically significant increases in the 
mineralization marker on day 21 compared to day 7 (24.33±5.84 versus 1.13±0.21, 
p<0.001) and on day 28 compared to day 7 (61.55±5.39 versus 1.13±0.21, p<0.001).  
 
Figure 3.4 shows that there was an increase in the mineralization in series 2 and series 3 
compared to series 1 and series 4. However, the results of alizarin red analysis showed 
there are no differences between series 2 and series 3 (95.79±4.220 versus 95.06±3.026, 
p>0.05) of osteogenic medium on day 28 as osteoblasts are mature (see figure 3.4). 
Series 2 (10% FCS, 10 mM of β-glycerophosphate and 50 µg/ml of ascorbic acid for 14 
days and at day 15, 10
-8
 M of dexamethasone was added) of osteogenic medium was 
chosen as a differentiation medium in this project.  
 
 
 
Determining the role of N-cadherin in the formation of the myeloma niche 
  
 Page 98 
 
Figure 3.2: ALP activity during osteoblast differentiation. Primary osteoblasts 
were differentiated in four different osteogenic medium. Panel A shows the first 
series, 10% FCS, 10 mM of β-glycerophosphate and 50 µg/ml of ascorbic acid for 28 
days. Panel B shows the second series, 10% FCS, 10 mM of β-glycerophosphate and 
50 µg/ml of ascorbic acid for 14 days and at day 15, 10
-8
 M of dexamethasone was 
added. Panel C shows the third series, 10% FCS, 10 mM of β-glycerophosphate, 50 
µg/ml of ascorbic acid and 10
-8
 M of dexamethasone for 28 days. Panel D shows the 
fourth series, 10% FCS, 10 mM of β-glycerophosphate, 50 µg/ml of ascorbic acid and 
distilled water as a control for dexamethasone. ALP activity data shows there are no 
differences between all conditions of osteogenic medium. *** = p<0.001.                  
** = p<0.01. * = p<0.05. ANOVA test was used. (n=3). 
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Figure 3.3: Alizarin red staining during osteoblast mineralization. Primary 
osteoblasts were differentiated in different osteogenic medium. Panel A shows the 
first series, 10% FCS, 10 mM of β-glycerophosphate and 50 µg/ml of ascorbic acid 
for 28 days. Panel B shows the second series, 10% FCS, 10 mM of β-
glycerophosphate and 50 µg/ml of ascorbic acid for 14 days and at day 15, 10
-8
 M of 
dexamethasone was added. Panel C shows the third series, 10% FCS, 10 mM of β-
glycerophosphate, 50 µg/ml of ascorbic acid and 10
-8
 M of dexamethasone for 28 
days. Panel D shows the fourth series, 10% FCS, 10 mM of β-glycerophosphate, 50 
µg/ml of ascorbic acid and distilled water as a control for dexamethasone Alizarin red 
staining data showed there is no difference between all series of osteogenic medium. 
*** = p<0.001. ANOVA test was used. (n=3). 
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Figure 3.4: Differences in the alizarin red staining between different series on 
day 28 as the osteoblasts are mature. Primary osteoblasts were differentiated in 
different osteogenic medium. There are no differences between series 2 and series 3 
(95793±4.220 versus 95.06±3.026, p>0.05) of osteogenic medium on day 28 as 
osteoblasts are mature. Series 2 (10% FCS, 10 mM of β-glycerophosphate and 50 
µg/ml of ascorbic acid for 14 days and at day 15, 10
-8
 M of dexamethasone was 
added) of osteogenic medium was chosen as a differentiation medium in this project. 
ANOVA test was used. (n=3). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
3.4.2 Evaluation of the expression of osteoblast differentiation markers  
3.4.2.1 ALP activity increased during osteoblast differentiation  
The early stage differentiation of mouse primary osteoblasts was analyzed using the 
ALP activity assay. Cells were seeded on day 0 and ALP activity was analyzed on days 
7, 14, 21 and 28, respectively. Cells were incubated in osteogenic medium; α-MEM 
containing 10% FCS, 10 mM of β-glycerophosphate and 50 µg/ml of ascorbic acid for 
14 days. At day 15, a 10
-8
 M concentration of dexamethasone was added to the 
osteogenic medium to promote differentiation. ALP activity was normalized to cell 
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Figure 3.5: ALP activity increased during culture of primary osteoblasts in 
osteogenic medium day 14, 21 and decreased day 28. Primary osteoblasts were 
differentiated in osteogenic medium; 10 mM of β-glycerophosphate, 50 μg/ml of 
ascorbic acid from day 0 to day 14. 10
-8
 M dexamethasone was added to the 
osteogenic medium at day 15 to increase differentiation. ALP activity was normalised 
to cell DNA content. Data shows significant increases in the ALP activity of primary 
osteoblasts on day 14 and 21 comparing to day 7, and decreases on day 28.             
*** = p<0.001. ** = p<0.01. * = p<0.05. ANOVA test was used. (n=3). 
DNA content. Figure 3.5 shows the results of ALP activity of primary osteoblasts in 
three independent experiments (n=3). The result demonstrated statistically significant 
increases in ALP activity of primary osteoblasts on day 14 compared to day 7 
(78.65±13.70 versus 12.87±0.85, p<0.001) and on day 21 compared to day 7 
(131.90±24.81 versus 12.87±0.85, p<0.001). On day 28, ALP activity was significantly 
decreased compared to ALP activity on day 21 (62.74±11.68 versus 12.87±0.85, 
p<0.001).  
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3.4.2.2 Alizarin red staining increased during osteoblasts differentiation   
The late stage differentiation of mouse primary osteoblasts was analyzed using alizarin 
red staining. Cells were seeded on day 0 and mineralization of primary osteoblasts was 
analyzed on days 7, 14, 21 and 28, respectively. Cells were incubated in osteogenic 
medium; α-MEM containing 10% FCS, 10 mM of β-glycerophosphate and 50 µg/ml of 
ascorbic acid for 14 days. On day 15, a 10
-8
 M concentration of dexamethasone was 
added to the osteogenic medium to promote differentiation. ALP activity was 
normalized to cell DNA content. Figure 3.6 shows the results of alizarin red staining, as 
a matrix mineralization marker in primary osteoblasts in three independent experiments 
(n=3) and demonstrated that there was a statistically significant increase during 
osteoblastogenesis. The results showed statistically significant increases in the 
mineralization marker on day 14 compared to day 7 (29.60±6.35 versus 1.26±0.58, 
p<0.001), day 21 compared to day 7 (52.58±4.38 versus 1.26±0.58, p<0.001) and on 
day 28 compared to day 7 (67.26±8.12 versus 1.26±0.58, p<0.001).  
 
3.4.2.3 Assessment of the quality of the mouse primary osteoblast purified RNAs and 
synthesized cDNAs  
Total RNA was extracted over 4 weeks differentiation of primary osteoblasts cultured in 
vitro. Figure 3.7 shows the electrophoresis of RNA isolated from primary osteoblasts 
during differentiation; days 7, 14, 21 and 28. Clear dens 28S and 18S bands, ribosomal 
RNAs, were present and little low molecular weight fragments indicating of good 
quality undamaged RNA. Figure 3.8 shows RT-PCR of GAPDH with expected size of 
354 bp in differentiated mouse primary osteoblasts after reverse transcription (+RT) or 
no reverse transcription (-RT). Expression of GAPDH in +RT and not in -RT indicated 
that there was no genomic contamination in cDNA preparation.  
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Figure 3.6: Mineralisation increased during culture of primary osteoblasts in 
osteogenic medium. Primary osteoblasts were differentiated in osteogenic medium; 
10 mM of β-glycerophosphate, 50 μg/ml of ascorbic acid from day 0 to day 14. 10-8 M 
dexamethasone was added to the osteogenic medium on day 15 to help cells more 
differentiated. Data shows significant increases in the mineralisation of primary 
osteoblast during cells differentiation from day 0 to day 28. *** = p<0.001.               
** = p<0.01. ANOVA test was used. (n=3). 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
Figure 3.7: Electrophoresis of total mRNA isolated from cells during 
osteoblastogenesis. RNA was extracted from mouse primary osteoblasts at days 7, 14, 
21 and 28. Clear 28S and 18S bands, ribosomal RNAs, were indicates of good quality 
and undamaged RNA. (n=3). 
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3.4.2.4 Assessment of the relative levels of expression of Runx2 mRNA, COL1A2 
mRNA and osteocalcin mRNA  
The level of expression of osteoblast markers; Runx2, COL1A2 and osteocalcin genes 
were analysed using TaqMan. Expression of these genes was normalised to the 
expression of a housekeeping gene, β-actin. Figure 3.9 panel A shows that there was a 
positive correlation between increased Runx2 mRNA expression and primary osteoblast 
differentiation. Data showed statistically significant increases in the relative expression 
of Runx2 mRNA on day 28 compared to day 7 (169.10±46.74 versus 3.18±1.51, 
p<0.01). Figure 3.9 panel B shows that there was a positive correlation between 
increased COL1A2 mRNA expression and primary osteoblasts differentiation. There 
was a statistically significant increase in the relative expression of COL1A2 mRNA in 
day 28 compared to day 7 (734.60±283.80 versus 3.20±0.90, p<0.01). Figure 3.9    
Figure 3.8: RT-PCR analysis of GAPDH mRNA during osteoblastogenesis. RNA 
was extracted from mouse primary osteoblasts at days 7, 14, 21 and 28. RT-PCR was 
performed using GAPDH, gene specific primers. GAPDH expression was detected in 
+RT with expected size of 354 bp and not in - RT demonstrating no genomic DNA 
contamination in prepared cDNAs. Water was used as a negative control. (n=3). 
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panel C shows the expression of Osteocalcin mRNA during primary osteoblasts 
differentiation. There was no statistically significant increase in the relative expression 
of Osteocalcin mRNA during osteoblastogenesis in these experiments.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.9: TaqMan analysis of osteoblast marker genes; Runx2, COL1A2 and 
osteocalcin expression during mouse primary osteoblasts differentiation. RNA 
was extracted from mouse primary osteoblasts at days 7, 14, 21 and 28. The relative 
expression of osteoblast marker genes was adjusted relative to expression of 
housekeeping gene, β-actin. Data shows significant increases in Runx2 mRNA and 
COL1A2 mRNA in mature osteoblasts (day 28) compared with the expression of 
these genes in pre-osteoblasts (day 7). However, data shows there is no difference in 
the relative expression of osteocalcin (OCN) mRNA during osteoblastogenesis. Table 
3.1 shows the CT values of Runx2, COL1A2, osteocalcin (OCN) and β-actin.           
** = p<0.01. * = p<0.05. ANOVA test was used. Table 3.1 shows the CT value of 
Runx2 mRNA, COL1A2 mRNA, OCN mRNA and β-actin mRNA. (n=3). 
Table 3.1: CT value  
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3.4.3 Determination and quantification of the relative expression of N-cadherin 
mRNA during osteoblastogenesis   
3.4.3.1 N-cadherin mRNA was expressed during osteoblast differentiation  
Total RNA were extracted and cDNAs were synthesised from mouse primary 
osteoblasts cultured in vitro and differentiated up to 4 weeks. Figure 3.10 shows that     
N-cadherin was expressed during mouse primary osteoblasts differentiation; days 7, 14, 
21 and 28. End-point RT-PCR is not a quantitative technique and was only used initially 
to establish if N-cadherin specific mRNA was expressed in cells. Bands were excised 
and sent for sequencing (Figure 3.11) and gave 100% homology with GenBank (Figure 
3.12). Real time PCR (TaqMan) was used to study the relative levels of expression of 
N-cadherin during mouse primary osteoblasts differentiation.  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.10: RT-PCR analysis of N-cadherin mRNA during osteoblastogenesis. 
RNA was extracted from mouse primary osteoblasts at days 7, 14, 21 and 28. RT-
PCR was performed using N-cadherin, gene specific primers. Data shows N-cadherin 
was expressed in primary osteoblast during cells differentiation with expected size of 
560 bp. (n=3). 
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Figure 3.12: 
Using genomic 
website to 
identify the 
matching gene. 
Sequence 
received from the 
Core Genomic 
Facility was blast 
in NCBI browser 
(http://blast.ncbi.
nlm.nih.gov/Blast
.cgi) gave 100% 
homology with 
GenBank. (n=3). 
 
Figure 3.11: N-cadherin cDNA sequencing. RNA was extracted from mouse 
primary osteoblasts at days 7, 14, 21 and 28. RT-PCR was performed using              
N-cadherin, gene specific primers. Bands were sequenced in University of Sheffield 
Core Genomic Facility (http://genetics.group.shef.ac.uk/dna-sequencing.html). This 
sequence was received from the Core Genomic Facility. (n=3). 
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3.4.3.2 Relative expression of N-cadherin mRNA increased during osteoblast 
differentiation  
The quantitation expression of N-cadherin mRNA was analysed using TaqMan analysis. 
Expression of N-cadherin was normalised to expression of the housekeeping gene,       
β-actin. Figure 3.13 shows the relative expression of N-cadherin mRNA during the 
differentiation of primary osteoblasts. Data showed a statistically significant increase in 
the relative expression of N-cadherin mRNA on day 28, in mature osteoblasts, 
compared to day 7, pre-osteoblasts, (134.80±37.27 versus 5.53±3.75, p<0.01).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.13: N-cadherin mRNA expression increased during osteoblast 
differentiation. RNA was extracted from mouse primary osteoblasts at days 7, 14, 
21 and 28. Data shows significant increase in the relative expression of N-cadherin 
mRNA in mature osteoblasts (day 28) compared with pre-osteoblasts (day 7).         
** = p<0.01. ANOVA test was used. Table 3.2 shows the CT value of N-cadherin 
mRNA and β-actin mRNA. (n=3). 
Table 3.2: CT value  
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3.4.4 Immuno-localization of N-cadherin protein on osteoblasts  
3.4.4.1 Determination of the optimal concentration of primary antibody required for 
immunofluorescent localization of N-cadherin  
A rabbit monoclonal, anti-N-cadherin antibody (Millipore, UK) and isotype control, 
normal rabbit IgG antibody (R&D systems, UK) were used in these studies. A donkey 
anti-rabbit IgG secondary antibody conjugated to fluorochrome northern light (NL637) 
was used for detection. Figure 3.14 panel A shows positive staining (red fluorescence) 
of N-cadherin when mouse primary osteoblasts were incubated with the primary rabbit 
monoclonal anti-N-cadherin antibody at a 1:50 dilution and no staining was observed 
with isotype control (Figure 3.14 panel B). Figure 3.14 panel C shows no red 
fluorescence staining was observed when mouse primary osteoblasts were incubated 
with rabbit monoclonal anti-N-cadherin antibody at a 1:100 dilution (Figure 3.14 panel 
D shows the negative control isotype at a dilution of 1:100). Therefore, 1:50 dilution 
was chosen as an optimal primary antibody concentration for immunofluorescence.  
 
3.4.4.2 Contiguous expression of N-cadherin was observed on the membranes of 
adjacent osteoblasts  
Rabbit monoclonal anti-N-cadherin antibody (Millipore, UK) or isotype control, normal 
rabbit IgG antibody (R&D systems, UK) were used to determine possible localisation of 
N-cadherin in osteoblast cultures. A donkey anti-rabbit IgG secondary antibody 
conjugated by fluorochrome northern light (NL637) was used for detection. Figure 3.15 
panel A shows specific positive staining (red fluorescence) for N-cadherin and no 
staining with isotype control (Figure 3.15 panel B). Figure 3.15 panel C shows an 
enlarged picture illustrating contiguous expression of N-cadherin protein on the 
membranes of adjacent osteoblasts.  
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Figure 3.14: Immunofluorescence optimization of N-cadherin protein in primary 
osteoblasts. Fixed and permeabilized cells were stained with rabbit monoclonal anti-
N-cadherin primary antibody or isotype control, normal rabbit IgG antibody. Nuclei 
were counterstained with DAPI (blue fluorescence). Cells were examined under Zeiss 
510 multiphoton laser scanning microscope with 20x objective. Data shows there was 
no staining (red fluorescence) at 1:100 antibody dilution (panel C). Panel A shows the 
optimal antibody concentration (1:50 dilution) for N-cadherin (red fluorescence) 
around the cells and no staining with isotype control (panel D) using primary 
osteoblasts. (n=3). 
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Figure 3.15: N-cadherin protein expression in primary osteoblasts. Fixed and 
permeabilized cells were stained with rabbit monoclonal primary anti-N-cadherin 
antibody or isotype control, normal rabbit IgG antibody. Nuclei were counterstained 
with DAPI (blue fluorescence). Cells were examined under Zeiss 510 multiphoton 
laser scanning microscope with 20x objective. Panel A shows the N-cadherin protein 
expression (red fluorescence) around most cells. Panel B shows isotype control with 
no staining. Panel C shows an enlarged picture illustrating contiguously expression of 
N-cadherin (red fluorescence) on the membranes of adjacent osteoblasts. (n=3). 
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3.4.5 Determination of the percentage and relative expression of N-cadherin 
protein during osteoblastogenesis  
3.4.5.1 Determination of the optimal procedures to harvest adherent osteoblasts  
Flow cytometry was performed using a mouse monoclonal primary anti-N-cadherin 
antibody (Sigma, UK) and an isotype control, mouse IgG antibody (Vector laboratories, 
UK). Anti-N-cadherin antibody (Sigma, UK) and mouse IgG antibody (Vector 
laboratories, UK) were labeled with Lightning-Link
TM
 Atto637 (Innova Biosciences, 
UK). Four different methods were used to harvest and prepare cells for flow cytometry. 
Figure 3.16 panel A and B show N-cadherin positive cell populations and negative 
controls, respectively, generated using 0.25% trypsin-EDTA. Figure 3.16 panel C and D 
show N-cadherin positive cell populations and negative controls, respectively, generated 
using cell scrapers. Figure 3.16 panel E and F show N-cadherin positive cell populations 
and negative controls, respectively, generated using 1X sodium citrate. Figure 3.15 
panel G and H show N-cadherin positive cell populations and negative controls, 
respectively, generated using 1% of 280 units/mg collagenase II in 1X sodium citrate.  
 
The results demonstrated that using 1X sodium citrate and/or 1% of 280 units/mg 
collagenase II in 1X sodium citrate are the best ways to harvest osteoblasts and maintain 
N-cadherin positive populations. When 1X sodium citrate was used to harvest mature 
osteoblasts (day 21 and day 28), cells clumped together with the matrix and prohibited 
analysis by the flow cytometry machine due to the machine blocking. However, the use 
of 1% of 280 units/mg collagenase II in 1X sodium citrate is the only procedure to 
release and harvest the mature osteoblasts with generated matrix and maintain N-
cadherin positive populations. Therefore, 1% of 280 units/mg collagenase II in 1X 
sodium citrate was chosen to harvest osteoblasts for flow cytometry.  
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Figure 3.16:  Optimising different ways to harvest adherent cells; primary 
osteoblasts. Four different methods were used to harvest and prepare cells for flow 
cytometric experiment before cells stained with mouse monoclonal anti-N-cadherin 
antibody or isotype control, mouse IgG antibody. Cells were analyzed using FACS 
Calibur. Data shows using 0.25% trypsin-EDTA (panel A) or cell scrapers (panel C) 
lead do loose the N-cadherin molecules. Using 1X sodium citrate (panel E) and using 
1% of 280 units/mg collagenase II in 1X sodium citrate (panel G) are the best ways to 
harvest adherent cells. However, when 1X sodium citrate was used to harvest mature 
osteoblasts (day 21 and day 28), cells clumped together with the matrix and prohibited 
analysis by the flow cytometry machine to avoid blocking. Panel B, D, F and H show 
the negative control, mouse IgG. (n=3). 
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3.4.5.2 Determination of the optimal concentration of anti-N-cadherin antibody 
used for flow cytometry  
Flow cytometry was performed using a mouse monoclonal anti-N-cadherin antibody 
(Sigma, UK) and an isotype control, mouse IgG antibody (Vector laboratories, UK). 
Anti-N-cadherin antibody (Sigma, UK) and mouse IgG antibody (Vector laboratories, 
UK) were labeled by Lightning-Link
TM
 Atto637 (Innova Biosciences, UK). Figure 3.17 
panels A, C, E and G show N-cadherin positive populations (red dots) in mouse primary 
osteoblast cultures using anti-N-cadherin antibody at 1:100, 1:200, 1:400 and 1:800 
dilutions, respectively, in the right half of the FACS plots. However, the positive 
populations in 1:400 and 1:800 dilutions were not clearly defined compared to the 
negative population. Figure 3.17 panels B, D, F and H show no positive red populations 
in the right half of the FACS plots with isotype control at 1:100, 1:200, 1:400 and 1:800 
dilutions, respectively. Therefore, 1:200 dilution was chosen as an optimal antibody 
concentration for flow cytometry because the positive population can be clearly defined 
from to the negative population with using a minimum volume of antibody.  
 
3.4.5.3 Percentage of N-cadherin+ osteoblast, as measured by FACS, did not change 
during osteoblast differentiation  
A mouse monoclonal anti-N-cadherin antibody (Sigma, UK) and an isotype control, 
mouse IgG antibody (Vector laboratories, UK) were used in these experiments. Both 
antibodies were labeled with Lightning-Link
TM
 Atto637 (Innova Biosciences, UK). 
Figure 3.18 panel A shows the percentage of N-cadherin positive cells in immature 
osteoblast populations, and no positive cells in the isotype controls (Figure 3.18 panel 
B). The data demonstrated that 10% of immature osteoblasts expressed N-cadherin. 
Figure 3.18 panel C shows the percentage of N-cadherin positive cells in mature 
osteoblast populations, and no positive cells with isotype control (Figure 3.18 panel D). 
Again, the data demonstrated 10% of mature osteoblasts expressed N-cadherin.  
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Figure 3.17:  Optimising the concentration of anti-N-cadherin antibody using 
flow cytometry. Four different dilutions; 1:100, 1:200, 1:400 and 1:400 were used to 
stain cells with mouse monoclonal anti-N-cadherin antibody or isotype control, mouse 
IgG antibody. Cells were analyzed using FACS Calibur. Data shows that 1:200 
dilution is the optimal concentration that clearly determines the N-cadherin positive 
cells because the positive population can be clearly defined from to the negative 
population with using a minimal antibody. Panel B, D, F and H show the negative 
control, mouse IgG isotype. (n=3). 
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Figure 3.18: The percentage of   N-cadherin
+
 osteoblasts did not change during 
osteoblast differentiation. Live cells were stained with a mouse monoclonal anti-N-
cadherin antibody or an isotype control, mouse IgG antibody. Cells were analyzed 
using FACs Calibur. Panel A shows 10% of immature osteoblasts express N-cadherin 
(red fluorescence in the right half). Panel B shows isotype control. Panel C shows 
10% of mature osteoblasts express N-cadherin (red fluorescence in the right half). 
Panel D shows the isotype control. (n=3). 
 
 
 
 
 
 
 
 
 
 
 
 
 
3.4.5.4 The relative expression of N-cadherin protein increased during osteoblast 
differentiation using immunofluorescence  
Fixed and permeablilized osteoblasts were stained using a rabbit monoclonal anti-N-
cadherin antibody (Millipore, UK). A normal rabbit IgG isotype control antibody (R&D 
systems, UK) was used. Figure 3.19 panel A shows the relative staining of N-cadherin 
in immature osteoblast and mature osteoblasts. Data showed statistically significant 
increase in the amount of N-cadherin protein in cultures of day 28, mature osteoblasts, 
compared to day 7, immature osteoblasts, (70.00±2.49 versus 2.56±0.69, p<0.001). 
Figure 3.19 panels B and C show positive staining (red fluorescence) of N-cadherin in 
pre-osteoblasts and mature osteoblasts during osteoblastogenesis, respectively.  
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Figure 3.19: N-cadherin protein expression increased during osteoblast 
differentiation using immunofluorescence. Fixed and permeabilized cells were 
stained with rabbit monoclonal anti-N-cadherin antibody or an isotype control, normal 
rabbit IgG antibody. Panel A shows significant increase in the relative expression of 
N-cadherin protein in mature osteoblasts (day 28) compared with immature 
osteoblasts (day 7). Panel B and C show representative images of N-cadherin protein 
expression (red fluorescence) in immature osteoblasts and mature osteoblasts.         
*** = p<0.001. t test was used. (n=3). 
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3.4.5.5 The relative expression of N-cadherin protein increased during osteoblast 
differentiation using western blot  
A rabbit monoclonal anti-N-cadherin antibody (Millipore, UK) and donkey anti-rabbit 
IgG antibodies (R&D systems, UK) (1:1000 dilution), secondary antibody were used to 
detect N-cadherin protein during osteoblastogenesis by western blot. Figure 3.20    
panel A shows the N-cadherin protein levels in immature osteoblasts and mature 
osteoblasts. It was found that an osteocyte-like cell line, MLO-Y4 was not expressed  
N-cadherin (Kawaguchi et al., 2001). Therefore, MLO-Y4 was used as a negative 
control to determine if there is a positive false expression and brain rat used as a 
positive control to determine if there is a negative false expression. Figure 3.20 panel B 
shows that a significant increase was observed in the relative expression of N-cadherin 
protein in day 28, mature osteoblasts, compared to day 7, immature osteoblasts 
(68.24±13.10 versus 23.95±7.13, p<0.001). Figure 3.20 panel C shows the expression of 
the positive control, β-actin.  
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Figure 3.20: N-cadherin protein expression increased during osteoblast 
differentiation using western blot. Whole cell lysis preparation electrophoresed in 
12.5% SDS PAGE gels for N-cadherin and 15% SDS PAGE gels for β-actin, and 
transferred to PVDF membranes were probed with a rabbit monoclonal anti-N-
cadherin antibody and donkey anti-rabbit IgG antibodies (R&D systems, UK) (1:1000 
dilution), secondary antibody. Panel A shows N-cadherin protein expression during 
osteoblastogenesis. The osteocyte-like cell line, MLO-Y4 used as negative control 
and brain rat used as positive control. Panel B shows a significant increase in the 
relative expression of N-cadherin protein in mature osteoblasts (day 28) compared 
with immature osteoblasts (day 7). Panel C shows the expression of β-actin control.           
*** = p<0.001. Mann Whitney test was used. (n=3). 
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3.4.6 Determination of the relative expression of N-cadherin mRNA in myeloma 
cell lines, 5T33MM and 5TGM1  
3.4.6.1 Determination of the quality of the purified RNAs and synthesized cDNAs  
RNAs were extracted from 5T33MM cells and 5TGM1 cells cultured in vitro. Figure 
3.21 shows the electrophoresis of RNA isolated from 5T33MM cells and 5TGM1 cells. 
Clear 28S and 18S bands, ribosomal RNAs, are observed, indicating good quality and 
undamaged RNA. Figure 3.22 shows RT-PCR of GAPDH with expected size of 354 bp 
in RNA isolated from myeloma cells after reverse transcription (+RT) or no reverse 
transcription (-RT). Expression of GAPDH in +RT and not in -RT demonstrated no 
genomic contamination was present in cDNAs preparation.  
 
3.4.6.2 N-cadherin mRNA was expressed in Myeloma cell  
RNAs were extracted from 5T33MM cells and 5TGM1 cells cultured in vitro and 
cDNAs were synthesised. Figure 3.23 shows that N-cadherin was expressed in 
5T33MM cells and 5TGM1 cells. End-point RT-PCR is not a quantitative technique and 
was used to establish if N-cadherin specific mRNAs were expressed in cells. Bands for 
specific products were sent for sequencing (Figure 3.24) and gave 100% homology with 
GenBank (Figure 3.25). Therefore, TaqMan was used to study the relative levels of 
expression of N-cadherin in myeloma cells.  
 
 
 
 
 
 
Figure 3.21:  Electrophoresis 
of total RNA isolated from 
myeloma cells. RNA was 
extracted from myeloma cell 
lines; 5T33MM and 
5TGM1MM. Clear 28S and 
18S bands, ribosomal RNAs 
were indicate of good quality 
and undamaged RNA. (n=3). 
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Figure 3.22: RT-PCR analysis of GAPDH mRNA in myeloma cell lines; 
5T33MM and 5TGM1MM. RNA was extracted from myeloma cell lines; 5T33MM 
and 5TGM1MM. RT-PCR was performed using GAPDH, gene specific primers. 
Data shows GAPDH expressed in +RT with expected size of 354 bp and not in - RT 
demonstrating no genomic DNA contamination in prepared cDNAs. Water was used 
as a negative control. (n=3). 
Figure 3.23:  RT-PCR analysis of N-cadherin mRNA in myeloma cells; 5T33MM 
and 5TGM1. RNA was extracted from myeloma cell lines; 5T33MM and 
5TGM1MM. RT-PCR was performed using N-cadherin, gene specific primers. Data 
shows N-cadherin was expressed in myeloma cells with expected size of 560 bp. 
(n=3). 
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Figure 3.25: 
Using genomic 
website to 
identify the 
matching gene. 
Sequence 
received from the 
Core Genomic 
Facility was blast 
in NCBI browser 
(http://blast.ncbi.
nlm.nih.gov/Blast
.cgi) gave 100% 
homology with 
GenBank. (n=3). 
 
Figure 3.24: N-cadherin cDNA sequencing. RNA was extracted from myeloma 
cells. RT-PCR was performed using N-cadherin, gene specific primers. Bands were 
sequenced in University of Sheffield Core Genomic Facility 
(http://genetics.group.shef.ac.uk/dna-sequencing.html). This sequence was received 
from the Core Genomic Facility. (n=3). 
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3.4.6.3 The relative expression of N-cadherin mRNA was higher in 5TGM1 cells 
compared to 5T33MM cells  
cDNAs were synthesised from myeloma cell lines; 5T33MM and 5TGM1 cultured in 
vitro and N-cadherin mRNA expression analysed by real time PCR using TaqMan. 
Expression of N-cadherin was normalised to the expression of the housekeeping gene, 
β-actin. Figure 3.26 shows the relative expression of N-cadherin mRNA in 5T33MM 
cells and 5TGM1 cells. Data showed statistically significant high relative expression of 
N-cadherin mRNA in 5TGM1 cells compared to 5T33MM cells (169.20±50.60 versus 
5.09±1.66, p<0.001).  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.26: Relative expression of N-cadherin mRNA was increased in 5TGM1 
cells compared with 5T33MM cells. cDNAs were synthesised from 5T33 cells and 
5TGM1 cells cultured in vitro and N-cadherin mRNA expression analysed using 
TaqMan. Expression of N-cadherin was normalized to expression of housekeeping 
gene, β-actin. Data shows significant increase in the relive expression of N-cadherin 
mRNA in 5TGM1 cells compared to 5T33MM cells. *** = p<0.001. t test was used. 
(n=3). 
Table 3.3: CT value  
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3.4.7 Immuno-localization of N-cadherin protein in myeloma cell lines, 5T33MM 
and 5TGM1  
A rabbit monoclonal anti-mouse-N-cadherin antibody (Millipore, UK) and an isotype 
control, normal rabbit IgG antibody (R&D systems, UK) were used to determine 
possible localization of N-cadherin in 5T33MM and 5TGM1 myeloma cells. Northern 
light anti-rabbit IgG (NL637) antibody, (secondary antibody for immunofluorescence) 
or biotinylated anti-rabbit IgG antibody, (secondary antibody for 
immunocytochemistry) was used for detection of primary antibody. Figure 3.27 panel A 
shows positive staining (red fluorescence) of N-cadherin in 5T33MM cells and no 
staining with isotype control (Figure 3.27 panel B). Data determined that the 
distribution of N-cadherin was focal on 5T33MM cells using immunofluorescence. 
Figure 3.27 panel C shows positive staining (brown staining) of N-cadherin on the 
membrane of 5T33MM cells and no staining with isotype control (Figure 3.27 panel D). 
This results also demonstrated that N-cadherin is focal on the myeloma cell line, 
5T33MM. Figure 3.27 panel E shows positive staining (brown staining) of N-cadherin 
on the membrane of 5TGM1 cells and no staining with isotype control (Figure 3.27 
panel F). This result demonstrated that N-cadherin was also focal on 5TGM1 cells.  
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Figure 3.27: N-cadherin protein expression in myeloma cell lines; 5T33MM and 
5TGM1MM. Fixed and permeabilized cells were stained with rabbit monoclonal anti-
N-cadherin antibody or isotype control, normal rabbit IgG antibody. Nuclei were 
counterstained with DAPI (blue fluorescence) or hematoxylin (blue staining). Cells 
were examined under Zeiss 510 multiphoton laser scanning microscope or Leitz 
DMRB microscope. Panel A shows focal staining of N-cadherin (red) in 5T33MM 
cells. Immunocytochemistry using rabbit monoclonal anti-N-cadherin antibody also 
shows focal staining of N-cadherin (brown) on the membranes of 5T33MM cells.. 
Panel E shows focal expression of N-cadherin (brown staining) on the membranes of 
5TGM1 cells using immunocytochemistry. Panel B, D and F show the isotype control 
for these experiments. (n=3). 
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3.4.8 Determination of the percentage and relative expression of N-cadherin 
protein in myeloma cell lines, 5T33MM and 5TGM1  
3.4.8.1 The frequency of N-cadherin positive cells was higher in 5TGM1 cells than 
in 5T33MM cells 
A mouse monoclonal anti-N-cadherin antibody (Sigma, UK) and an isotype control, 
mouse IgG antibodies (Vector laboratories, UK) were used to determine the percentage 
of N-cadherin positive on myeloma cells using flow cytometry. Figure 3.28 shows the 
percentage of N-cadherin positive myeloma cells in populations, and no positive cells in 
the isotype controls. The data demonstrated that 1% of 5T33MM cells and 6% of 
5TGM1 cells expressed N-cadherin. Figure 3.29 shows the percentage of N-cadherin 
positive 5T33MM cells and N-cadherin positive 5TGM1 cells. Data showed statistically 
significant higher relative frequency of N-cadherin positive cells in 5TGM1 cells 
compared to 5T33MM cells using flow cytometry (5.00±0.20 versus 1.00±0.14, 
p<0.05).  
 
3.4.8.2 The relative levels of N-cadherin protein was higher in 5TGM1 cells than to 
5T33MM cells compared by western blot  
A rabbit monoclonal anti-N-cadherin antibody (Millipore, UK) was used to detect       
N-cadherin protein in 5T33MM cells and 5TGM1 cells analysed by western blot. Figure 
3.30 panel A shows the N-cadherin protein levels in 5T33MM cells and 5TGM1 cells. It 
was found that an osteocyte-like cell line, MLO-Y4 was not expressed N-cadherin 
(Kawaguchi et al., 2001). Therefore, MLO-Y4 was used as a negative control. Figure 
3.30 panel B shows significant increase in the relative levels of N-cadherin protein in 
5TGM1 cells compared to 5T33MM cells (38.17±10.52 versus 13.07±1.57, p<0.001). 
Figure 3.28 panel C shows the expression of the positive control, β-actin.  
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Figure 3.29: Relative level of N-cadherin protein on 5TGM1 cells compared with 
5T33MM cells using flow cytometry. Data shows significant highest relative levels 
of N-cadherin protein in 5TGM1 cells compared to 5T33MM cells (n=4). * = p<0.05. 
Mann Whitney test was used. (n=3). 
Figure 3.28: The percentage of N-cadherin
+
 myeloma cells. Live cells were stained 
with a mouse monoclonal anti-N-cadherin antibody or an isotype control, mouse IgG 
antibody. Cells were analyzed using FACs Calibur. Data shows 1% of 5T33MM cells 
and 5% of 5TGM1 cells express N-cadherin (red fluorescence in the right half). Panel 
B shows isotype control. (n=3). 
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Figure 3.30: Relative expression of N-cadherin protein was highest in 5TGM1 
cells compared with 5T33MM cells using western blot. Whole cell lysis 
preparation electrophoresed in 12.5% SDS PAGE gels for N-cadherin and 15% SDS 
PAGE gels for β-actin, and transferred to PVDF membranes were probed with a 
rabbit monoclonal anti-N-cadherin antibody or an isotype control, normal rabbit IgG 
antibody. Panel A shows N-cadherin protein levels in 5T33MM cells and 5TGM1 
cells. The osteocyte-like cell line, MLO-Y4 was used as a negative control. Panel B 
shows significant highest relative levels of N-cadherin protein in 5TGM1 cells 
compared with 5T33MM cells. Panel C shows the expression of β-actin control.         
*** = p<0.001. Mann Whitney test was used. (n=3). 
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3.4.9 A comparison in the expression of N-cadherin between myeloma cells and 
osteoblasts  
cDNAs were synthesised from myeloma cell lines, 5T33MM and 5TGM1, and mouse 
primary osteoblasts cultured in vitro and N-cadherin mRNA expression analysed by real 
time PCR using TaqMan. Expression of N-cadherin was normalised to the expression of 
the housekeeping gene, β-actin. Figure 3.31 shows the relative expression of N-cadherin 
mRNA in 5T33MM cells, 5TGM1 cells, immature osteoblasts (day 7) and mature 
osteoblasts (day 28). In addition, a rabbit monoclonal anti-N-cadherin antibody 
(Millipore, UK) was used to detect N-cadherin protein in myeloma cells and osteoblasts 
analysed by western blot. GS-710 calibrated imaging densitometer was used to measure 
the density of bands. Figure 3.32 shows the relative levels of N-cadherin protein in 
5T33MM cells, 5TGM1 cells, immature osteoblasts and mature osteoblasts.   
 
 
 
 
 
 
 
 
 
 
 
Figure 3.31: Relative expression of N-cadherin mRNA in myeloma cells and 
osteoblasts. cDNAs were synthesised from 5T33MM cells, 5TGM1 cells, immature 
osteoblasts and mature osteoblasts cultured in vitro and N-cadherin mRNA expression 
analysed using TaqMan. Expression of N-cadherin was normalized to expression of 
housekeeping gene, β-actin. Data show high expression of N-cadherin mRNA in 
5TGM1 cells and mature osteoblasts compared to 5T33MM cells and immature 
osteoblasts. (n=3). 
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Figure 3.32: Relative expression of N-cadherin protein in myeloma cells and 
osteoblasts using western blot. Whole cell lysis preparation electrophoresed in 
12.5% SDS PAGE gels for N-cadherin and in 15% SDS PAGE gels for β-actin. Data 
show high expression of N-cadherin protein in 5TGM1 cells and mature osteoblasts 
compared to 5T33MM cells and immature osteoblasts. (n=3). 
Determining the role of N-cadherin in the formation of the myeloma niche 
  
 Page 131 
 
3.5 Discussion  
In this chapter an in vitro model of mouse osteoblastogenesis was developed. The 
expression of N-cadherin mRNA and the levels of N-cadherin protein at different stages 
of osteoblastogenesis were determined. Primary cultures of calvarial mouse osteoblasts 
were differentiated to mature functional osteoblasts using different osteogenic medium 
to address the effect of dexamethasone on osteoblastogenesis. Gilbert et al (2002) 
differentiated osteoblasts to mature osteoblasts using α-MEM medium containing; 10% 
FCS, 10 mM of β-glycerophosphate and 50 µg/ml of ascorbic (Gilbert et al., 2002). 
However, Bancroft et al (2002) differentiated osteoblasts to mature osteoblasts using   
α-MEM medium containing; 10% FCS, 10 mM of β-glycerophosphate, 50 µg/ml of 
ascorbic acid and 10
-8
 M of dexamethasone (Bancroft et al., 2002). Therefore, in my 
study different osteogenic medium were used to determine if adding 10
-8
 M of 
dexamethasone promotes the differentiation of osteoblasts.  
 
In the first series, cells were incubated in α-MEM medium containing; 10% FCS, 10 
mM of β-glycerophosphate and 50 µg/ml of ascorbic acid for 28 days. In the second 
series, cells were incubated in α-MEM medium containing; 10% FCS, 10 mM of                     
β-glycerophosphate and 50 µg/ml of ascorbic acid for 14 days and at day 15, 10-8 M of 
dexamethasone was added to the osteogenic medium to promote differentiation. In the 
third series, cells were incubated in α-MEM medium containing; 10% FCS, 10 mM of  
β-glycerophosphate, 50 µg/ml of ascorbic acid and 10-8 M of dexamethasone for 28 
days. In the fourth series, cells were incubated in α-MEM medium containing; 10% 
FCS, 10 mM of β-glycerophosphate, 50 µg/ml of ascorbic acid and water for 28 days. 
The results demonstrated that osteoblasts can be differentiated to mature functional 
osteoblasts with and without using 10
-8
 M of dexamethasone. However, the results of 
alizarin red analysis showed that there was an increase in the mineralization of cells on 
day 28 when 10
-8
 M of dexamethasone was added into the osteogenic medium. The data 
also demonstrated that there was no difference in the mineralization of cells on day 28 
between the second series, when 10
-8
 M of dexamethasone was added into the 
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osteogenic medium at day 15, and the third series, when 10
-8
 M of dexamethasone was 
added into the osteogenic medium at day 0. In my study the second series, α-MEM 
medium containing; 10% FCS, 10 mM of β-glycerophosphate and 50 µg/ml of ascorbic 
acid was used for 14 days and at day 15, 10
-8
 M of dexamethasone was added to the 
osteogenic medium, and used as a medium for the osteoblastogenesis in vitro to 
promote cell differentiation. This was because I wanted to examine cells in less well 
differentiation versus well differentiated states and series 2 appeared to alter lower 
differentiation on day 7 to higher differentiated states on day 28. This allows clearer 
distinction between differentiating and differentiated cell types.  
 
ALP activity and alizarin red staining were used as an osteoblast differentiation and 
mineralization markers. Xiao et al (2006) demonstrated that ALP activity and alizarin 
red staining increased during mouse osteoblastogenesis (Xiao et al., 2006). In addition, 
Hay et al also showed that ALP activity and alizarin red staining increased during 
mouse osteoblastogenesis (Hay et al., 2009a). In this study, ALP activity and alizarin 
red staining were also used as osteoblast differentiation and mineralization markers. My 
experiments also showed the ALP activity and alizarin red staining increased during 
mouse osteoblastogenesis.  
 
In this study, the quantification of relative levels of expression of Runx2 mRNA and 
COL1A2 mRNA was analysed to determine the relevance between osteoblast markers, 
Runx2 and COL1A2, and osteoblastogenesis. Runx2 is a transcriptional activator 
necessary for bone formation and osteoblast differentiation in mice (Ducy et al., 1997). 
Runx2-null mice resulted in a complete lack of bone formation and suggested that 
Runx2 plays an essential role in osteoblastogenesis in mice (Komori et al., 1997). My 
experiments demonstrated that the relative expression of Runx2 mRNA significantly 
increased during osteoblastogenesis. COL1A2 gene encodes one of the chains for type I 
collagen and mutations in this gene produced an osteogenesis imperfecta a type IV 
phenotype (Wenstrup et al., 1988). Both Runx2 and COL1A2 are induced at an early 
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stage in osteoblast differentiation (Sila-Asna et al., 2007). My experiments 
demonstrated that the relative expression of COL1A2 mRNA significantly increased 
during osteoblastogenesis. Therefore, this study showed that not only ALP activity and 
alizarin red staining are useful as osteoblast differentiation and mineralization markers, 
but also the relative expression of Runx2 mRNA and COL1A2 mRNA can be used as 
markers for mouse osteoblastogenesis. I found that there were some limitations in this 
experiment, in which some variability in the tissue cultures of osteoblast differentiation 
in vitro between experiments. This variability could be due to the differences in the age 
of mice used to obtain osteoblasts. In published protocols, Hay et al, (2009) obtained 
primary osteoblasts of calvarias from 2-5 day old mice (Hay et al., 2009a). 
Subramaniam et al (2005) obtained primary osteoblasts of calvarias from 1-3 day old 
mice (Subramaniam et al., 2005). Mukherjee et al (2010) obtained primary osteoblasts 
of calvarias from 2-7 day old mice (Mukherjee et al., 2010). In this study osteoblasts 
obtained from 2-4 day old C57Bl/6J mice due to the policy of arriving time and the 
policy of The University of Sheffield biological services laboratory. Although there was 
variability, I can say that in week one and two the osteoblasts are in the differentiating 
phase but in week three and four the osteoblasts are fully differentiated.  
 
N-cadherin
+
 osteoblasts are a key cell type to which HSCs home to on the endosteal 
bone surface (Xie et al., 2009). The authors offered that N-cadherin
+
 cells were 
probably pre-osteoblasts, osterix
+
 cells, however, Nakashima et al (2002) have shown 
osterix to be expressed in all subsets of osteoblasts; pre-osteoblasts and mature 
osteoblasts (Nakashima et al., 2002). Previously, Wennberg et al (2000) showed that   
N-cadherin is expressed in mouse primary osteoblasts (Wennberg et al., 2000). In this 
study specific primers and an antibody against N-cadherin were used to analyze the 
relative expression of N-cadherin mRNA and the levels of N-cadherin protein, 
respectively, during osteoblastogenesis. TaqMan analysis of primary calvarial 
osteoblasts cDNA demonstrated an increase in the expression of N-cadherin mRNA 
during osteoblastogenesis from day 7 to day 28. The data showed a significant increase 
in the N-cadherin mRNA expression in mature osteoblasts (day 28) compared with 
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immature osteoblasts (day 7). Flow cytometry demonstrated that there was no 
difference in the levels of N-cadherin protein between immature osteoblasts and mature 
osteoblasts. This was unexpected and could be because the osteoblasts were separated 
from each other when prepared for flow cytometry. Alternatively, it may be that the 
flow cytometry underscored the levels of N-cadherin due to general issues of the 
antibody sensitivity. However, immunofluorescence and western blot showed a 
significant increase in the levels of N-cadherin protein in mature osteoblasts (day 28) 
compared to immature osteoblasts (day 7) and this suggested a low levels of N-cadherin 
expression in immature osteoblasts and relatively high levels of N-cadherin expression 
in mature osteoblasts during osteoblastogenesis. The approach taken to controlling the 
loading of protein was to run 2 gels: that for N-cadherin analysis designed for higher 
molecular weight (50-200 kD) and that for the loading control (β-actin) for lower 
molecular weight (20-100 kD). These gels were run simultaneously with the same 
samples and this allowed good resolution over the expected target molecular weights for 
the 2 proteins analyzed.  
 
These observations are supported by previous work performed by Ferrari et al (2000) 
and by Kawaguchi et al (2001). Ferrari et al (2000) showed that N-cadherin mRNA 
expression was increased during osteoblastogenesis of the human cell line, SaOS-2, rat 
cell line, ROS, and primary osteoblast cells prepared from fetal rat calvariae. This study 
supported the role of N-cadherin in the late stage of osteoblast differentiation (Ferrari et 
al., 2000). Kawaguchi et al (2001) showed that the mouse osteoblast cell line, MC3T3-
E1, expressed N-cadherin and this expression was increased during MC3T3-E1 cell 
differentiation (Kawaguchi et al., 2001). In contrast, Greenbaum et al (2012) 
demonstrated a decrease in the relative expression of N-cadherin during 
osteoblastogenesis using western blot. In this published study, osteoblasts were 
originated from the differentiation of bone marrow stromal cells using Cdh2
flox/flox
 mice,   
backcrossed to more than 99% congenic with the C57BL/6 background. In addition, for 
differentiation they used α-MEM (Invitrogen) with 20% FCS, 50 µM ascorbic acid and 
10 µM β-glycerophosphate (Greenbaum et al., 2012). These discrepancies may be due 
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to differences in culture conditions and N-cadherin analysis methods. My data clearly 
showed an increase in the relative levels of N-cadherin mRNA and protein during 
osteoblastogenesis in culture using TaqMan analysis, immunofluorescence and western 
blot, and although the flow cytometric analysis data did not show increased percentage 
in N-cadherin labelled cells this may have been due to the culture disruption and 
underscoring issues.  
 
The flow cytometry analysis may underscore the actual levels of N-cadherin positivity 
within a population. Resolving of this could be by generating a new anti-N-cadherin 
antibody with high affinity to the extracellular domain of N-cadherin for flow 
cytometry. The antibody used in this project for flow cytometry is anti-N-cadherin 
antibody, GC-4 (Sigma, UK). To date, the flow cytometry analysis of N-cadherin as a 
surface molecule are extremely limited. Wein et al (2010) used anti-N-cadherin 
antibody, GC-4 (Sigma, UK) and anti- N-cadherin antibody (MNCD2) for flow 
cytometry to detect the N-cadherin in human hematopoietic progenitor cells (HPCs). 
They demonstrated that the percentage of N-cadherin
+
 HPC varied between different 
samples from 5% to 50% between different samples and this might be due to the 
available antibodies (Wein et al., 2010). More recently, Groen et al (2011) used anti-N-
cadherin antibody, GC-4 (Sigma, UK) for flow cytometry and anti-N-cadherin, clone 32 
(BD Biosciences, Erembodegem, Belgium) for immuno-staining and western blot to 
detect the N-cadherin in myeloma cells. They demonstrated that there were some 
differences in the expression of N-cadherin in myeloma cells when western blotting and 
flow cytometry were used. It was found that N-cadherin expression in NCI-H929 and 
LME-1 myeloma cells was high by western blot whereas N-cadherin expression by flow 
cytometry in the same cells was found to be low (Groen et al., 2011). Although, this 
issue has been raised for the anti-N-cadherin antibody, to date anti-N-cadherin antibody, 
GC-4 (Sigma, UK) is used by resent publication for flow cytometry. Therefore, this 
antibody was used in this study for flow cytometry. In western blot and immuno-
staining I used another antibody, rabbit monoclonal, anti-N-cadherin antibody 
(Millipore, UK).  
Determining the role of N-cadherin in the formation of the myeloma niche 
  
 Page 136 
 
Dring et al (2004) demonstrated that N-cadherin was expressed in t4;14 MM patients 
using gene array studies (Dring et al., 2004). In addition, Groen et al (2011) 
demonstrated that N-cadherin was expressed in myeloma cell lines; OPM-1, NCI-H929 
and LME-1 as well as in primary MM using western blot, immunocytochemistry and 
immunohistochemistry (Groen et al., 2011). These support my observation, in which  
N-cadherin is expressed in murine myeloma cell lines; 5T33MM and 5TGM1. A novel 
finding in my study was that N-cadherin distribution in 5T33MM and 5TGM1 cells was 
focal using immunofluorescence and immunocytochemistry, similar to N-cadherin 
expression in mouse HSCs (Xie et al., 2009) and human HSCs (Wein et al., 2010). Flow 
cytometriy data demonstrated that 1% of 5T33MM cells expressed N-cadherin whereas 
5% of 5TGM1 cells express N-cadherin. Western blot data showed higher levels of     
N-cadherin protein in 5TGM1 cells compared with 5T33MM cells. In addition, TaqMan 
analysis demonstrated higher expression of N-cadherin in 5TGM1 cells compared with 
5T33MM cells. Taken together these findings suggest that N-cadherin expression and 
surface levels of N-cadherin are higher in 5TGM1 cells than in 5T33MM cells.  
 
Alizarin red staining is a dye used as an in vitro mineralisation marker by binding to 
calcium in matrix deposited by osteoblasts (Xiao et al., 2006). N-cadherin is a member 
of the Ca
2+
-dependent cell-cell adhesion receptor family (Miyatani et al., 1992, 
Gumbiner, 2005). My study showed that there was a correlation between N-cadherin 
expression and bone mineralisation. My data demonstrated a significant increase in the 
expression of N-cadherin in correlation to a significant increase in alizarin red staining 
in mature osteoblast (day 28), this could be because of the presence of calcium. 
Potentially, colonising N-cadherin
+
 myeloma cell bind to a population of osteoblast 
expressing high level of N-cadherin, mature osteoblast, initiating the formation of the 
myeloma niche and tumour cells growth.  
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In conclusion, this chapter demonstrated that I had generated a consistent in vitro model 
for osteoblast differentiation using primary osteoblast lineage cells derived from mouse 
calvariae. My studies showed that N-cadherin was expressed at increasing levels during 
differentiation in this model. Studies with the 5T33MM and 5TGM1 cells showed that 
these cells produced N-cadherin and that this was focally distributed on the surface of 
these cells. 5TGM1 cells appeared to produce more N-cadherin than 5T33MM cells. 
These findings indicate the potential for interactions between myeloma cells and 
osteoblasts mediated via N-cadherin, and these will be investigated in the next chapter.  
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4 Chapter 4: N-cadherin mediates the interaction of 
myeloma cells with osteoblasts in vitro  
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4.1 Introduction  
4.1.1 N-cadherin maintains the HSCs quiescent in the HSC niche 
One of the regulatory molecules in the HSC niche is N-cadherin, which is expressed by 
both HSCs and osteoblasts mediating their association (Zhang et al., 2003, Xie et al., 
2009).  N-cadherin is a member of a Ca
2+
-dependent cell-cell adhesion receptor family 
known as cadherin 2, and contains an extracellular domain, transmembrane domain and 
a cytoplasmic domain that interacts with catenins and mediates signalling pathway 
following cell-cell adhesion (Gumbiner, 2005).  
 
Puch et al (2001) showed human CD34
+
 HSCs express N-cadherin. It was shown that 
treatment of these cells with monoclonal anti-N-cadherin antibodies resulted in a 
reduction in colony formation when HSCs were injected into experimental animals, 
which suggested a direct interaction between osteoblasts and HSCs via N-cadherin 
(Puch et al., 2001). Zhang et al (2003) demonstrated that there is a correlation between 
an increase in the number of spindle-shaped N-cadherin
+
CD45
-
 osteoblastic cells and an 
increase in the number of HSCs. In addition, it was found that persistent HSCs attached 
to SNO cells via N-cadherin and β-catenin (Zhang et al., 2003). In vitro, Aria and Suda 
(2007) showed enhancements of both HSCs and stromal cell adhesion and inhibition of 
cell division of HSCs by enforced N-cadherin expression, suggesting a key role of             
N-cadherin-mediated adhesion in maintaining HSCs quiescence in the osteoblastic 
niche (Arai and Suda, 2007). Using a new technology, ex vivo real-time imaging, and 
immunoassaying found that HSCs home to the ‘osteoblast niche’ via attachment to     
N-cadherin
+
 osteoblasts on endosteal bone surfaces (Xie et al., 2009). Recently, 
Hosokawa et al (2010) showed that N-cadherin is expressed in LT-HSCs and in the 
osteoblasts mediating cell adhesion in the HSC niche. Knockdown of N-cadherin 
showed an enhanced cell division and reduced long-term engraftment activity of HSCs 
in the BM in vivo (Hosokawa et al., 2010).  
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4.1.2 N-cadherin molecular interactions may be exploited to establish multiple 
myeloma cell colonisation in the HSC niche  
4.1.2.1 Cadherin switching in tumours  
During tumour progression in solid tumours, the invasion and metastatic properties 
acquired by cancer cells have been linked to expression of N-adhesion molecules and 
cadherin switching from E-cadherin to N-cadherin. Changes in expression of adhesion 
molecules mediate the interaction of cancer cells from their primary site to establish 
new interactions with the surrounding microenvironment. In melanoma, Li et al (2001) 
showed that expression of N-cadherin increased invasion, metastasis and promoted 
survival of melanoma cells (Li et al., 2001). In bladder cancer, Lascombe et al (2006) 
demonstrated that N-cadherin expression was absent in normal urothelium. During 
tumour progression or invasive increased N-cadherin expression was observed in 
association with loss of E-cadherin expression suggesting that N-cadherin is a 
prognostic marker of progression in urothelial tumours (Lascombe et al., 2006). In 
prostate cancer, Gravdal et al (2007) demonstrated that cadherin switch from E-cadherin 
to N-cadherin, increased N-cadherin and reduced E-cadherin expression, increased 
invasion and metastasis of the cancer cells, and associated with shorter survival times in 
prostate cancer progression patient. Loss of E-cadherin in a member of epithelial to 
mesenchymal transition a process that increase invasion of tumour cells in progress of 
prostate cancer (Gravdal et al., 2007).  
 
4.1.2.2 Role of N-cadherin in tumours  
N-cadherin is expressed in several cancers including melanoma, prostate, breast, gastric 
carcinoma, bladder carcinoma and overian carcinoma. Expression of N-cadherin in 
cancer cells mediates the invasion and interaction of cancer cells from their primary site 
to establish new interactions with the surrounding microenvironment (Hazan et al., 
2004, Yanagimoto et al., 2001, Lascombe et al., 2006, Sarrio et al., 2006). Shintani et al 
(2008) demonstrated that using a cyclic pentapeptide, ADH-1, targeting N-cadherin, 
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significantly reduced growth and metastasis of pancreatic cancer cells in transgenic 
mice (Shintani et al., 2008).  
 
In melanoma, Augustine et al (2008) showed that N-cadherin was expressed in human 
melanoma-derived cell lines. Targeting N-cadherin with ADH-1 pentapeptide in 
combination with chemotherapy drug (Melphalan) was used as a novel therapeutic 
approach and significantly reduced tumour growth and enhanced the antitumor activity 
to treat melanoma (Augustine et al., 2008). Clinically, Beasley et al (2009) 
demonstrated that ADH-1 at a dose of 4000 mg in combination with melphalan on days 
1 and 8 was safe and well tolerated by patients in phase I studies and was a potential 
novel targeted therapy approach in melanoma  (Beasley et al., 2009).  
 
In prostate cancer, Tanaka et al (2010) demonstrated that prostate cancer metastasis and 
castration resistance are mainly caused by N-cadherin. Targeting N-cadherin using 
monoclonal antibodies against N-cadherin resulted in a reduction in proliferation, 
adhesion and invasion of prostate cancer cells in vitro and delayed the castration 
resistance progression in vivo. In addition, Tanaka et al (2010) indicated the possibility 
of using N-cadherin as a marker for castration-resistant stem cells in prostate cancer, in 
which N-cadherin
+
 cells were tumourigenic. Moreover, Tanaka et al (2010) 
demonstrated that N-cadherin was expressed by small proportion of human primary 
tumours (Tanaka et al., 2010).   
 
In myeloma, using gene array studies, Dring et al (2004) showed that N-cadherin was 
expressed in t(4;14) chromosomal translocation MM patients cases. The t(4;14) are 
cases of MM that represent about 10–20% of MM patients and it has been suggested 
that this subset have poor prognosis. 127 genes were identified with significant 
differences between t(4;14) and non-t(4;14) cases by using global gene expression.     
N-cadherin (CDH2) was one of these genes with significant mean different, p value = 
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0.04, (Dring et al., 2004). More recently, Groen et al (2011) showed that myeloma cells 
express N-cadherin. The expression of N-cadherin directly mediated the bone marrow 
localization/retention of myeloma cells in vivo. In addition, it was found that expression 
of N-cadherin facilitated the interaction of myeloma cells with N-cadherin
+
 osteoblasts 
(Groen et al., 2011). This chapter will examine whether N-cadherin expression mediates 
the interaction of myeloma cells with osteoblasts in vitro as a potential mechanism used 
by colonising myeloma cells to establish the colonising on bone.  
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4.2 Hypothesis and objectives of this chapter  
4.2.1 Hypothesis  
Expression of N-cadherin mediates the adhesion of myeloma cells to osteoblasts in 
vitro.  
 
4.2.2 Objectives  
To test this hypothesis, I have determined:  
1. The incubation time required for myeloma cells to adhere to recombinant         
N-cadherin.  
2. The optimal concentration of recombinant N-cadherin required for myeloma cell 
adhesion.  
3. Whether expression of N-cadherin mediates adhesion of myeloma cells in vitro.  
4. Whether treating cultures with an anti-N-cadherin antibody blocks myeloma 
cells from adhering to recombinant N-cadherin in vitro.  
5. Whether expression of N-cadherin mediates the interaction of myeloma cells 
with osteoblasts in vitro.  
6. Whether treating cultures with an anti-N-cadherin antibody blocks myeloma 
cells from adhering to osteoblasts in vitro.  
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4.3 Materials and Methods  
4.3.1 Cell culture  
Non-adherent 5T33MM and 5TGM1 cells were cultured separately in vitro in 
RPMI1640 medium (Invitrogen, UK) containing 10% FCS, 100 units/ml Penicillin / 
100 µg/ml of Streptomycin, 1% Na2PO3 and 1% non-essential amino acids (NEAA). 
Mouse primary osteoblasts were prepared as described in section 2.1.9 and cultured in 
vitro in MEM alpha containing 10% FCS, 100 units/ml Penicillin / 100 µg/ml of 
Streptomycin and 1.36 μg/mL of amphotericin B. Both media were changed every 2 
days.  
 
4.3.2 Osteoblast differentiation  
Mouse primary osteoblasts were differentiated for 4 weeks to mature functional 
osteoblasts in osteogenic media; MEM alpha (Invitrogen, UK) containing 10 mM of    
β-glycerophosphate and 50 µg/ml of ascorbic acid in addition to 10% FCS, 100 units/ml 
Penicillin / 100 µg/ml of Streptomycin and 1.36 μg/mL of amphotericin B. medium was 
changed every 2 days.  
 
4.3.3 Cell adhesion assay   
4.3.3.1 Determining the incubation times  
96 well plates were coated overnight at 4°C with PBS containing 1 μg/ml recombinant 
N-cadherin/Fc chimera. 1x10
5
 cells/ml of myeloma cells were plated and incubated with 
recombinant N-cadherin at 37°C for different times; 0, 4, 8, 10, 15, 20, 30 and 60 
minutes to determine the incubation time required for myeloma cells to adhere to        
N-cadherin (see section in 2.2.9.1 materials and methods).  
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4.3.3.2 Determining the concentration of recombinant N-cadherin  
96 well plates were coated overnight at 4°C with PBS containing different 
concentrations of recombinant N-cadherin/Fc chimera (R&D Systems); 0, 0.1, 0.5, 1, 2, 
5, 10 µg/ml. 1x10
5
 cells/ml of myeloma cells were plated and incubated with these 
different recombinant N-cadherin concentration at 37°C for 20 minutes to determine the 
effect of increasing the concentration of recombinant N-cadherin required for myeloma 
cell adhesion (see section in 2.2.9.1 materials and methods).  
 
4.3.3.3 Blocking N-cadherin using anti-N-cadherin GC-4 antibody  
To block N-cadherin, cells were incubated with anti-N-cadherin 10 µg/ml GC-4 
antibody (Sigma, UK) at 37°C for 30 minutes. After blocking, 1x10
5
 cells/ml of 
myeloma cells were plated and incubated with recombinant N-cadherin at 37°C for 20 
minutes to determine the effect of blocking N-cadherin on the adhesion of myeloma 
cells (see section 2.2.9.2).  
 
4.3.4 Co-culture of myeloma cells with osteoblasts  
6x10
3
 cells/cm
2
 of mouse primary osteoblasts were seeded in 35mm glass bottom 
dishes. 5x10
4
 cells/ml of myeloma cells, 5T33MM-GFP and 5TGM1-GFP, were plated 
and incubated with osteoblasts as described in section 2.2.10. To block N-cadherin, 
cells were incubated with anti-N-cadherin GC-4 antibody (see section 2.2.10). GFP
+
 
expression allowed the identification of myeloma cells versus osteoblasts in these 
cultures.  
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4.3.5 Microscopy  
Osteomeasure software version 4.10 (Osteomerics Incorporated, Atlanta, USA) was 
used with a Leitz DMRB microscope and a drawing tablet, (CalComp Drawing Broad 
III) to determine the adhesion of myeloma cells with N-cadherin coated plates or PBS 
coated plates as described in section 2.2.14.2. A Zeiss 510 Multiphoton Laser Scanning 
Microscopy was used to visualise fluorescence as described in section 2.2.14.1.  
 
4.3.6 Statistical analysis  
The data were analysed using an ANOVA test (one-way analysis of variance) for more 
than two group comparisons or with t test for two group comparisons if the data was 
normally distributed. Tukey's test was used as post-hoc analysis when ANOVA test was 
used in normal distribution data. When data not normally distributed, ANOVA test 
(non-parametric Kruskal-Wallis test) was used for more than two group comparisons or 
non-parametric Mann–Whitney test was used for two group comparisons. Dunns test 
was used as post-hoc analysis when ANOVA test was used in not normally distributed 
data. Data were considered statistically significant when a p-value was equal to or less 
than 0.05. Results are expressed as mean ± values of standard deviation (SD).  
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4.4 Results  
4.4.1 Determination of the incubation time required for myeloma cells to adhere 
to recombinant N-cadherin  
5T33MM cells and 5TGM1 cells (1X10
5
 cells/100 μl) were plated and incubated with   
1 µg/ml of recombinant N-cadherin coated plates (Groen et al., 2011). Cells were 
incubated at 37°C for different times; 0, 4, 8, 10, 15, 20, 30 and 60 minutes. Figure 4.1 
shows the adherence of myeloma cells; 5T33MM and 5TGM1 to recombinant             
N-cadherin over times. The data clearly demonstrated an increase in the number of 
myeloma cells; 5T33MM and 5TGM1 that were adherent to recombinant N-cadherin 
from 0 minutes to 20 minutes and after 20 minutes the adherent numbers were reduced. 
Therefore, 20 minutes was chosen as an optimal incubation time to incubated myeloma 
cells with recombinant N-cadherin or with osteoblasts.  
 
 
 
 
 
 
 
 
 
 
 
Figure 4.1: Effect of increasing incubation time. 96-well plates were coated 
overnight with recombinant N-cadherin. 5T33MM cells and 5TGM1 cells were 
incubated with recombinant N-cadherin coated plates at 37°C for 0, 4, 8, 10, 15, 20, 
30 and 60 minutes. Wells were washed with PBS to remove non-adhering myeloma 
cells. Adherent cells were fixed and counted. 20 minutes was an optimal incubation 
time to incubated myeloma cells with recombinant N-cadherin or with osteoblasts. 
(n=4). 
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4.4.2 Determination the effect of increasing the concentration of recombinant    
N-cadherin required for myeloma cell adhesion  
5T33MM cells and 5TGM1 cells (1X10
5
 cells/100 μl) were plated and incubated in 
plates coated with different concentration of recombinant N-cadherin; 0, 0.1, 0.5, 1, 2, 5 
and 10 µg/ml at 37°C for 20 minutes. Figure 4.2 shows the adherence of myeloma cells; 
5T33MM and 5TGM1, to different concentrations of recombinant N-cadherin. The data 
clearly demonstrated an increase in the number of myeloma cells; 5T33MM and 
5TGM1 that were adherent to recombinant N-cadherin from 0 µg/ml to 2 µg/ml and this 
did not change with higher concentrations. 1 µg/ml was chosen as an effective 
concentration to incubate myeloma cells with recombinant N-cadherin as it was used in 
published protocol (Groen et al., 2011).  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.2: Effect of increasing the concentration of recombinant N-cadherin 
concentration. 96-well plates were coated overnight with 0, 0.1, 0.5, 1, 2, 5 and 10 
µg/ml of recombinant N-cadherin. 5T33MM cells and 5TGM1 cells were incubated 
with recombinant N-cadherin at 37°C for 20 minutes. Wells were washed with PBS to 
remove non-adhering myeloma cells. Adherent cells were fixed and counted. 1 µg/ml 
concentration was used as a concentration of recombinant N-cadherin. (n=4). 
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4.4.3 Myeloma cells:  5T33MM and 5TGM1 adhere to N-cadherin coated plates 
in vitro  
5T33MM cells and 5TGM1 cells (1X10
5
 cells/100 μl) were plated and incubated with 
recombinant N-cadherin at 37°C for 20 minutes. Figure 4.3 panel A shows the             
N-cadherin-positive 5T33MM cells specifically adhered to recombinant N-cadherin 
compared to PBS-coated plates as a negative control (2.45±0.24 versus 0.23±0.079, 
p<0.001). Figure 4.3 panel B shows the N-cadherin-positive 5TGM1 cells specifically 
adhered at higher frequency to recombinant N-cadherin compared to PBS-coated plates 
as a negative control (10.06±0.98 versus 0.42±0.17, p<0.001). In addition, data showed 
that there is some non-specific binding of myeloma cells with PBS-coated plates. 
However, these non-specific bindings represent less than 1%.  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.3: N-cadherin specifically increased the adhesion of myeloma cells: 
5T33MM and 5TGM1 in vitro. 96-well plates were coated overnight with 
recombinant N-cadherin. 5T33MM cells and 5TGM1 cells were incubated in plates 
with recombinant N-cadherin or PBS as a negative control at 37°C for 20 minutes. 
Wells were washed with PBS to remove non-adhering myeloma cells. Adherent cells 
were fixed (4% PFA) and counted using a light microscope. Results demonstrated               
N-cadherin-positive myeloma cells specifically adhered to recombinant N-cadherin 
coated plates compared to PBS-coated plates. *** = p<0.001. t test was used. (n=4). 
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4.4.4 Blocking N-cadherin significantly reduced the adhesion of myeloma cells: 
5T33MM and 5TGM1 to recombinant N-cadherin in vitro  
5T33MM cells or 5TGM1 cells were firstly treated with 10 μg/ml of anti-N-cadherin 
antibody (Sigma, UK) to block N-cadherin, or with 10 μg/ml of mouse IgG1 antibody 
(Dako, Denmark) as a negative control. 1X10
5
 cells/100 μl were plated and incubated 
with recombinant N-cadherin coated plates at 37°C for 20 minutes. Figure 4.4 panel A 
shows a statistically significant decrease in the adhesion of 5T33MM cells to 
recombinant N-cadherin when N-cadherin was blocked by anti-N-cadherin antibody 
compared with isotype control (0.51±0.20 versus 2.50±0.24, p<0.001). Figure 4.4 panel 
B shows a statistically significant decrease in the adhesion of 5TGM1 cells to 
recombinant N-cadherin when N-cadherin blocked by anti-N-cadherin antibody 
compared with isotype control (1.76±0.46 versus 10.36±0.75, p<0.001).  
 
In addition, figure 4.4 A and B also show that binding in the absence of N-cadherin was 
not affected by antibody treatment (Column 1 and 2). Myeloma cells, 5T33MM and 
5TGM1, were pre-treated with 10 μg/ml of anti-N-cadherin antibody or with 10 μg/ml 
of mouse IgG1 antibody and then plated onto plates incubated with PBS. The data 
showed that non-specific binding represent less that 1%. In addition, the data showed 
that when N-cadherin was blocked in myeloma cells with 10 μg/ml of anti-N-cadherin 
antibody, GC-4, the adhesion of non-specific binding was not affected compared with 
myeloma cells treated with 10 μg/ml of mouse IgG1 antibody plated onto plates 
incubated with PBS.  
 
 
 
 
Determining the role of N-cadherin in the formation of the myeloma niche 
  
 Page 151 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.4: Myeloma cells adherence to recombinant N-cadherin coated plates 
was blocked using an anti-N-cadherin antibody. 96-well plates were coated 
overnight with recombinant N-cadherin or PBS. 5T33MM cells and 5TGM1 cells 
were pre-treated with 10 μg/ml of anti-N-cadherin antibody or 10 μg/ml of mouse 
IgG1 antibody as a negative control and incubated with recombinant N-cadherin or 
PBS as a negative control at 37°C for 20 minutes. Wells were washed with PBS to 
remove non-adhering myeloma cells. Adherent cells were fixed (4% PFA) and 
counted using light microscopy. Results demonstrated significant decrease in the 
adhesion of 5T33MM cells (panel A) and 5TGM1 cells (panel C) when N-cadherin 
blocked by anti-N-cadherin antibody. PBS coated plates were used as negative control 
for the adhesion of 5T33MM cells and 5TGM1 cells, in which treated myeloma cells 
were plated and incubated with PBS coated plates. *** = p<0.001. ANOVA was used. 
(n=4). 
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4.4.5 N-cadherin was present in the attachment of myeloma cells:  5T33MM and 
5TGM1 to osteoblasts in vitro  
4.4.5.1 N-cadherin expression was observed at the junction of adherent myeloma 
cells and osteoblasts using immunofluorescence in vitro  
6X10
3
 cells/cm
2
 of mouse primary osteoblasts were seeded and differentiated for 7 days 
as the level of N-cadherin expression is low. 5x10
4
 cells/ml of 5T33MM-GFP cells and 
5TGM1-GFP cells were plated and incubated with immature osteoblasts (day 7) at 37°C 
for 20 minutes. The adhesion of myeloma cells with osteoblasts was determined by 
using immunofluorescence microscopy for GFP and immunostaining for N-cadherin 
(red). Figure 4.5 panel A shows the co-culture of 5T33MM cells with immature 
osteoblasts. Figure 4.5 panel B shows that N-cadherin is present in the interaction of 
adherent 5T33MM cells with osteoblasts. Figure 4.5 panel C shows the co-culture of 
5TGM1 cells with immature osteoblasts. Figure 4.5 panel D shows that N-cadherin is 
present in the interaction of adherent 5TGM1 cells with osteoblasts.  
 
 
 
 
 
 
 
 
 
 
Figure 4.5: N-cadherin expression was observed at the junction of myeloma cells 
and osteoblasts. Mouse primary osteoblasts were seeded and differentiated for           
7 days. Myeloma cells were plated and incubated with osteoblasts (day 7) at 37°C for 
20 minutes. Panel A and B show co-culture of 5T33MM-GFP cells with osteoblasts. 
Panel C and D show co-culture of 5TGM1-GFP cells with osteoblasts. (n=4). 
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4.4.5.2 Increased adhesion of myeloma cells, 5T33MM and 5TGM1, was observed 
with mature osteoblasts compared to pre-osteoblasts  
6X10
3
 cells/cm
2
 of mouse primary osteoblasts were seeded and differentiated for 4 
weeks in osteogenic media. 1X10
6
 cells/ml of 5T33MM cells and 5TGM1 were plated 
and incubated separately with pre-osteoblasts (day 7) and mature osteoblasts (day 28) at 
37°C for 20 minutes. Figure 4.6 panel A shows that adhesion of 5T33MM cells was 
significantly increased in co-cultures with mature osteoblasts compared to immature 
osteoblasts (4.70±0.70 versus 1.35±0.10, p<0.001). Figure 4.6 panel C shows that 
adhesion of 5TGM1 cells was significantly increased in co-culture with mature 
osteoblasts compared to immature osteoblasts (9.26±1.52 versus 2.95±0.30, p<0.001).  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.6: Increased adhesion of myeloma cells with mature osteoblasts 
compared to immature osteoblasts. Mouse primary osteoblasts were seeded and. 
1X10
6
 cells/ml of myeloma cells were plated and incubated with immature osteoblasts 
(day 7) and mature osteoblasts (day 28) at 37°C for 20 minutes. Wells were washed 
with PBS to remove non-adhering myeloma cells. Adherent cells were fixed and 
counted. Panel A shows significant increase in the adhesion of 5T33MM cells with 
mature osteoblasts compared with immature osteoblasts. Panel C shows significant 
increase in the adhesion of 5TGM1 cells with mature osteoblasts compared with 
immature osteoblasts. Panel B and D show representative images of the co-culture of 
myeloma cells with osteoblasts. *** = p<0.001. t test was used. (n=4). 
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4.4.5.3 Anti-N-cadherin antibody blocked the adhesion of myeloma cells: 5T33MM 
and 5TGM1 co-cultured with osteoblasts in vitro  
6X10
3
 cells/cm
2
 of mouse primary osteoblasts were seeded and differentiated for up to  
4 weeks from immature osteoblasts to mature functional osteoblasts in osteogenic 
media. 5T33MM cells and 5TGM1 cells were pre-treated using 10 μg/ml of anti-N-
cadherin antibody (Sigma, UK) to block N-cadherin, or 10 μg/ml of mouse IgG1 
antibody (Dako, Denmark) as a negative control. 1X10
6
 cells/100 μl of myeloma cells 
were plated and incubated with osteoblasts at 37°C for 20 minutes. Figure 4.7 panel A 
shows that adhesion of 5T33MM cells with immature osteoblasts (day 7) was 
significantly decreased when cells were treated with anti-N-cadherin antibody compared 
to untreated cells (0.60±0.09 versus 1.35±0.16, p<0.001) and cells treated with isotype 
control (0.60±0.09 versus 1.38±0.28, p<0.001). Figure 4.7 panel C shows a similar 
significant decrease in the adhesion of 5T33MM cells to mature osteoblasts (day 28) 
when cells were treated with anti-N-cadherin antibody compared to untreated cells 
(2.26±0.49 versus 4.70±0.70, p<0.001) and cells treated with isotype control (2.26±0.49 
versus 4.76±0.60, p<0.001). Figure 4.7 panel B and D shows representative images of 
the co-culture of 5T33MM cells with immature osteoblasts (day 7) and mature 
osteoblasts (day 28), respectively, with and without treatment.  
 
Figure 4.8 panel A shows that adhesion of 5TGM1 cells to immature osteoblasts (day 7) 
was significantly decreased when cells were treated with anti-N-cadherin antibody 
compared to untreated cells (1.17±0.11 versus 2.95±0.30, p<0.001) and cells treated 
with isotype control (1.17±0.11 versus 3.00±0.23, p<0.001). Figure 4.8 panel C shows a 
similar significant decrease in the adhesion of 5TGM1 cells to mature osteoblasts (day 
28) when cells treated with anti-N-cadherin antibody compared to untreated cells 
(4.45±1.01 versus 9.26±1.52, p<0.001) and cells treated with isotype control (4.45±1.01 
versus 9.62±0.60, p<0.001). Figure 4.8 panel B and D shows representative images of 
the co-culture of 5TGM1 cells with immature osteoblasts (day 7) and mature osteoblasts 
(day 28), respectively, with and without treatment.  
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Figure 4.7: 5T33MM cells adherence to osteoblasts was blocked using an anti-N-
cadherin antibody. 6X10
3
 cells/cm
2
 of mouse primary osteoblasts were seeded and 
differentiated for 4 weeks from immature osteoblasts to mature functional osteoblasts 
in osteogenic media. 5T33MM cells were pre-treated with 10 μg/ml of anti-N-
cadherin antibody or 10 μg/ml of mouse IgG1 antibody as a negative control and 
incubated with osteoblasts at 37°C for 20 minutes. Wells were washed with PBS to 
remove non-adhering myeloma cells. Adherent cells were fixed (4% PFA) and 
counted using light microscope. Results demonstrated significant decrease in the 
adhesion of 5T33MM cells with immature osteoblasts (panel A) and with mature 
osteoblasts (panel C) when N-cadherin blocked by anti-N-cadherin antibody. Panel B 
and D show representative images of the co-culture of 5T33MM cells with immature 
osteoblasts and mature osteoblasts with and without treatment. *** = p<0.001. 
ANOVA was used. (n=4). 
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Figure 4.8: 5TGM1 cells adherence to osteoblasts was blocked using an anti-N-
cadherin antibody. 6X10
3
 cells/cm
2
 of mouse primary osteoblasts were seeded and 
differentiated for 4 weeks from immature osteoblasts to mature functional osteoblasts 
in osteogenic media. 5TGM1 cells were pre-treated with 10 μg/ml of anti-N-cadherin 
antibody or 10 μg/ml of mouse IgG1 antibody as a negative control and incubated 
with osteoblasts at 37°C for 20 minutes. Wells were washed with PBS to remove non-
adhering myeloma cells. Adherent cells were fixed (4% PFA) and counted using light 
microscope. Results demonstrated significant decrease in the adhesion of 5TGM1 
cells with immature osteoblasts (panel A) and with mature osteoblasts (panel C) when       
N-cadherin blocked by anti-N-cadherin antibody. Panel B and D show representative 
images of the co-culture of 5TGM1 cells with immature osteoblasts and mature 
osteoblasts with and without treatment. *** = p<0.001. ANOVA was used. (n=4). 
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4.5 Discussion   
In this chapter I developed and optimized a co-culture system to study the interactions 
of MM cells with the osteoblasts via adhesion molecule, N-cadherin, in vitro. 5T33MM 
cells and 5TGM1 cells were cultured separately in vitro as described in methods. Mouse 
primary osteoblasts were obtained from calvarial bones of 2-4 day old C57Bl/6J mice, 
(Harlan, UK) and cultured in vitro as described in methods. Osteoblasts were 
differentiated into mature functional osteoblasts using an in vitro model of 
osteoblastogenesis, discussed in chapter 3. In co-cultures, myeloma cells were re-
suspended in 1 ml of RPMI media and seeded onto osteoblasts cultured in 24 well plates 
with each well containing 1 ml of α-MEM media.  
 
Increasing evidence indicates that the expression of N-cadherin in solid tumour cells 
mediates the invasion, metastasis and interaction of cancer cells from their primary site 
to establish new interactions with the surrounding microenvironment (Li et al., 2001, 
Lascombe et al., 2006, Gravdal et al., 2007). Shintani et al (2008) demonstrated that 
using a cyclic pentapeptide (ADH-1, N-Ac-CHAVC-NH2), targeting the HAV motif on 
EC1 of N-cadherin, significantly reduced growth and metastasis of pancreatic cancer 
cells in transgenic mice (Shintani et al., 2008). In addition, Beasley et al (2009) 
demonstrated that ADH-1 at a dose of 4000 mg in combination with melphalan on days 
1 and 8 was safe and well tolerated by patients in phase I studies and provided a novel 
targeted therapy approach in melanoma (Beasley et al., 2009). More recently, Tanaka et 
al (2010) demonstrated that prostate cancer metastasis and castration resistance are 
mainly caused by N-cadherin. Targeting N-cadherin using a monoclonal antibody 
against N-cadherin showed a reduction in proliferation, adhesion and invasion of 
prostate cancer cells in vitro and in vivo (Tanaka et al., 2010). Critically, no study has 
addressed blocking N-cadherin in myeloma.  
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Groen et al (2011) demonstrated that N-cadherin was expressed by myeloma cell lines, 
UM-1, OPM-1, NCI-H929 and LME-1, and primary myeloma cells. These cells 
specifically adhere to recombinant N-cadherin and this binding was showed to be 
specifically prevented by using an anti-N-cadherin antibody, GC-4 (10 μg/mL) (Groen 
et al., 2011). In this published protocol, myeloma cells were plated and incubated for 20 
minutes with recombinant N-cadherin (1 μg/ml). However, the authors did not show the 
optimal incubation period of myeloma cells with the recombinant N-cadherin. In 
addition, the authors did not show the optimal concentration required by the 
recombinant N-cadherin for the adhesion. In my study, Recombinant N-cadherin/Fc 
chimera (R&D Systems) was used to determine the optimal incubation period and 
recombinant N-cadherin concentration required for myeloma cells binding. I observed 
20 minutes to be the optimal incubation period of myeloma cells with recombinant      
N-cadherin or osteoblasts, with some loss of adherence after this. The reason for the 
latter are unclear but it may be that N-cadherin was lost from plastic surfaces with 
prolonged incubation, this needs to be evaluated. However, 20 minutes gave consistent, 
elevated rates of attachment and was a sufficient time frame for simple association to 
occur such as those provided by N-cadherin and was in line with other studies. In 
addition, I observed 2 µg/ml of recombinant N-cadherin is an effective concentration for 
adhesion assays. However, 1 µg/ml of recombinant N-cadherin was used in this study 
consistent with that used in published protocol (Groen et al., 2011). I also thought that 
higher levels of N-cadherin could be more difficult to block with antibodies in later 
experiments.  
 
In the adhesion assay experiments, I observed significant specific adhesion of myeloma 
cells to recombinant N-cadherin coated plates compared with PBS coated plates. 
Blocking N-cadherin with 10 μg/ml of anti-N-cadherin antibody showed significant 
decrease in the adhesion of myeloma cells with the recombinant N-cadherin. This 
observation is supported with the more recent work done by Groen et al (2011) who 
demonstrated that adhesion of myeloma cells was prevented by using an anti-N-
cadherin antibody, GC-4 (10 μg/mL) and suggests that N-cadherin is a specific 
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component of myeloma cell adhesion (Groen et al., 2011). In my adhesion assays some 
limitations were found. We showed non-specific binding of myeloma cells with PBS 
coated plates. However, this non-specific binding of myeloma cells with PBS coated 
plates represent approximately less that 1%. Additional controls were used to determine 
if this non-specific binding could be affected by anti-N-cadherin antibody. Myeloma 
cells, 5T33MM and 5TGM1, were pre-treated with 10 μg/ml of anti-N-cadherin 
antibody, GC-4, or with 10 μg/ml of mouse IgG1 antibody and plated onto plates 
incubated with PBS. The data showed that when N-cadherin was blocked in myeloma 
cells with 10 μg/ml of anti-N-cadherin antibody, GC-4, myeloma cells still bound to 
PBS coated plates and this binding was not prevented or decreased. These findings 
suggest that the non-specific binding was not affected by anti-N-cadherin antibody 
compared to mouse IgG1 antibody. In conclusion, since it was found that anti-N-
cadherin antibody, GC-4, only decreased the adhesion of myeloma cells to recombinant 
N-cadherin compared with PBS, this showed the specificity of the antibody used to 
block N-cadherin in these assays.  
 
I found that when N-cadherin was blocked in myeloma cells by 10 μg/ml of anti-N-
cadherin antibody, GC-4, the adhesion of myeloma cells was significantly decreased but 
not completely prevented. This could be due to the fact that the concentration of 
antibody used to block N-cadherin in myeloma cells was not enough to block N-
cadherin 100%. Groen et al (2011) demonstrated that 10 μg/ml of anti-N-cadherin 
antibody, GC-4, completely prevented the adhesion of myeloma cells, UM-1, OPM-1, 
NCI-H929, LME-1 and primary myeloma cells, with the recombinant N-cadherin 
(Groen et al., 2011). In contrast, Ciolczyk-Wierzbicka et al (2004) blocked N-cadherin 
in human melanoma cell lines using anti-N-cadherin antibody, GC-4, (40 µg/ml), a 
treatment which inhibited the migration of melanoma cells by about 40% in vitro 
(Ciolczyk-Wierzbicka et al., 2004). In addition, Wein et al (2010) blocked N-cadherin 
in human HSCs using anti-N-cadherin antibody, GC-4, (50 µg/ml), which significantly 
reduced the adhesion of HSCs to MSCs (Wein et al., 2010). It would be useful to know 
the concentration needed to completely block N-cadherin in cellular attachment and as 
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in the studies with recombinant N-cadherin. In future work different concentrations of 
anti-N-cadherin antibodies will need to be tested for the ability to block N-cadherin in 
myeloma cells to determine the effective antibody concentrations. It has been shown 
that myeloma cells use another molecule to bind to N-cadherin, as it was found that    
N-cadherin can bind to FGFR (Williams et al., 2001, Suyama et al., 2002, Sanchez-
Heras et al., 2006). Future work might consider blocking both N-cadherin and FGFR in 
myeloma cells to completely prevent the adhesion of myeloma cells with recombinant 
N-cadherin. Earlier studies by Shintani et al (2008) demonstrated that using the cyclic 
ADH-1 pentapeptide, N-cadherin antagonist, significantly reduced growth and 
metastasis of pancreatic cancer cells in transgenic mice (Shintani et al., 2008). In 
addition, ADH-1 might be considered to effectively block N-cadherin in myeloma cells 
to completely prevent the adhesion of myeloma cells with recombinant N-cadherin.  
 
A previous study by Groen et al (2011) demonstrated that myeloma cells adhere to 
osteoblasts, and this adhesion is prevented by using an N-cadherin blocking antibody,  
GC-4 (10 μg/mL) (Groen et al., 2011). However, the previous study did not investigate 
differences between adhesion of myeloma cells to immature osteoblasts compared to 
mature osteoblasts. My data showed that N-cadherin was expressed at the junction of 
myeloma cells with osteoblasts suggesting a direct interaction of myeloma cells with 
osteoblasts via N-cadherin. This was the first time this has been visualized as part of the 
attachment of myeloma cells to osteoblasts using immunocytochemistry and again 
suggests that N-cadherin is specifically involved in these interactions. When myeloma 
cells were co-cultured with immature osteoblasts (day 7), the level of N-cadherin 
expression was significantly lower than in mature osteoblasts, and this therefore 
allowed very specific associations between cells to be demonstrated with attachment 
shown only between adjacent osteoblasts when N-cadherin could be shown to be 
present.  
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My study also demonstrated that there was a significant increase in the adhesion of 
myeloma cells with mature osteoblasts compared to immature osteoblasts and this is 
due to the fact that the expression of N-cadherin is significantly increased in mature 
osteoblasts compared to immature osteoblasts as described in chapter 3. Blocking      
N-cadherin with 10 μg/ml of anti-N-cadherin antibody showed a significant decrease in 
the adhesion of myeloma cells to osteoblasts. These data suggest that colonising          
N-cadherin
+
 myeloma cell can bind to both immature and mature osteoblasts and either 
may be involved in the formation of the myeloma niche in vivo. Colonising N-cadherin
+
 
myeloma cell could be more likely to attach to mature osteoblasts in vivo due to the 
higher N-cadherin expression in the these cells. However, the ubiquitous distribution of 
N-cadherin in the latter may not supply the specific positioning allowed by that 
provided by the junctions between immature osteoblasts, which association represent 
“niches” remains to be determined. When N-cadherin was blocked in myeloma cells by 
10 μg/ml of anti-N-cadherin antibody, GC-4, the adhesion of myeloma cells with 
osteoblasts was significantly decreased but not completely prevented. This could be 
because the concentration of antibody used to block N-cadherin in myeloma cells was 
not enough to block N-cadherin 100%. Alternatively, interaction of N-cadherin with 
FGFR or the presence of other molecules could be contributing to these interaction 
(Williams et al., 2001, Suyama et al., 2002, Sanchez-Heras et al., 2006).  
 
In summary, I can conclude that N-cadherin is at least part of the process of adherence 
of myeloma cells to osteoblasts. My observations may support a role for mature 
osteoblasts being likely niche components for myeloma cells since they express high 
levels of N-cadherin and bind more myeloma cells significantly in vitro. This may mean 
that the interactions of myeloma cells with mature functional osteoblasts are more likely 
in vivo and these will be investigated in the next chapter by determining different bone 
microenvironments in calvarial bones.  
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5 Chapter 5: Different calvarial bones; frontal, 
parietal and interparietal contain different bone 
microenvironments 
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5.1 Introduction  
To support our understanding of MM bone disease, preclinical mouse models have been 
developed. C57BL/KaLwRijHsd mice develop a high frequency of monoclonal 
proliferative B-cell disorders. Cells within BM provide a microenvironment for 
myeloma cells survival and potentially for the development of drug resistance. Murine 
models of multiple myeloma have been developed over the last four decades. The 
5TMM series of myeloma models originate from spontaneously developed MM in 
C57BL/KaLwRijHsd mice and have many of the human features of the disease (Radl et 
al., 1978, Radl et al., 1979, Vanderkerken et al., 1997). Several murine models of MM 
exist, but 5T2, 5T33 and 5TGM1 are the best characterized and used in most recent 
studies (Vanderkerken et al., 2000, Croucher et al., 2003, Alici et al., 2004, Van 
Valckenborgh et al., 2012, Olson et al., 2005, Edwards et al., 2009, Fowler et al., 2012). 
Oyajobi et al (2007) demonstrated the murine myeloma 5TGM1-GFP tumour was 
detectable in calvariae between 10-14 days post intravenous inoculation into animals 
suggesting that these cells home to calvarial BM (Oyajobi et al., 2007). However, this 
study lacked the imaging capability to study the arrival of single cells in calvarial BM. 
There are no publications that demonstrate the murine myeloma 5T33MM model can 
home to calvarial BM in C57BL/KaLwRijHsd mice.  
 
The 5T2MM model originated from spontaneously developed myeloma in aging mice 
and represents a model of human MM disease with inducing osteolytic bone lesions 
(Radl et al., 1985, Vanderkerken et al., 1997, Asosingh et al., 2000b, Croucher et al., 
2003). The 5T33MM model also originated from a spontaneously developed myeloma 
in aging mice and represents a model of human MM disease, but without inducing 
osteolytic bone lesions (Manning et al., 1992, Vanderkerken et al., 1997, Asosingh et 
al., 2000b). The 5TGM1 model was derived from the 5T33 model, in which 5T33MM 
cells were passaged in mice and the cells were then obtained from the marrow of 
5T33MM-bearing mice, cultured and cloned.  The 5TGM1 model represents a model of 
human MM disease that induces osteolytic bone lesions (Garrett et al., 1997, Dallas et 
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al., 1999). The 5T33MM and 5TGM1 models can grow in vitro as well as in vivo 
whereas the 5T2MM model only grows slowly in vivo and not in vitro (Radl et al., 
1985, Vanderkerken et al., 1997, Garrett et al., 1997, Dallas et al., 1999). In this study, 
the 5T33MM model and 5TGM1 model have been used. The 5T2MM model was not 
used because I did not have an access to this model, which is restricted. Together the 
5T33MM and 5TGM1 models offer advantages to address MM-bone interactions. The 
5T33MM cell line is not osteolytic in character whereas the 5TGM1 is. Both use the 
same genetic background. Both grow in syngeneic immuno-completed hosts in vivo. 
Havening an intact immune system allows the induction of all potential interacting cell 
types in bone. This is not offered by xenograft models.  
 
It was shown that in calvarial mice, MSCs differentiate into osteoprogenitor cells then 
differentiate into osteoblasts that differentiate into osteocytes, which become embedded 
within the bone matrix. In this case cells participating in bone formation include: MSCs, 
osteoprogenitor cells, osteoblasts and osteocytes. In contrast, in long bones, MSCs 
differentiate into chondrocytes forming the cartilage anlagen. Cells from the 
perichondrium of cartilage anlagen differentiate into osteoblasts, and the periphery of 
the cartilage anlage becomes hypertrophic. Matrix surrounding these hypertrophic 
chondrocytes calcifies and longitudinal growth is stimulated as cartilaginous matrix. In 
this case cells participating in bone formation include: MSCs, perichondrium, 
chondrocytes, periosteum, hypertrophic chondrocytes, osteoclasts osteoblasts and 
osteocytes (Nakashima and de Crombrugghe, 2003). As we are interested in osteoblasts, 
we expected to see more osteoblasts compared to other cells in the calvariae. In this 
chapter I focused on the calvarial bones of C57BL/KaLwRijHsd mice. 
C57BL/KaLwRijHsd mice were purchased from Harlan, Netherlands and housed by 
University of Sheffield Biological Services Laboratory. The calvariae of 
C57BL/KaLwRijHsd mice are composed of five bones: two frontal bones, two parietal 
bones and one interparietal bone (Figure 5.1). In preliminary studies I determined the 
distribution of osteoclasts, osteoblasts and bone lining cells in each part of calvariae: 
frontal, parietal and interparietal to determine if different calvarial bones contain 
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different bone microenvironments. Then, I used the 5T33MM and 5TGM1 models, 
where these cells were inoculated into C57BL/KaLwRijHsd mice via their tail veins. 
The aim of this chapter was to determine if different calvarial bones contain different 
bone microenvironments and to study single cell arrival in calvarial BM.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.1: A microCT three-dimensional reconstruction of C57BL/KaLwRijHsd 
mice calvarial bone. microCT model of a murine skull showing calvariae are 
composed of two frontal bones, two parietal bones and one interparietal bone (red 
arrows). Frontal and parietal bones are separated longitudinally by sagittal suture. 
Coronal suture separates frontal bones from parietal bones. Lamboidal suture 
separates parietal bones from interparietal bone.  
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5.2 Hypothesis and objectives of this chapter  
5.2.1 Hypothesis  
Different calvarial bones; frontal, parietal and interparietal contain different bone 
microenvironments for the support of myeloma survival and growth.  
 
5.2.2 Objectives   
To test this hypothesis I have:  
1. Determined the bone surface area and BM area in C57BL/KaLwRijHsd 
calvariae.  
2. Determined the distribution of osteoclasts in C57BL/KaLwRijHsd calvariae.  
3. Determined the distribution of osteoblasts in C57BL/KaLwRijHsd calvariae.  
4. Determined the distribution of bone lining cells in C57BL/KaLwRijHsd 
calvariae.  
5. Determined the new bone formation in C57BL/KaLwRijHsd calvariae.  
6. Determined the growth of tumours in C57BL/KaLwRijHsd calvarial BM using 
5T33MM and 5TGM1 models.  
7. Determined the single myeloma cell number in C57BL/KaLwRijHsd calvarial 
BM using 5T33MM and 5TGM1 models.  
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5.3 Materials and Methods   
5.3.1 Study to determine the distribution of osteoclasts, osteoblasts and quiescent 
bone in C57BL/KaLwRijHsd calvariae  
C57BL/KaLwRijHsd calvariae were excised carefully from 5 male mice, 6 weeks of 
age and stored in formalin. Frontal, parietal, and interparietal bones were dissected to 
determine the bone microenvironment in calvariae as described in section 2.2.17. TRAP 
staining was used to determine the distribution of osteoclasts as described in section 
2.2.13.1. Haematoxylin and eosin staining was used to determine the frequency of 
osteoblasts and bone lining cells as described in section 2.2.13.2. Osteomeasure 
software version 4.10 (Osteomerics Incorporated, Atlanta, USA) was used to analyse 
the sections.  
 
5.3.2 Study to determine the distribution of new bone formation in 
C57BL/KaLwRijHsd calvariae  
4 male C57BL/KaLwRijHsd mice, 6 weeks of age, were injected with 200μl of calcein-
GFP (3 mg/ml in PBS) each at day 0. After 3 days, mice were sacrificed and calvariae 
were excised to determine the new bone formation in different part of calvariae bones: 
frontal, parietal and interparietal as described in section 2.2.18. Zeiss 510 multiphoton 
laser scanning microscope was used to analyse the new bone formation.  
 
5.3.3 Study to determine if myeloma tumour can grow in C57BL/KaLwRijHsd 
calvarial BM  
9 male C57BL/KaLwRijHsd mice, 6 weeks of age, were used in this experiment and 
separated to 3 groups to determine the myeloma tumour growth in calvarial BM as 
described in section 2.2.19. Lightools system used to obtain optical images of 
fluorescent tumour growth in calvarial BM.  
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5.3.4 Study to determine the single cell numbers arriving in C57BL/KaLwRijHsd 
calvarial BM 
12 male C57BL/KaLwRijHsd mice, 6 weeks of age, were used in this experiment and 
separated into 4 groups to determine the single cell numbers in calvarial BM in the early 
and late stage of disease as described in section 2.2.20. Zeiss 510 multiphoton laser 
scanning microscope was used to determine the cell numbers in C57BL/KalwRij 
calvarial BM.  
 
5.3.5 Cell labelling with DiD  
5T33MM cells and 5TGM1 cells were labelled with DiD (Invitrogen, UK) to easily 
identified myeloma cells under fluorescent microscopy as described in section 2.2.11.  
 
5.3.6 Inoculation of MM cells into C57BL/KaLwRijHsd mice  
Myeloma cells for injection were re-suspended in PBS (2x10
6
 cells/200 µl). 
C57BL/KaLwRijHsd mice were handled and their tails were anesthetized using 
EMLA
TM
 cream 5% (AstraZeneca, UK) and myeloma cells were inoculated into mouse 
via their tail veins as described in section 2.2.12.  
 
5.3.7 Microscopic examination  
Osteomeasure software version 4.10 (Osteomerics Incorporated, Atlanta, USA) was 
used with a Leitz DMRB microscope and a drawing tablet, (CalComp Drawing Broad 
III) to determine the distribution of osteoclasts, osteoblasts and bone lining as described 
in section 2.2.14.2. A Zeiss 510 Multiphoton Laser Scanning Microscopy was used to 
visualise fluorescence as described in section 2.2.14.1.  
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5.3.8 Using the Lightools image analysis system to detect the tumour in 
C57BL/KaLwRijHsd mice  
All calvariae were analysed using Fluorescence Cheda Lightools Illumatools System 
(LT-9900 Bright Light System) in the University of Sheffield biological services 
laboratory to determine the tumour growth in calvariae as described in section 2.2.15.  
 
5.3.9 Statistical analysis  
The data were analysed using an ANOVA test (one-way analysis of variance) for more 
than two group comparisons or with t test for two group comparisons if the data was 
normally distributed. Tukey's test was used as post-hoc analysis when ANOVA test was 
used in normal distribution data. When data not normally distributed, ANOVA test 
(non-parametric Kruskal-Wallis test) was used for more than two group comparisons or 
non-parametric Mann–Whitney test was used for two group comparisons. Dunns test 
was used as post-hoc analysis when ANOVA test was used in not normally distributed 
data. Data were considered statistically significant when a p-value was equal to or less 
than 0.05. Results are expressed as mean ± values of standard deviation (SD).  
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5.4 Results  
5.4.1 Determination of the bone surface area and BM area in 
C57BL/KaLwRijHsd calvariae 
The bone surface area and BM area in C57BL/KaLwRijHsd calvariae was determined 
(Figure 5.2). Histological analysis demonstrated statistically significant increases in the 
bone surface area in interparietal bones compared to frontal bones (1.3±0.17 versus 
0.76±0.15, p<0.001) and parietal bones (1.3±0.17 versus 0.55±0.10, p<0.001) (Figure 
5.3 A). Furthermore, data demonstrated statistically significant increases in the BM area 
in interparietal bones compared to frontal bones (2.55±0.48 versus 0.41±0.05, p<0.001) 
and parietal bones (2.55±0.48 versus 0.21±0.02, p<0.001) (Figure 5.3 B). The ratio of 
the volume of BM to the bone surface area was significant increases in the interparietal 
bones compared to frontal bones (1.85±0.31 versus 0.60±0.25, p<0.001) and parietal 
bones (1.85±0.31 versus 0.42±0.05, p<0.001) (Figure 5.3 C).  
 
5.4.2 Determination of the percentage of osteoclast surfaces in 
C57BL/KaLwRijHsd calvariae  
Cortical bone was identified as an outside solid bone with a regular structure whereas 
trabecular bone identified as a bone inside the BM with an irregular structure (see figure 
5.2 B). Endo-cortical bone surface is a surface of the cortical bone inside the BM. The 
distribution of osteoclasts was determined on endo-cortical and trabecular surfaces in 
interparietal bones and on endo-cortical surfaces in frontal and parietal bones. No 
trabeculae were observed in frontal and parietal bones. Histological analysis 
demonstrated that there was no statistically significant difference in the percentage of 
bone surface covered by osteoclasts in the interparietal bones compared to frontal bones 
(15.61±6.42 versus 18.84±7.88, p>0.05) and parietal bones (15.61±6.42 versus 
12.80±3.04, p>0.05) (Figure 5.4 A). Analysis did show there was a significant increase 
in the frequency of osteoclasts in the lower endo-cortical surfaces compared to the 
upper endo-cortical surfaces in frontal bones (32.77±14.19 versus 4.90±2.69, p<0.05) 
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Figure 5.2: Sectioning of calvarial bones across their regions of interest. Panel A 
is microCT model of a murine skull showing calvariae are composed of frontal (F), 
parietal (P) and interparietal (IP) bones, respectively. Panels B, C and D show cross-
sections of frontal, parietal and interparietal bones, respectively. BM is bone marrow, 
CB is cortical bone and TB is trabecular bone. (n=5). 
(Figure 5.5 A) and in parietal bones (22.11±6.71 versus 3.94±1.73, p<0.05) (Figure 5.5 
B). In interparietal bones there was a similar trend, but this was not significant, 
(19.19±10.97 versus 8.63±6.04, p=0.07) (Figure 5.5 C).  
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Figure 5.3: There was an increase in the bone surface area and BM areas in the 
interparietal bones compared to frontal and parietal bones in male 
C57BL/KalwRiJHsD mice. There was a significant increase in the bone surface in 
interparietal bones compared to frontal and parietal bones (A), in the volume of BM in 
interparietal bones compared to frontal and parietal bones (B) and in ration of the 
volume of BM to the bone surface (C). *** = p<0.001. ANOVA test was used. (n=5). 
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Figure 5.4: There was no difference 
the percentage of osteoclast surfaces 
between the different parts of 
calvariae in male 
C57BL/KalwRiJHsD mice. Frontal, 
parietal and interparietal sections of 
calvariae were stained with TRAP. 
Panel A shows there was no 
statistically significant difference in 
the distribution of osteoclasts in the 
different part of calvariae. Panels B 
shows a representative 
photomicrographic image of 
osteoclasts (black arrow). ANOVA 
test was used. (n=5). 
Figure 5.5: There was an increase in the percentage of osteoclast covered 
surfaces in the lower endo-cortical surfaces compared to the upper endo-cortical 
surfaces in male C57BL/KalwRiJHsD mice. There was a significant increase in the 
distribution of osteoclasts in the lower endo-cortical surfaces compared to the upper 
endo-cortical surfaces in frontal bones (A) and parietal (B), but not in interparietal 
(C). In the interparietal bones (C) there was no significant difference in the 
distribution of osteoblasts between trabecular surfaces and endo-cortical surfaces.      
* = p<0.05. ANOVA and Mann Whitney tests were used. (n=5). 
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5.4.3 Determination of the percentage of osteoblast surfaces in 
C57BL/KaLwRijHsd calvariae  
The distribution of osteoblasts was determined on endo-cortical and trabecular surfaces 
in interparietal bones and on endo-cortical surfaces in frontal and parietal bones. 
Histological analysis demonstrated statistically significant increases in the distribution 
of osteoblasts in interparietal bones compared to frontal bones (55.05±5.47 versus 
32.20±6.84, P<0.01) and parietal bones (55.05±5.47 versus 33.85±7.22, P<0.01) (Figure 
5.6 A). Data showed there is no statistically significant difference in the distribution of 
osteoblasts between frontal and parietal bones (32.20±6.84 versus 33.85±7.22). 
Furthermore, data showed there was significant increase in the distribution of 
osteoblasts in the upper endo-cortical surfaces compared to the lower endo-cortical 
surfaces in parietal bones (40.29±6.45 versus 27.41±8.15, p<0.05) (Figure 5.7 A) but 
not in frontal bones (Figure 5.7 B) and interparietal bones (Figure 5.7 C).  
 
5.4.4 Determination of the percentage of bone lining cell surfaces in 
C57BL/KaLwRijHsd calvariae  
The distribution of bone lining cells was determined on endo-cortical and trabecular 
surfaces in interparietal bones and on endo-cortical surfaces in frontal and parietal 
bones. Histological analysis demonstrated statistically significant decreases in the 
distribution of bone lining cells in interparietal bones compared to frontal bones 
(30.65±10.72 versus 49.17±5.74, P<0.05) and parietal bones (30.65±10.72 versus 
51.51±8.98, P<0.05) (Figure 5.14 A). Data showed there is no statistically significant 
deference in distribution of bone lining cells between frontal and parietal bones (Figure 
5.8 A). Furthermore, data showed there was no statistically significant difference in the 
distribution of bone lining cells in the lower endo-cortical surfaces compared to the 
upper endo-cortical surfaces in frontals bones (Figure 5.9 A), in parietal bones (Figure 
5.9 B) and interparietal bones (Figure 5.9 C).  
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Figure 5.6: There was an increase in 
the percentage of osteoblast 
surfaces in the interparietal bones 
compared to the frontal and 
parietal bones in male 
C57BL/KalwRiJHsD mice. Frontal, 
parietal and interparietal sections of 
calvariae were stained with 
haematoxylin and eosin. Panel A 
shows there was a statistically 
significant increase in the distribution 
of osteoblasts in the interparietal bone 
of calvariae. Panels B shows a 
representative photomicrographic 
image of osteoblasts (black arrow).  
** = p<0.01. ANOVA test was used. 
(n=5). 
Figure 5.7: The percentage of osteoblast surfaces in the lower endo-cortical 
surfaces compared to the upper endo-cortical surfaces in male 
C57BL/KalwRiJHsD mice. There was a significant increase in the distribution of 
osteoblasts in the upper endo-cortical surfaces compared to the lower endo-cortical 
surfaces in parietal bones (B), but not in frontal (A) and interparietal (C). In the 
interparietal bones (C) there was a significant decrease in the distribution of 
osteoblasts in trabecular surfaces compared to endo-cortical surfaces. * = p<0.05. 
ANOVA and Mann Whitney tests were used. (n=5). 
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Figure 5.8: There was a decrease in 
the percentage of bone lining cell 
surfaces in the interparietal bones 
compared to the frontal and 
parietal bones in male 
C57BL/KalwRiJHsD mice. Frontal, 
parietal and interparietal sections of 
calvariae were stained with 
haematoxylin and eosin. Panel A 
shows there was a statistically 
significant decrease in the distribution 
of bone lining cells in the interparietal 
bone of calvariae. Panel B shows a 
representative photomicrographic 
image of bone lining cells (black 
arrow). * = p<0.05. ANOVA test was 
used. (n=5). 
Figure 5.9: The percentage of bone lining cells surfaces in the lower endo-cortical 
surfaces compared to the upper endo-cortical surfaces in male 
C57BL/KalwRiJHsD mice. There was a significant decrease in the distribution of 
bone lining cells in the lower endo-cortical surfaces compared to the upper endo-
cortical surfaces in frontal bones (A), but not in parietal (B) and interparietal (C). In 
the interparietal bones (C) there was a significant increase in the distribution of bone 
lining cells in trabecular surfaces compared to endo-cortical surfaces. * = p<0.05. 
ANOVA and Mann Whitney tests were used. (n=5). 
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5.4.5 Determination of the sites of new bone formation in C57BL/KaLwRijHsd 
calvariae  
New bone formation was determined on endo-cortical and trabecular surfaces in 
interparietal bones and on endo-cortical surfaces in frontal and parietal bones. Mice 
were injected with 200μl of 3 mg/ml calcein-GFP each and after 3 days mice were 
sacrificed and calvariae were excised carefully. The results illustrated that there was an 
increase in the new bone formation (in green) in the interparietal bones compared to 
frontal bones (22.90±13.28 versus 10.83±4.11, p=0.09) and parietal bones (22.90±13.28 
versus 9.26±1.00, p=0.07) after 3 days, but this is not significant (Figure 5.10 E). Figure 
5.10 B, C & D show representative photomicrographic images of interparietal, parietal 
and frontal bones respectively 3 days post calcein-GFP injection.  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.10: There was an increase in new bone formation in the interparietal 
bones in male C57BL/KalwRiJHsD mice. Mice were sacrificed and calvariae were 
excised carefully 3 days post calcein-GFP injection. The results illustrated an increase 
in the new bone formation (in green) in interparietal compared to frontal and parietal 
(E), but this is not significant. Panels B, C & D show representative 
photomicrographic images of interparietal, parietal and frontal bones. (n=4). 
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5.4.6 Determination the growth of tumour in C57BL/KaLwRijHsd calvarial BM 
using 5T33MM and 5TGM1 models  
C57BL/KaLwRijHsd mice were inoculated with PBS, 2x10
6
 5T33MM-GFP cells and 
5TGM1-GFP cells via their tail vein. 21 days post inoculation calvariae were analysed 
using Fluorescence Lightools Illumatools System (LT-9900 Bright Light System). 
Figure 5.11 B shows GFP-expressing of 5T33MM tumour growth only in interparietal 
bones, but not in frontal or parietal bones. Figure 5.11 C shows GFP-expressing of 
5TGM1 tumour growth in frontal and interparietal bones, but not in parietal bones. 
Figure 5.11 A shows a PBS injected control after 21 days. Figure 5.11 D shows the 
semi-quantitative analysis of myeloma tumour growth using 5T33MM model and 
5TGM1 model. Data showed that there was a significant increase in the GFP signal in 
mice infected with tumour cells compared to the naive mice (5T33MM: 14.32±4.04 
versus 0.00±0.00, P<0.001) (5TGM1: 26.39±2.00 versus 0.00±0.00, P<0.001).  
 
 
 
 
 
 
 
 
 
 
 
Figure 5.11: Myeloma tumour growth was detected in calvarial BM male 
C57BL/KalwRiJHsD mice. Mice were inoculated with 5T33MM-GFP and 5TGM1-
GFP cells. 21 days post inoculation mice were sacrificed and calvariae were excised. 
The results illustrated that murine myeloma 5T33MM-GFP (B) and 5TGM1-GFP (C) 
tumour were detectable in calvarial BM. Panel A shows the PBS injected control 
mouse after 21 days. Panel D shows the percentage of myeloma tumour growth. 
ANOVA test was used. (n=3/group). 
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5.4.7 Determination of single cell numbers in C57BL/KaLwRijHsd calvarial BM 
using 5T33MM and 5TGM1 models  
5.4.7.1 Determination of single cell numbers in calvarial bone marrow using 
5T33MM model in the early stage of disease  
C57BL/KaLwRijHsd mice were inoculated with 2x10
6
 5T33MM-DiD cells via their tail 
vein. 3 days post inoculation, mice were harvested and calvariae were analysed using a 
Zeiss 510 laser scanning microscope. Figure 5.12 A shows that there was a statistically 
significant increase in the number of 5T33MM-DiD cells present in the interparietal 
bones compared to frontal bones (98.71±42.48 versus 20.71±15.98, P<0.001) and 
parietal bones (98.71±42.48 versus 5.57±3.45, P<0.001). Figure 5.12 B, C & D show 
representative photomicrographic images of frontal, parietal and interparietal bones 
respectively 3 days post 5T33MM-DiD cells inoculation.  
 
 
 
 
 
 
 
 
 
 
 
Figure 5.12: 5T33MM cells are detectable in calvarial BM male 
C57BL/KalwRiJHsD mice. Mice were inoculated with 5T33MM-DiD cells. 3 days 
post inoculation mice were sacrificed and calvariae were excised. Panel A shows a 
significant increase in the number of 5T33MM cells in interparietal bones compared 
to frontal and parietal bones. Panels B, C & D show representative photomicrographic 
images of interparietal, parietal and frontal bones. *** = p<0.001. ANOVA test was 
used. Blue fluorescence is the bone and red fluorescence is 5T33MM-DiD cells. Size 
between 500 – 20,000 µm3 was considered as individual DiD labelled cell. (n=3). 
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5.4.7.2 Determination of single cell numbers in calvarial bone marrow using 
5TGM1 model in the early stage of disease  
C57BL/KaLwRijHsd mice were inoculated with 2x10
6
 5TGM1-DiD cells via their tail 
vein. 3 days post inoculation, mice were harvested and calvariae were analysed using a 
Zeiss 510 laser scanning microscope. Figure 5.13 A shows that there was a statistically 
significant increase in the number of 5TGM1-DiD cells present in the interparietal 
bones compared to frontal bones (81.67±40.50 versus 9.33±11.02, P<0.05) and parietal 
bones (81.67±40.50 versus 6.33±8.38, P<0.05). Figure 5.13 B, C & D show 
representative photomicrographic images of frontal, parietal and interparietal bones 
respectively 3 days post 5TGM1-DiD cells inoculation.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.13: 5TGM1 cells are detectable in calvarial BM male 
C57BL/KalwRiJHsD mice. Mice were inoculated with 5TGM1-DiD cells. 3 days 
post inoculation mice were sacrificed and calvariae were excised. Panel A shows a 
significant increase in the number of 5TGM1 cells in interparietal bones compared to 
frontal and parietal bones. Panels B, C & D show representative photomicrographic 
images of interparietal, parietal and frontal bones. * = p<0.05. ANOVA test was used. 
Blue fluorescence is the bone and red fluorescence is 5TGM1-DiD cells. Size between 
500 – 20,000 µm3 was considered as individual DiD labelled cell. (n=3). 
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5.4.7.3 Determination of quiescent cell numbers in calvarial bone marrow using 
5T33MM model in the late stage of disease  
C57BL/KaLwRijHsd mice were inoculated with 2x10
6
 5T33MM-DiD cells via their tail 
vein. 21 days post inoculation, mice were harvested and calvariae were analysed using a 
Zeiss 510 laser scanning microscope. Figure 5.14 A shows that there was a statistically 
significant increase in the number of quiescent 5T33MM cells, cells did not losing DiD 
dye, present in the interparietal bones compared to frontal bones (562.00±178.90 versus 
117.00±7.55, P<0.01) and parietal bones (562.00±178.90 versus 67.00±13.75, P<0.01). 
Figure 5.14 B, C & D show representative photomicrographic images of frontal, parietal 
and interparietal bones respectively 21 days post 5T33MM-DiD cells inoculation.  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.14: 5T33MM cells are detectable in calvarial BM male 
C57BL/KalwRiJHsD mice. Mice were inoculated with 5T33MM-DiD cells. 21 days 
post inoculation mice were sacrificed and calvariae were excised. Panel A shows a 
significant increase in the number of quiescent 5T33MM cells in interparietal bones 
compared to frontal and parietal bones. Panels B, C & D show representative 
photomicrographic images of interparietal, parietal and frontal bones. ** = p<0.01. 
ANOVA test was used. Blue fluorescence is the bone and red fluorescence is 
5T33MM-DiD cells. Size between 500 – 20,000 µm3 was considered as individual 
DiD labelled cell. (n=3). 
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5.4.7.4 Determination of quiescent cell numbers in calvarial bone marrow using 
5TGM1 model in the late stage of disease  
C57BL/KaLwRijHsd mice were inoculated with 2x10
6
 5TGM1-DiD cells via their tail 
vein. 21 days post inoculation, mice were harvested and calvariae were analysed using a 
Zeiss 510 laser scanning microscope. Figure 5.15 A shows that there was a statistically 
significant increase in the number of quiescent 5TGM1 cells, cells did not losing DiD 
dye, present in the interparietal bones compared to frontal bones (233.00±53.84 versus 
79.67±18.77, P<0.05) and parietal bones (233.00±53.84 versus 27.33±10.41, P<0.05). 
Figure 5.15 B, C & D show representative photomicrographic images of frontal, parietal 
and interparietal bones respectively 21 days post 5TGM1-DiD cells inoculation.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.15: 5TGM1 cells are detectable in calvarial BM male 
C57BL/KalwRiJHsD mice. Mice were inoculated with 5TGM1-DiD cells. 21 days 
post inoculation mice were sacrificed and calvariae were excised. Panel A shows a 
significant increase in the number of quiescent 5TGM1 cells in interparietal bones 
compared to frontal and parietal bones. Panels B, C & D show representative 
photomicrographic images of interparietal, parietal and frontal bones. ** = p<0.05. 
ANOVA test was used. Blue fluorescence is the bone and red fluorescence is 5TGM1-
DiD cells. Size between 500 – 20,000 µm3 was considered as individual DiD labelled 
cell. (n=3). 
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5.5 Discussion  
In this chapter the bone surfaces of calvariae: frontal, parietal and interparietal were 
analyzed. The primary aim was to test the hypothesis that calvarial bones contained 
different bone microenvironments. This was done by determining the frequency of 
osteoclasts, osteoblasts and bone lining cells, and new bone formation in 
C57BL/KaLwRijHsd calvariae to establish the potential myeloma niche, and then by 
inoculating mice with myeloma cells to determine the single cell/quiescent cell numbers 
and tumour growth in C57BL/KaLwRijHsd calvarial bones.  
 
Previous studies demonstrated two HSC niches: osteoblastic niche on endosteal surfaces 
and the vascular niche (sinusoidal vessels). HSCs home to, and reside, in the HSC niche 
‘osteoblast niche’ via attachment to spindle shaped N-cadherin+ osteoblast cells on the 
endosteal bone surface (Zhang et al., 2003, Xie et al., 2009). This may represents a 
quiescent soil to maintain HSC survival and maintenance. Lo Celso et al (2009) 
analysed the frontal bones of calvariae to study individual HSC in their niche; the 
osteoblastic niche (Lo Celso et al., 2009). The authors offered no biological explanation 
why the frontal region of bone was analysed. The authors also did not report if there 
were discrete micro-anatomical sites within the region of bone analysed. However, it is 
unknown which part of the calvariae is a niche or containing a higher number of 
osteoblast responsible for quiescent HSCs. Micro-anatomical sites with different 
osteoblast numbers may exert different effect upon adjacent cells; for example, higher 
osteoblast numbers in one specific site may provide increase interaction between 
osteoblasts and myeloma cells compared to other sites. In my study bone surfaces area 
and BM area were analysed in frontal, parietal and interparietal regions of calvariae. In 
addition, the percentage of osteoclasts, osteoblasts and bone lining cells was determined 
on endo-cortical surfaces in frontal, parietal and interparietal bones to determine if 
different part of calvarial bone contains different bone microenvironments.  
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Parfitt et al (1987) summarised a unified system of terminology for bone 
histomorphometry. The bone histomorphometry community decided to measure BM 
volume as marrow area (Ma.Ar). In addition, they decided to measure bone surface as 
perimeter (B.Pm) (Parfitt et al., 1987). According to this terminology, in this study the 
bone surface areas and the BM areas of the frontal, parietal and interparietal regions of 
calvariae were analyzed. There were increases in the bone surface area and BM area in 
interparietal bones compared to frontal and parietal bones. The percentage of 
osteoclasts, osteoblasts and bone lining cells was also determined on endo-cortical 
surfaces in frontal, parietal and interparietal bones. The bone histomorphometry 
community (Parfitt et al., 1987) decided to measure osteoclast surface and osteoblast 
surface as a percentage of osteoclast surface or osteoblast surface to bone surface 
(Oc.S/BS or Ob.S/BS). Furthermore, they defined the osteoclasts as cells containing 
lysosomes and acid phosphate that are resorbing bone. The term of osteoblasts is 
defined as cells that are currently making bone and does not refer to all cells with 
osteogenic potential. The term, bone lining cells, is defined as inactive osteoblasts that 
may have osteogenic potential (Parfitt et al., 1987).  
 
My study showed that there were increases in the percentage of osteoblasts observed in 
the interparietal bones compared to the frontal and parietal bones. In contrast, the 
percentage of bone lining cells was decreased in interparietal bones compared to frontal 
and parietal bones.  Furthermore, we have shown that the percentage of osteoclasts did 
not change between the different parts of calvariae. These data suggest there are unique 
micro-anatomical sites in the interparietal bone compared to the frontal and parietal 
bones. Higher osteoblast numbers in interparietal bones may provide increased 
interactions between myeloma cells and osteoblasts compared to frontal and parietal 
bones. These data suggest that the interparietal bone is a novel model to study myeloma 
colonisation and growth in vivo.  
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In previous studies, Zhang et al (2003) showed that an increase in trabecular bone 
and/or trabecular N-cadherin
+
 osteoblasts correlated with an increase in HSCs in long 
bone (Zhang et al., 2003). In addition, Xie et al (2009) demonstrated that 83.8% of 
HSCs homed to trabecular surfaces compared to 16.2% of HSCs homing to cortical 
surfaces in long bone (Xie et al., 2009). These studies suggested that the endosteal 
surfaces of trabecular bone are important to maintain HSCs in the long bone. In this 
study the percentages of osteoclasts, osteoblasts and bone lining cells were analysed on 
both cortical and trabeculae surfaces. No trabeculae were observed in frontal and 
parietal bones. This work demonstrated an increase in the surface area of osteoblasts on 
the endo-cortical surface of interparietal bones compared to the trabecular surfaces of 
interparietal bones. In contrast, there was a decrease in the surface area of bone lining 
cells on the endo-cortical surface of interparietal bones compared to the trabecular 
surfaces of interparietal bones. Moreover, there was no difference in the surface area of 
osteoclasts on the endo-cortical and trabecular surfaces of interparietal bones. These 
studies suggested that the endo-cortical bone surfaces may provide higher bone turnover 
and interaction between osteoblasts and myeloma cells compared with trabecular bone 
surfaces in the interparietal bones.  
 
For further testing, the percentages of osteoclasts, osteoblasts and bone lining cells were 
analysed on the upper and lower endo-cortical surfaces to determine if there is a 
difference in cellular distribution frequency. This work demonstrated that the 
percentage of osteoblasts on the lower endo-cortical surface and upper endo-cortical 
surface did not change in frontal, parietal and interparietal bones. In addition, I found 
that the percentage of bone lining cells on the lower endo-cortical surface and upper 
endo-cortical surface did not change in frontal, parietal and interparietal bones. 
However, the study did show an increase in the percentage of osteoclasts on the lower 
endo-cortical surface of frontal, parietal and interparietal bones compared to the upper 
endo-cortical surface. This may provide the capacity for higher bone disease and 
osteolytic bone lesions in the lower cortical bones compared to the upper cortical bones 
in calvariae when myeloma cells colonize in the bone.  
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Further studies are required to establish if there is an increase in bone turnover in 
interparietal bones compared to frontal and parietal bones. Calcein (C30H26N2O13) is a 
ﬂuorescent chromophore that binds to calcium and was used to determine the bone 
formation or bone turnover rate (Ducy et al., 2000, Du et al., 2001). In this study mice 
were injected with 200μl of 3 mg/ml calcein-GFP each and after 3 days mice were 
sacrificed and the calvariae excised and analysed to determine the differences in the 
new bone formation in different parts of the calvariae. This work suggested an increase 
in the new bone formation on the endo-cortical surface of interparietal bones compared 
to frontal and parietal bones, although this was not significant. Increases in the new 
bone formation together with an increase in the percentage of osteoblasts in the 
interparietal bones compared with frontal and parietal bones suggested that interparietal 
bones may have higher bone turnover compared with frontal and parietal bones. 
Previous studies demonstrated that tumour cells metastasise to skeletal sites with active 
bone turnover (Schneider et al., 2005, van der Pluijm et al., 2005). My data suggested 
that the higher bone turnover in interparietal bones may provide increased interactions 
between myeloma cells and osteoblasts compared to frontal and parietal bones.  
 
The growth of myeloma tumour in C57BL/KaLwRijHsd calvarial BM was assessed 
using 5T33MM model and 5TGM1 model. These tumour cells may home to many 
tissues but there may be specific characteristics of particular bone marrows, or regions 
within bone marrow, that permit colonisation, survival and growth of these myeloma 
cells. This study demonstrated that 5T33MM-GFP tumours developed in the 
interparietal bones and not in the frontal and parietal bones after 3 weeks. In addition, I 
found that 5TGM1-GFP tumours developed in the interparietal bones and in the frontal 
bones, not in the parietal bones after 3 weeks. This observation is supported by Oyajobi 
et al (2007), in which 5TGM1-GFP cells were shown to grow in interparietal and frontal 
bones but not in parietal bones (Oyajobi et al., 2007). This study showed an increase in 
the bone surface area and BM area of the interparietal bones compared to frontal and 
parietal bones. There were also increases in the percentage of osteoblast surfaces in the 
interparietal bones compared to the frontal and parietal bones. The findings presented 
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here offer a potential explanation for why the myeloma cells, 5T33MM and 5TGM1, 
form large tumours in interparietal bones and not in frontal or parietal: more tumour 
cells arrive and are retained in theses bones and the environment is more conducive to 
growth. Together these studies demonstrated that the micro-anatomical site in the 
interparietal bone may have unique characteristics in which to study myeloma 
colonisation and growth in bone.  
 
In this experiment, I found differences between the 5T33MM and 5TGM1 models. It 
was found that the 5T33MM and 5TGM1 models share some common features 
including the selective localization of MM cells in the BM, presence of serum             
M-component, and expression of LFA-1, CD44, VLA-4 and VLA-5 adhesion 
molecules. Both models represent a model of human MM disease and can grow in vitro 
and in vivo. However, mouse models do not essentially accurately reproduce human 
disease. Some differences were found between both models. The 5T33MM model does 
not induce osteolytic bone lesions however this could be due to the aggressive tumour 
causing rapid morbidity whereas the 5TGM1 model does induce osteolytic bone lesions 
similar to MM in humans (Radl et al., 1978, Radl et al., 1979, Vanderkerken et al., 
1997). This study showed another difference between 5T33MM and 5TGM1 models, in 
which 5TGM1 grew in interparietal and frontal bones while 5T33MM only grew in 
interparietal bone and not in frontal bones. This is may be due to the 5TGM1 model 
being associated with an extensive osteolysis and would be worth exploring in future. 
Limitations of the 5T33MM and 5TGM1 models include the dependency on a particular 
mouse strain, C57BL/KaLwRijHsd, of limited availability. Another limitation for this 
experiment could be the number of animal used. I used 3 animals per group to 
determine the growth of tumours in calvariae due to the cost of animals. However, 
many published studies used 3 mice per group. Lo Celso et al (2009) used 3 mice per 
group to visualize individual HSCs in their niche (Lo Celso et al., 2009). Xie et al 
(2009) used 3 mice per group to monitoring individual HSC behaviour using real-time 
imaging (Xie et al., 2009). Hosokawa et al (2010) also used 3 mice per group to address 
the long-term engraftment of N-cadherin knockdown HSCs (Hosokawa et al., 2010).  
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Multiphoton microscopy was used to determine the location of myeloma cells with 
respect to proximity to bone in calvariae. Xie et al (2009) have recently used a confocal 
laser scanning microscope LSM 510, multiphoton microscopy, to trace the homing of 
GFP
+
 HSCs and determine the distribution of these cells in the BM (Xie et al., 2009). In 
my study, 5T33MM cells and 5TGM1 cells were labelled with DiD (Invitrogen, UK), a 
dye bound to phospholipid bilayer membranes of the cells 
(http://products.invitrogen.com/ivgn/product/V22887). Previous work in our lab 
demonstrated that myeloma cells lose their DiD labelling during cell proliferation in 
vitro. However, some cells retained staining suggesting that these cells are mitotically 
quiescent. In the present study there was a significant increase in the numbers of DiD 
positive, 5T33MM and 5TGM1 myeloma cells observed in the interparietal BM 
compared to the frontal and parietal BM after 3 days. In addition, there was a significant 
increase in the numbers of DiD positive, 5T33MM and 5TGM1, myeloma cells 
observed in the interparietal BM compared to the frontal and parietal BM after 21 days. 
This suggests that the interparietal bone is a more favorable environment for attachment 
of MM cells. This may be because this bone offers greats access and volume for 
colonizing tumour cells but it may also be environmentally different from the other 
calvarial bones and this remains to be evaluated. The increased tumour growth in the 
interparietal bones may affect the increased frequency of potential colony forming cell 
or again may be a result of potential environmental differences stimulates growth.  
 
As discussed before, the limitations of the 5T33MM and 5TGM1 models include the 
dependency on a particular mouse strain, C57BL/KaLwRijHsd, of limited availability. 
Another limitation for this experiment could be the number of animals used. I used 3 
animals per group to determine the growth of tumours in calvariae and this was due to 
the cost of animals, although as stated previously, some published studies used 3 mice 
per group (Xie et al., 2009, Lo Celso et al., 2009, Hosokawa et al., 2010). Another 
limitation in this experiment could be the quantification of the single cells in calvarial 
BM. Volocity
®
 3D Image Analysis Software was used to quantify the single cells in 
calvarial BM in images captured by confocal laser scanning microscope LSM 510. The 
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size of red fluorescence, DiD dye, labelled objects between 500 – 20,000 µm3 was 
considered as individual DiD labelled cells and others were excluded in this study. 
Differential counting of different size ranges may yield more information, but this was 
difficult to give the reliability in images produced by microscopy.  
 
In my experiments, I found that different calvarial bones; frontal, parietal and 
interparietal contain different bone microenvironments. Using modern microscopy, 
multiphoton microscopy, permitted us to visualized single myeloma cells in the 
calvarial BM. Using Lightools analysis showed that myeloma cells homed and grew in 
areas of the skeletal with active bone turnover. These findings indicate that the 
5T33MM and 5TGM1 models can be used and injected to C57BL/KaLwRijHsd mice to 
determine the effect of blocking N-cadherin in myeloma cells on myeloma colonization 
in bone, on myeloma tumour growth and on myeloma bone disease in vivo, and these 
will be investigated in the next chapter.  
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6 Chapter 6: N-cadherin in the interactions of 
myeloma cells with osteoblasts in vivo  
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6.1 Introduction  
Recently, Xie et al (2009) demonstrated that HSCs home to, and reside in a state of 
quiescence in, the ‘osteoblast niche’ via attachment to N-cadherin+ osteoblasts on 
endosteal bone surfaces using a new technology, ex vivo real-time imaging. In contrast, 
HSCs underwent active division and expansion in central BM area (Xie et al., 2009). On 
the other hand, increasing evidence indicates that expression of N-cadherin in solid 
tumour cells including melanoma, breast cancer, prostatic cancer, gastric carcinoma, 
bladder carcinoma, overian carcinoma and pancreatic cancer mediates the invasion, 
metastasis and interaction of cancer cells from their primary site to establish new 
interactions with the surrounding microenvironment (Li et al., 2001, Augustine et al., 
2008, Hazan et al., 2004, Tanaka et al., 2010, Yanagimoto et al., 2001, Lascombe et al., 
2006, Sarrio et al., 2006, Shintani et al., 2008).  
 
In Chapter 4, I observed significant increases in the adhesion of myeloma cells to 
recombinant N-cadherin coated plates compared with PBS coated plates. In addition,  
N-cadherin expression was observed at the junction of myeloma cells and osteoblasts. 
Pre-treatment of myeloma cells with anti-N-cadherin antibody significantly reduced the 
adhesion of myeloma cells to recombinant N-cadherin coated plates and to osteoblasts 
in vitro. TaqMan analysis of mouse primary osteoblast cDNA demonstrated that the 
expression of N-cadherin was increased during osteoblastogenesis: by 3 fold in 
immature osteoblasts, 12 fold in mature osteoblasts and 24 fold in mature mineralised 
osteoblasts compared to pre-osteoblasts (1 fold), suggesting myeloma cells may have an 
increased capacity to interact with mature osteoblasts. These results were supported by 
recently published data by Groen et al (2011) who showed that N-cadherin was 
expressed by myeloma cells and that this facilitated the interaction of myeloma cells 
with N-cadherin
+
 osteoblasts (Groen et al., 2011).  
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Pre-clinically the novel pentapeptide (ADH-1), an N-cadherin antagonist, significantly 
reduced the pancreatic tumour growth and the metastasis of these tumours to the lung in 
a mouse model (Shintani et al., 2008). In addition, ADH-1 pentapeptide in combination 
with chemotherapy (Melphalan) was used as novel therapeutic approach that 
significantly reduced tumour growth and enhanced the antitumor activity in the 
treatment of melanoma (Augustine et al., 2008). Clinically, ADH-1 in combination with 
melphalan was well-tolerated in a phase 1 study as a novel targeted therapeutics 
approach (Beasley et al., 2009). Critically, no study has addressed blocking N-cadherin 
in myeloma in preclinical mouse models.  
 
Several murine models of MM exist, but the 5T2, 5T33 and 5TGM1 are the best well 
characterized and used in most recent studies (Vanderkerken et al., 2000, Croucher et 
al., 2003, Alici et al., 2004, Van Valckenborgh et al., 2012, Olson et al., 2005, Edwards 
et al., 2009, Fowler et al., 2012). In this study, the 5T33MM model and 5TGM1 model 
have been used to determine the effect of blocking N-cadherin in myeloma cells in vivo. 
The 5T2MM model was not used in this study because I did not have an access to use 
this model. As N-cadherin is expressed by osteoblasts and not by osteoclasts or 
osteocytes (Mbalaviele et al., 1995, Ferrari et al., 2000, Kawaguchi et al., 2001), and 
there being more osteoblasts compared to other cells in the calvariae compared the long 
bones (Nakashima and de Crombrugghe, 2003), calvarial bones were analysed in this 
study.  
 
The present study uses a new technology, multiphoton microscopy, to study the early 
colonization of myeloma cells in bone. This chapter will describe studies that suggest 
N-cadherin expression is important in the interaction of myeloma cells with osteoblasts 
in vivo. Other studies will describe the effect of blocking N-cadherin on myeloma 
colonization in bone and myeloma bone disease in vivo.  
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6.2 Hypothesis and objectives of this chapter  
6.2.1 Hypothesis:  
Expression of N-cadherin is important in the interaction of myeloma cells with 
osteoblasts in vivo.  
 
6.2.2 Objectives:  
To test this hypothesis, I have used the 5T33MM and 5TGM1 mouse models of 
myeloma and:  
 
1. Determined if myeloma cells reside near to N-cadherin+ osteoblasts in IP bones 
of calvariae.  
2. Determined the effect of blocking N-cadherin on myeloma colonization in bone 
in vivo.  
3. Determined the effect of blocking N-cadherin on colonization of quiescent 
myeloma in bone in vivo.  
4. Determined the effect of blocking N-cadherin on tumour burden in vivo.  
5. Determined the effect of blocking N-cadherin on myeloma bone disease in vivo.  
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6.3 Materials and Methods  
6.3.1 Assessment of the cellular distribution of N-cadherin in vivo  
9 male C57BL/KaLwRijHsd mice, 6 weeks of age, were used in this experiment and 
separated to 3 groups to determine the distribution of N-cadherin in vivo as described in 
section 2.2.21. Rabbit monoclonal anti-N-cadherin antibody (Millipore, UK) and 
donkey anti-rabbit IgG antibodies (R&D systems, UK), isotype negative control were 
used as described in section 2.2.13.4.  
 
6.3.2 Study to determine the effect of blocking N-cadherin on myeloma 
colonization in bone in vivo  
18 male C57BL/KaLwRijHsd mice, 6 weeks of age, were used in this experiment and 
separated to 3 groups to determine the effect of blocking N-cadherin in the colonization 
of myeloma cells into the bone after 3 days as described in section 2.2.22. Section were 
analysed under Zeiss 510 multiphoton laser scanning microscope to determine the 
myeloma cell numbers and the distance of myeloma cells to bone between different 
groups in C57BL/KalwRij calvarial BM: frontal, parietal and interparietal.  
 
6.3.3 Study to determine the effect of blocking N-cadherin on myeloma bone 
disease in vivo  
9 male C57BL/KaLwRijHsd mice, 6 weeks of age, were used in this experiment and 
separated into 3 groups to determine the effect of blocking N-cadherin on myeloma 
bone disease after 21 days as described in section 2.2.23. Section (left side) were 
analysed under Zeiss 510 multiphoton laser scanning microscope to determine the 
quiescent myeloma cell numbers and the distance of quiescent myeloma cells to bone 
between different groups in C57BL/KalwRij calvarial BM. Section (right side) were 
analysed using the µCT to determine the bone disease.  
Determining the role of N-cadherin in the formation of the myeloma niche 
  
 Page 195 
 
6.3.4 Cell labelling with DiD and blocking N-cadherin using anti-N-cadherin 
antibody  
5T33MM cells and 5TGM1 cells were labelled with DiD (Invitrogen, UK). Myeloma 
cells were re-suspended in RPMI1640 medium (Invitrogen, UK) in T75 flasks 
containing DiD (5 µl of 1 µg/ml DiD to each 1x10
6
 cells/ml) for 20 minutes at 37°C as 
described in section 2.2.11. Anti-N-cadherin GC-4 antibody (Sigma, UK) was used to 
block surface N-cadherin. Myeloma cells (1x10
6
 cells/ml) were incubated with anti-N-
cadherin GC-4 antibody (Sigma, UK) (40 µg/ml) or Mouse IgG1 antibody (Dako, 
Denmark) as a negative control for 30 minutes at 37 °C as described in section 2.2.11 .  
 
6.3.5 Inoculation of MM cells into C57BL/KaLwRijHsd mice  
Myeloma cells were re-suspended in PBS (2x10
6
 cells/200 µl) for injection. 
C57BL/KaLwRijHsd mice were inoculated with 200 µl of those above suspension of 
each MM cell line: 5T33MM and 5TGM1 (2x10
6
 cells/200 µl), via their tail veins as 
described in section 2.2.12.  
 
6.3.6 Microscopic examination  
Osteomeasure software version 4.10 (Osteomerics Incorporated, Atlanta, USA) was 
used with a Leitz DMRB microscope and a drawing tablet, (CalComp Drawing Broad 
III) to determine the myeloma growth between different groups in C57BL/KaLwRijHsd 
calvarial BM as described in section 2.2.14.2. A Zeiss 510 Multiphoton Laser Scanning 
Microscopy was used to visualise fluorescence as described in section 2.2.214.1.  
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6.3.7 High-resolution micro–computed tomography (µCT)  
A high resolution µCT scanner (model 1172; Skyscan, Belgium) was used to scan 
calvarial bones to determine the extent of bone disease in different treatment groups of 
C57BL/KalwRij calvarial BM as described in section 2.2.16. This is a non-destructive 
technique that provides three-dimensional micro-structure of bone.  
 
6.3.8 Statistical analysis  
The data were analysed using an ANOVA test (one-way analysis of variance) for more 
than two group comparisons or with t test for two group comparisons if the data was 
normally distributed. Tukey's test was used as post-hoc analysis when ANOVA test was 
used in normal distribution data. When data not normally distributed, ANOVA test 
(non-parametric Kruskal-Wallis test) was used for more than two group comparisons or 
non-parametric Mann–Whitney test was used for two group comparisons. Dunns test 
was used as post-hoc analysis when ANOVA test was used in not normally distributed 
data. Data were considered statistically significant when a p-value was equal to or less 
than 0.05. Results are expressed as mean ± values of standard deviation (SD).  
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6.4 Results  
6.4.1  N-cadherin was expressed at the junction of myeloma cells and osteoblasts 
in vivo in C57BL/KaLwRijHsd mice  
C57BL/KaLwRijHsd mice were inoculated with either PBS, 2x10
6
 5T33MM-DiD cells 
or 2x10
6
 5T33MM-DiD cells separately via their tail veins. 7 days post inoculation mice 
were harvested as colonies of myeloma cells can be seen. Calvariae were excised and 
sections of interparietal bones of calvariae were dissected for immunohistochemistry. 
Figure 6.1 A shows strong N-cadherin staining in osteoblasts in interparietal bone of 
control mice. Figure 6.1 B shows immunohistochemistry analysis using isotype control 
in interparietal bone of naïve mice.  
 
Figure 6.1 C and E show strong N-cadherin staining in osteoblasts and myeloma cells 
after 7 days of injection in interparietal bone of 5T33MM-bearing and 5TGM1-bearing 
mice, respectively. Myeloma cells were identified by their structure, in which they 
include large nuclei and atypical cytoplasmic features. N-cadherin expression was 
observed when myeloma cells were in contact with osteoblasts. In addition, some 
myeloma cells not in contact with osteoblast also expressed N-cadherin. Figure 6.1 D 
and F show immunohistochemistry analysis using isotype control in interparietal bone 
of tumour-bearing mice.  
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Figure 6.1: N-cadherin was expressed at the junction of myeloma cells and 
osteoblasts in vivo. Mice were inoculated with either PBS or myeloma cells. 7 days 
post inoculation mice were sacrificed and calvariae were excised. Panel A shows 
strong N-cadherin staining (brown) in osteoblasts of control mice in IP bones of 
calvariae. Panels C & E show N-cadherin expression (brown) was observed when 
myeloma cells were in contact with osteoblasts. Myeloma cells were identified by 
their structure, in which they include large nuclei and atypical cytoplasmic features. 
Panels B, D & F show isotype control in naïve mice, 5T33MM-bearing mice and 
5TGM1-bearing mice. (n=3/group). 
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6.4.2 Effect of blocking N-cadherin on myeloma colonization in bone in vivo in 
C57BL/KaLwRijHsd mice  
6.4.2.1 Effect of blocking N-cadherin on 5T33MM colonization in frontal bones  
C57BL/KaLwRijHsd mice were inoculated with either 2x10
6
 5T33MM-DiD cells, 
2x10
6
 5T33MM-DiD cells pre-treated with isotype or 2x10
6
 5T33MM-DiD cells pre-
treated with anti-N-cadherin antibody separately via their tail veins. 3 days post 
inoculation mice were harvested and calvariae were dissected. Frontal, parietal, and 
interparietal bones were analysed using a Zeiss 510 laser scanning microscope to 
determine the effect of blocking N-cadherin on myeloma colonization in bone. 
5T33MM-DiD cells and 5T33MM-DiD cells pre-treated with isotype were used as a 
control groups. Figure 6.2 A shows that there was no difference in the total number of 
5T33MM-DiD cells that arrived in the frontal BM 3 days after inoculation between cells 
treated with anti-N-cadherin antibody and the control, 5T33MM-DiD cells or 5T33MM-
DiD cells pre-treated with isotype negative control.  
 
However, the localization pattern of 5T33MM-DiD cells that arrived in the frontal BM 
after 3 days did show some differences. Figure 6.2 B shows that 5T33MM-DiD cells 
pre-treated with anti-N-cadherin antibody home significantly further from bone 
compared with 5T33MM-DiD cells control (19.21 µm ± 2.93 µm versus 8.77 µm ± 1.10 
µm, P<0.001), but there was no difference compared with 5T33MM-DiD cells pre-
treated with isotype control (19.21 µm ± 2.93 µm versus 15.98 µm ± 1.50 µm, P=0.13). 
Figure 6.2 C, D & E show representative photomicrographic images of frontal bones 
after 3 days post inoculation with 5T33MM-DiD cells, 5T33MM-DiD cells pre-treated 
with isotype and 5T33MM-DiD cells pre-treated with anti-N-cadherin antibody, 
respectively.  
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Figure 6.2: Effect of blocking N-cadherin on myeloma colonization in frontal 
bones using male C57BL/KalwRiJHsD mice. Mice were inoculated with 5T33MM-
DiD cells. 3 days post inoculation, mice were sacrificed and calvariae were excised. 
Panel A shows there was no difference in the number of 5T33MM-DiD cells in frontal 
BM between groups. Panel B shows a significant increase in the distance of 
5T33MM-DiD cells from bone when pre-treated with anti-N-cadherin antibody. 
Panels C, D & E show representative photomicrographic images inoculation of 
5T33MM-DiD cells, 5T33MM-DiD cells pre-treated with isotype or anti-N-cadherin 
antibody, respectively, in frontal bones after 3 days. *** = p<0.001. ANOVA test was 
used. Blue fluorescent is the bone and red fluorescent is 5T33MM-DiD cells. Size 
between 500 – 20,000 µm3 was considered as individual DiD labelled cell. 
(n=6/group). 
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6.4.2.2 Effect of blocking N-cadherin on 5T33MM colonization in parietal bones  
C57BL/KaLwRijHsd mice were inoculated with 5T33MM-DiD cells +/- pre-treatment 
with isotype or anti-N-cadherin antibodies, as described above and animals killed 3 days 
later. Figure 6.3 A shows that there was no difference in the number of 5T33MM-DiD 
cells that arrived in the parietal BM 3 days post inoculation between cells treated with 
anti-N-cadherin antibody and the control, 5T33MM-DiD cells or 5T33MM-DiD cells 
pre-treated with isotype negative control. In contrast to the frontal bones, figure 6.3 B 
shows that there was no differences in the localization when 5T33MM-DiD cells pre-
treated with anti-N-cadherin antibody compared with 5T33MM-DiD cells control or 
with 5T33MM-DiD cells pre-treated with isotype control. Figure 6.3 C, D & E show 
representative photomicrographic images of parietal bones after 3 days post inoculation 
with 5T33MM-DiD cells, 5T33MM-DiD cells pre-treated with isotype and 5T33MM-
DiD cells pre-treated with anti-N-cadherin antibody, respectively.  
 
6.4.2.3 Effect of blocking N-cadherin on 5T33MM colonization in IP bones  
C57BL/KaLwRijHsd mice were inoculated with 5T33MM-DiD cells +/- pre-treatment 
with isotype or anti-N-cadherin antibodies, as described above and animals killed 3 days 
later. Figure 6.4 A shows that there was no difference in the number of 5T33MM-DiD 
cells arrived in the interparietal BM at 3 days post inoculation between cells treated with 
anti-N-cadherin antibody and the control, 5T33MM-DiD cells or 5T33MM-DiD cells 
pre-treated with isotype negative control. In contrast, there were differences in the 
localization of 5T33MM-DiD cells that arrived in the interparietal BM after 3 days. 
Figure 6.4 B shows that when 5T33MM-DiD cells pre-treated with anti-N-cadherin 
antibody homed significantly further from bone compared with 5T33MM-DiD cells 
control (29.28 µm ± 1.86 µm versus 20.00 µm ± 0.77 µm, P<0.001), and compared with 
5T33MM-DiD cells pre-treated with isotype control (29.28 µm ± 1.86 µm versus 23.80 
µm ± 1.23 µm, P<0.05). Figure 6.4 C, D & E show representative photomicrographic 
images of interparietal bones after 3 days post inoculation with 5T33MM-DiD cells, 
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5T33MM-DiD cells pre-treated with isotype and 5T33MM-DiD cells pre-treated with 
anti-N-cadherin antibody, respectively.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.3: Effect of blocking N-cadherin on myeloma colonization in parietal 
bones using male C57BL/KalwRiJHsD mice. Mice were inoculated with 5T33MM-
DiD cells. 3 days post inoculation, mice were sacrificed and calvariae were excised. 
Panel A shows there was no difference in the number of 5T33MM-DiD cells in 
parietal BM between groups. Panel B shows there was no difference in the distance of 
5T33MM-DiD cells to the bone when cells pre-treated with anti-N-cadherin antibody. 
Panels C, D & E show representative photomicrographic images inoculation of 
5T33MM-DiD cells, 5T33MM-DiD cells pre-treated with isotype or anti-N-cadherin 
antibody, respectively, in parietal bone after 3 days. *** = p<0.001. ANOVA test was 
used. Blue fluorescent is the bone and red fluorescent is 5T33MM-DiD cells. Size 
between 500 – 20,000 µm3 was considered as individual DiD labelled cell. 
(n=6/group). 
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Figure 6.4: Effect of blocking N-cadherin on myeloma colonization in 
interparietal bones using male C57BL/KalwRiJHsD mice. Mice were inoculated 
with 5T33MM-DiD cells. 3 days post inoculation, mice were sacrificed and calvariae 
were excised. Panel A shows there was no difference in the number of 5T33MM-DiD 
cells in interparietal BM between groups. Panel B shows a significant increase in the 
distance of 5T33MM-DiD cells from bone when pre-treated with anti-N-cadherin 
antibody. Panels C, D & E show representative photomicrographic images inoculation 
of 5T33MM-DiD cells, 5T33MM-DiD cells pre-treated with isotype or anti-N-
cadherin antibody, respectively, in interparietal bone after 3 days. *** = p<0.001. 
ANOVA test was used. Blue fluorescent is the bone and red fluorescent is 5T33MM-
DiD cells. Size between 500 – 20,000 µm3 was considered as individual DiD labelled 
cell. (n=6/group). 
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6.4.3 Effect of blocking N-cadherin on the colonization of quiescent myeloma 
cells in vivo in C57BL/KaLwRijHsd mice  
6.4.3.1 Effect of blocking N-cadherin on the colonization of 5TGM1 cells in frontal 
bones  
C57BL/KaLwRijHsd mice were inoculated with either 2x10
6
 5TGM1-DiD cells, 2x10
6
 
5TGM1-DiD cells pre-treated with isotype or 2x10
6
 5TGM1-DiD cells pre-treated with 
anti-N-cadherin antibody via their tail veins. 21 days post inoculation, mice were 
harvested and calvariae were carefully dissected. Frontal, parietal, and interparietal 
bones were analysed using a Zeiss 510 laser scanning microscope to determine the 
effect of blocking N-cadherin on colonization of mitotically quiescent myeloma cells in 
bone. 5TGM1-DiD cells and 5TGM1-DiD cells pre-treated with isotype were used as a 
control groups. Figure 6.5 A shows that there was no difference in the number of 
quiescent 5TGM1-DiD cells in the frontal BM at 21 days post inoculation between cells 
treated with anti-N-cadherin antibody and the control, 5TGM1-DiD cells or 5TGM1-
DiD cells pre-treated with isotype negative control.  
 
As in the previous experiment, when 5T33MM cells were injected and animals 
evaluated after 3 days, there were differences in the localization of quiescent 5TGM1 
cells apparent in the frontal bones after 21 days. Figure 6.5 B shows that 5TGM1-DiD 
cells pre-treated with anti-N-cadherin antibody homed significantly further from bone 
compared with 5TGM1-DiD cells control (15.90 µm ± 1.77 µm versus 12.43 µm ± 1.14 
µm, P<0.05), and compared with 5TGM1-DiD cells pre-treated with isotype control 
(15.90 µm ± 1.77 µm versus 11.49 µm ± 1.01 µm, P<0.05). Figure 6.5 C, D & E show 
representative photomicrographic images of frontal bones after 21 days post inoculation 
with 5TGM1-DiD cells, 5TGM1-DiD cells pre-treated with isotype and 5TGM1-DiD 
cells pre-treated with anti-N-cadherin antibody, respectively.  
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Figure 6.5: Effect of blocking N-cadherin on colonization of quiescent myeloma 
cells in bone in frontal bones using male C57BL/KalwRiJHsD mice. Mice were 
inoculated with 5TGM1-DiD cells. 21 days post inoculation, mice were sacrificed and 
calvariae were excised. Panel A shows there was no difference in the number of 
quiescent 5TGM1-DiD cells in frontal BM between groups. Panel B shows a 
significant increase in the distance of 5TGM1-DiD cells from bone when pre-treated 
with anti-N-cadherin antibody. Panels C, D & E show representative 
photomicrographic images inoculation of 5TGM1-DiD cells, 5TGM1-DiD cells pre-
treated with isotype or anti-N-cadherin antibody, respectively, in frontal bones after 
21 days. *** = p<0.001. ANOVA test was used. Blue fluorescence is the bone and red 
fluorescence is 5TGM1-DiD cells. Size between 500 – 20,000 µm3 was considered as 
individual DiD labelled cell. (n=3/group). 
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6.4.3.2 Effect of blocking N-cadherin on the colonization of 5TGM1 cells in parietal 
bones  
C57BL/KaLwRijHsd mice were inoculated with 5TGM1-DiD cells +/- pre-treatment 
with isotype or anti-N-cadherin antibodies, as described above and animals killed 21 
days later. Figure 6.6 A shows that there was no difference in the number of quiescent 
5TGM1-DiD cells in the parietal BM at 21 days post inoculation between cells treated 
with anti-N-cadherin antibody and the control, 5TGM1-DiD cells or 5TGM1-DiD cells 
pre-treated with isotype negative control. Experiments of localization of MM cells in 
the parietal bones also showed there was no difference in distances from bone between 
groups (Figure 6.6 B). Figure 6.6 C, D & E show images of parietal bones at 21 days 
post inoculation with 5TGM1-DiD cells, 5TGM1-DiD cells pre-treated with isotype and 
5TGM1-DiD cells pre-treated with anti-N-cadherin antibody, respectively.  
 
6.4.3.3 Effect of blocking N-cadherin on the colonization of 5TGM1 cells in 
interparietal bones  
C57BL/KaLwRijHsd mice were inoculated with 5TGM1-DiD cells +/- pre-treatment 
with isotype or anti-N-cadherin antibodies, as described above and animals killed 21 
days later. Figure 6.7 A shows that there was no difference in the number of quiescent 
5TGM1-DiD cells in the parietal BM at 21 days post inoculation between cells treated 
with anti-N-cadherin antibody and the control, 5TGM1-DiD cells or 5TGM1-DiD cells 
pre-treated with isotype negative control. As in the frontal bones, there were differences 
in the localization of myeloma cells between groups. Figure 6.7 B shows that when 
5TGM1-DiD cells pre-treated with anti-N-cadherin antibody, myeloma cells homed 
significantly further from bone compared with 5TGM1-DiD cells control (24.64 µm ± 
1.28 µm versus 17.72 µm ± 0.86 µm, P<0.001), and compared with 5TGM1-DiD cells 
pre-treated with isotype control (24.64 µm ± 1.28 µm versus 18.56 µm ± 1.00 µm, 
P<0.001). Figure 6.7 C, D & E show representative photomicrographic images of 
parietal bones at 21 days post inoculation with 5TGM1-DiD cells, 5TGM1-DiD cells 
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pre-treated with isotype and 5TGM1-DiD cells pre-treated with anti-N-cadherin 
antibody, respectively.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.6: Effect of blocking N-cadherin on colonization of quiescent myeloma 
cells in bone in parietal bones using male C57BL/KalwRiJHsD mice. Mice were 
inoculated with 5TGM1-DiD cells. 21 days post inoculation, mice were sacrificed and 
calvariae were excised. Panel A shows there was no difference in the number of 
quiescent 5TGM1-DiD cells in parietal BM between groups. Panel B shows there was 
no difference in the distance of quiescent 5TGM1-DiD cells to the bone when cells 
pre-treated with anti-N-cadherin antibody. Panels C, D & E show representative 
photomicrographic images inoculation of 5TGM1-DiD cells, 5TGM1-DiD cells pre-
treated with isotype or anti-N-cadherin antibody, respectively, in parietal bone after 
21 days. *** = p<0.001. ANOVA test was used. Blue fluorescent is the bone and red 
fluorescent is 5TGM1-DiD cells. Size between 500 – 20,000 µm3 was considered as 
individual DiD labelled cell. (n=3/group). 
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Figure 6.7: Effect of blocking N-cadherin on colonization of quiescent myeloma 
cells in bone in interparietal bones using male C57BL/KalwRiJHsD mice. Mice 
were inoculated with 5TGM1-DiD cells. 21 days post inoculation, mice were 
sacrificed and calvariae were excised. Panel A shows there was no difference in the 
number of quiescent 5TGM1-DiD cells in interparietal BM between groups. Panel B 
shows a significant increase in the distance of 5TGM1-DiD cells from bone when pre-
treated with anti-N-cadherin antibody. Panels C, D & E show representative 
photomicrographic images inoculation of 5TGM1-DiD cells, 5TGM1-DiD cells pre-
treated with isotype or anti-N-cadherin antibody, respectively, in interparietal bone 
after 21 days. *** = p<0.001. ANOVA test was used. Blue fluorescent is the bone and 
red fluorescent is 5TGM1-DiD cells. Size between 500 – 20,000 µm3 was considered 
as individual DiD labelled cell. (n=3/group). 
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6.4.4 Effect of blocking N-cadherin on tumour burden in vivo  
6.4.4.1 Effect of blocking N-cadherin on overall tumour burden in frontal BM  
C57BL/KaLwRijHsd mice were inoculated with either 2x10
6
 5TGM1 cells, 2x10
6
 
5TGM1 cells pre-treated with isotype or 2x10
6
 5TGM1 cells pre-treated with anti-N-
cadherin antibody via their tail veins and sacrificed after 21 days. Figure 6.8 A shows 
that there was a significant reduction in tumour growth in frontal BM when 5TGM1 
cells were pre-treated with anti-N-cadherin antibody compared with untreated 5TGM1 
control cells (59.92±5.96 versus 77.90±8.21, P<0.001), and compared with 5TGM1 
cells pre-treated with isotype control antibody (59.92±5.96 versus 81.66±6.48, 
P<0.001). Figure 6.8 B, C & D show representative photomicrographic images of 
frontal BM at 21 days post inoculation with 5TGM1 cells, 5TGM1 cells pre-treated 
with isotype and 5TGM1 cells pre-treated with anti-N-cadherin antibody, respectively.  
 
 
 
 
 
 
 
 
 
 
 
Figure 6.8: Effect of blocking N-cadherin on tumour burden in frontal BM using 
male C57BL/KalwRiJHsD mice. Mice were inoculated with 5TGM1 cells and 
sacrificed 21 days later. Panel A shows that there was a significant reduction in 
tumour growth in frontal BM when 5TGM1 cells pre-treated with anti-N-cadherin 
antibody. Panels B, C & D show representative photomicrographic images of frontal 
bones after 21 days of inoculation. *** = p<0.001. ANOVA test was used. 
(n=3/group). 
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6.4.4.2 Effect of blocking N-cadherin on tumour burden in interparietal BM  
C57BL/KaLwRijHsd mice were inoculated with either 2x10
6
 5TGM1 cells, 2x10
6
 
5TGM1 cells pre-treated with isotype or 2x10
6
 5TGM1 cells pre-treated with anti-N-
cadherin antibody via their tail veins and sacrificed after 21 days. Figure 6.9 A shows 
that there was a significant reduction in tumour growth in interparietal BM when 
5TGM1 cells were pre-treated with anti-N-cadherin antibody compared with untreated 
5TGM1 control cells (60.93±5.63 versus 83.12±0.86, P<0.001), and compared with 
5TGM1 cells pre-treated with isotype control antibody (60.93±5.63 versus 81.31±11.03, 
P<0.001). Figure 6.9 B, C & D show images of interparietal BM at 21 days post 
inoculation with 5TGM1 cells, 5TGM1 cells pre-treated with isotype and 5TGM1 cells 
pre-treated with anti-N-cadherin antibody, respectively.  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.9: Effect of blocking N-cadherin on tumour burden in IP BM using male 
C57BL/KalwRiJHsD mice. Mice were inoculated with 5TGM1 cells and sacrificed 
in 21 days later. Panel A shows that there was a significant reduction in tumour 
growth in frontal BM when 5TGM1 cells pre-treated with anti-N-cadherin antibody. 
Panels B, C & D show representative photomicrographic images of interparietal bones 
after 21 days of inoculation. *** = p<0.001. ANOVA test was used. (n=3/group). 
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6.4.5 Effect of blocking N-cadherin on bone disease in vivo in 
C57BL/KaLwRijHsd mice  
6.4.5.1 Effect of blocking N-cadherin on the bone disease in the cortical 
interparietal bones  
C57BL/KaLwRijHsd mice were inoculated with either 2x10
6
 5TGM1 cells, 2x10
6
 
5TGM1 cells pre-treated with isotype or 2x10
6
 5TGM1 cells pre-treated with anti-N-
cadherin antibody via their tail veins. 21 days post inoculation, mice were harvested and 
calvariae were carefully dissected. Interparietal bones were analysed using a high 
resolution µCT scanner (model 1172; Skyscan, Belgium) to determine the effect of 
blocking N-cadherin on bone disease. 5TGM1 cells and 5TGM1 cells pre-treated with 
isotype were used as a control groups. Figure 6.10 A shows there was no difference in 
the osteolytic lesion number in upper cortical of 5TGM1-bearing mice when cells were 
pre-treated with anti-N-cadherin antibody compared with 5TGM1-bearing mice or cells 
pre-treated with isotype control. Figure 6.10 B shows there was no difference in the 
osteolytic lesion number in lower cortical of 5TGM1-bearing mice when cells were pre-
treated with anti-N-cadherin antibody compared with 5TGM1-bearing mice or cells pre-
treated with isotype control. Figure 6.10 C, D, E and F show 3D µCT-reconstructed 
images of interparietal upper cortical bones showing there was no osteolytic lesions in 
the interparietal upper cortical bones in 5TGM1-bearing mice. Figure 6.10 G, H, I and J 
show 3D µCT-reconstructed images of interparietal lower cortical bones showing 
osteolytic lesions in the interparietal lower cortical bones in 5TGM1-bearing mice. 
Interestingly, the osteolytic bone lesions were only found in the lower cortical 
interparietal bones, but not in the upper cortical interparietal bones in 5TGM1 bearing-
mice.  
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Figure 6.10: Effect of blocking N-cadherin on bone disease in cortical 
interparietal bone using male C57BL/KalwRiJHsD mice. Mice were inoculated 
with 5TGM1 cells and sacrificed after 21 days. Panel A & B show that there was no 
difference in the osteolytic lesion number in interparietal bones of 5TGM1-bearing 
mice when cells pre-treated with anti-N-cadherin antibody compared with 5TGM1-
bearing mice or cells pre-treated with isotype control. Panels C, D, E & F show 3D 
µCT-reconstructed images of interparietal upper cortical bones after 21 days of 
inoculation. Panels G, H, I & J show 3D µCT-reconstructed images of interparietal 
lower cortical bones after 21 days of inoculation. White colour shows the bone 
surface. Black colour shows the osteolytic lesions in bone. ANOVA test was used. 
(n=3/group). 
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6.4.5.2 Effect of blocking N-cadherin on the bone disease in the trabecular 
interparietal bones  
C57BL/KaLwRijHsd mice were inoculated with either 2x10
6
 5TGM1 cells, 2x10
6
 
5TGM1 cells pre-treated with isotype or 2x10
6
 5TGM1 cells pre-treated with anti-N-
cadherin antibody via their tail veins. 21 days post inoculation, mice were harvested and 
calvariae were carefully dissected. Interparietal bones were analysed using a high 
resolution µCT scanner (model 1172; Skyscan, Belgium) to determine the effect of 
blocking N-cadherin on bone disease. 5TGM1 cells and 5TGM1 cells pre-treated with 
isotype were used as a control groups. Figure 6.16 A shows there was no difference in 
the trabecular bone volume of 5TGM1-bearing mice when cells were pre-treated with 
anti-N-cadherin antibody compared with 5TGM1-bearing mice or cells pre-treated with 
isotype control. Figure 6.16 B shows there was no difference in the trabecular number 
of 5TGM1-bearing mice when cells were pre-treated anti-N-cadherin antibody 
compared with 5TGM1-bearing mice or cells pre-treated with isotype control. Figure 
6.16 C shows there was no difference in the trabecular thickness of 5TGM1-bearing 
mice when cells were pre-treated with anti-N-cadherin antibody compared with 
5TGM1-bearing mice or cells pre-treated with isotype control. Figure 6.16 D, E and F 
show 3D µCT-reconstructed images of interparietal trabecular bones in 5TGM1-bearing 
mice, 5TGM1, 5TGM1 pre-treated with isotype control and 5TGM1 pre-treated with 
anti-N-cadherin antibody.  
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Figure 6.16: Effect of blocking N-cadherin on bone disease in trabecular 
interparietal bone using male C57BL/KalwRiJHsD mice. Mice were inoculated 
with 5TGM1 cells and sacrificed after 21 days. Panel A, B & C show that there was 
no difference in the trabecular bone volume, trabecular number and trabecular 
thickness of 5TGM1-bearing mice when cells pre-treated with anti-N-cadherin 
antibody compared with 5TGM1-bearing mice or cells pre-treated with isotype 
control. Panels D, E & F show 3D µCT-reconstructed images of interparietal 
trabecular bones after 21 days of inoculation. White colour shows the trabecular bone 
that found in the BM. ANOVA test was used. (n=3/group). 
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6.5 Discussion  
In this chapter, I evaluated the interactions of MM cells with osteoblasts via the 
adhesion molecule, N-cadherin in vivo. In addition, I examined the effect of blocking  
N-cadherin on the colonization of myeloma cells, tumour burden and bone disease in 
vivo. Recently Groen et al (2011) demonstrated that N-cadherin mediated the adhesion 
of myeloma cells with osteoblasts and this adhesion of myeloma cells with osteoblasts 
is prevented by using an N-cadherin blocking antibody, GC-4 (10 μg/mL) in vitro. 
Immunohistochemistry in sections from a MM patients showed that N-cadherin is often 
localized between myeloma cells and bone-lining cells (Groen et al., 2011). Critically, 
no study has addressed blocking N-cadherin in myeloma in vivo. This is the first pilot 
study to determine the effect of blocking N-cadherin in vivo in C57BL/KaLwRijHsd 
mice using the 5T33MM and 5TGM1 models, the best characterized models that are 
used in most recent studies of MM applications (Vanderkerken et al., 2000, Croucher et 
al., 2003, Alici et al., 2004, Van Valckenborgh et al., 2012, Olson et al., 2005, Edwards 
et al., 2009, Fowler et al., 2012).  
 
This study interestingly showed that all osteoblast lineage cells expressed N-cadherin. 
This observation supports work done by Ferrari et al (2000) who demonstrated that     
N-cadherin was expressed in rat and human bone in vivo (Ferrari et al., 2000). In 
addition, I observed N-cadherin expression at the junction of myeloma cells and 
osteoblasts in vivo using immunohistochemistry in mouse sections. This observation is 
supported by work done by Groen et al (2011) who demonstrated that the expression of 
N-cadherin is often localized between MM cells and the bone-lining cells in human 
sections from MM patients using immunohistochemistry (Groen et al., 2011).              
N-cadherin was not confined to the interaction between myeloma cells and osteoblasts 
however, and N-cadherin staining could clearly be seen in myeloma cells away from 
bone. This may suggests that N-cadherin is not only important for the adhesion of 
myeloma cells with osteoblasts, but also it could be important for the growth of 
myeloma tumours. In previous studies it was found that N-cadherin has a role in tumour 
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growth in solid tumours. Shintani et al (2008) demonstrated that using a cyclic 
pentapeptide, ADH-1, targeting N-cadherin, significantly reduced growth and 
metastasis of pancreatic cancer cells in transgenic mice (Shintani et al., 2008). In 
addition, Tanaka et al (2010) demonstrated that prostate cancer growth and metastasis 
can be affected by N-cadherin as targeting N-cadherin, using monoclonal antibodies 
against N-cadherin, resulted in a reduction in proliferation, adhesion and invasion of 
prostate cancer cells (Tanaka et al., 2010). I used 3 animals per group to determine if  
N-cadherin was expressed at the junction of myeloma cells and osteoblasts since these 
studies were essentially qualitative. One limitation in this experiment was that the 
identification of myeloma cells was only by their histological structure: large nuclei and 
atypical cytoplasmic features compared to BM cells. This did make identification of 
MM cells difficult when in low numbers. To resolve this issue, immunohistochemistry 
using an anti-CD138 antibody would be helpful in defining myeloma cells, however this 
was not possible in this study.  
 
Using strategies to block N-cadherin may therefore be able to inhibit adhesion of 
myeloma cells to osteoblasts and act as a new therapeutic approach to inhibit disease 
spread in patients. To test the effects on adhesion in this study, 5T33MM cells were pre-
treated with anti-N-cadherin antibody or mouse IgG1 antibody. After 3 days mice were 
harvested and the calvariae were dissected and analysed to determine the effect of 
blocking N-cadherin on myeloma colonization to bone. DiD labelling was used in these 
studies because this dye was easily and reliably identified in multiphoton imaging. 
Work in the Sheffield laboratories has also shows that this dye is lost as cells divide. 
This allows the identification of myeloma cells that arrive and are mitotically quiescent 
rather than cells that have proliferated. I observed that when 5T33MM-DiD cells were 
pre-treated with anti-N-cadherin antibody, cells homed significantly further away from 
bone compared with controls in both frontal and interparietal bones. However, in 
parietal bone there was no difference between groups. In contrast, I observed that there 
was no difference in the total number of 5T33MM-DiD cells that arrived in the frontal, 
parietal and interparietal BM after 3 days when 5T33MM-DiD cells were pre-treated 
Determining the role of N-cadherin in the formation of the myeloma niche 
  
 Page 217 
 
with anti-N-cadherin antibody. These results suggested that blocking N-cadherin in 
myeloma cells may have an important role in altering the location of myeloma cells in 
the bone, but not in the overall homing of myeloma cells into the BM. This finding was 
also observed previously in HSCs. Hosokawa et al (2010) showed that knockdown of         
N-cadherin in HSCs did not inhibit the homing of HSCs into the BM and spleen. 
However, knockdown of N-cadherin in HSCs significantly reduced the adhesion of 
HSCs onto the bone surface (Hosokawa et al., 2010). Interpretation of my experiment 
could be limited by the quantification of the single cells in calvarial BM. Volocity
®
 3D 
Image Analysis Software was used to quantify the single cells in calvarial BM in 
images captured by confocal laser scanning microscope LSM 510. The size of red 
fluorescence signals (DiD dye) between 500 – 20,000 µm3 was considered as individual 
DiD labelled cells and others were excluded in this study. The consideration that this 
range specially identified single cells is utilized by other users, but it may be useful to 
revisit these in future studies to collect signal ranges of objectives.  
 
In a separate study, 5TGM1-DiD cells were pre-treated with anti-N-cadherin antibody 
or mouse IgG1 antibody. After 21 days mice were harvested and the calvariae were 
dissected and analysed to determine the effect of blocking N-cadherin on the 
colonization of quiescent myeloma cells in bone. I observed that when 5TGM1-DiD 
cells were pre-treated with anti-N-cadherin antibody, cells homed significantly further 
away from bone compared with control in both frontal bones and interparietal bones. 
However, in parietal bone there was no difference between groups. In contrast, I 
observed that there was no difference in the total number of 5TGM1-DiD cells that 
arrived in the frontal, parietal and interparietal BM after 21 days when 5TGM1-DiD 
cells were pre-treated with anti-N-cadherin antibody. These results also suggested that 
blocking N-cadherin in myeloma cells may have an important role in targeting the 
colonization of quiescent myeloma cells into the bone, but not in the overall homing of 
myeloma cells into the BM. This finding also observed previously in HSCs (Hosokawa 
et al., 2010). Limitation for this experiment could be the number of animal used. I used 
3 animals per group to determine the growth of tumours in calvariae and this was due to 
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the cost of animals. In addition, some published studies used 3 mice per group (Xie et 
al., 2009, Lo Celso et al., 2009, Hosokawa et al., 2010). As stated before interpretation 
of my experiment could be limited by the quantification of the single cells in calvarial 
BM, in which red fluorescence signal (DiD dye) between 500 – 20,000 µm3 was 
considered as individual DiD labelled cells.  
 
In this study both MM models showed similar responses when N-cadherin was blocked 
by anti-N-cadherin antibody on the homing of quiescent, non-proliferating, myeloma 
cells and on the colonization into the bone. However, the 5T33MM-bearing mice were 
analysed after 3 days whereas the 5TGM1-bearing mice were analysed after 21 days. 
This was due to the limited availability of mice. We decided to use the 5T33MM model 
for the early stages of MM disease and the 5TGM1 model for the late stage of MM 
disease where we know this model caused osteolysis. In future work, N-cadherin will be 
blocked in 5TGM1 cells and 5TGM1-bearing mice will be analysed after 3 days to 
study the effect of N-cadherin blocking in early stage of MM disease. Given more time 
and resources we would have studied both models at early (3 days post-injection) and 
late (21 days post-injection) time points.  
 
The growth of myeloma tumour in C57BL/KaLwRijHsd calvarial BM was also 
assessed when N-cadherin was blocked with anti-N-cadherin antibody using the 
5TGM1 model. 5TGM1 cells were pre-treated with anti-N-cadherin antibody or with 
mouse IgG1 antibody. 5TGM1 cells and 5TGM1 cells pre-treated with isotype were 
used as a control groups. After 21 days, I observed a small but significant reduction in 
overall myeloma tumour size when 5TGM1 cells were pre-treated with anti-N-cadherin 
antibody compared with control in both frontal BM and interparietal BM. However, 
immunohistochemistry using anti-CD138 antibody would have been helpful in defining 
tumours in these studies but this was not applicable to my samples. This study 
suggested that blocking N-cadherin may have a role to target the growth of myeloma 
tumours. This finding was also observed previously in solid tumours. Shintani et al 
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(2008) demonstrated that using a cyclic pentapeptide, ADH-1, targeting N-cadherin, 
significantly reduced growth and metastasis of pancreatic cancer cells in transgenic 
mice (Shintani et al., 2008). The limitation of this experiment could be the number of 
animal used. I used 3 animals per group to determine the growth of tumours in calvariae 
and this was due to the cost of animals. In addition, some published studies used 3 mice 
per group (Xie et al., 2009, Lo Celso et al., 2009, Hosokawa et al., 2010).  
 
In addition, in this study I also addressed the effect of blocking N-cadherin on osteolysis 
in C57BL/KaLwRijHsd in vivo using the 5TGM1 model. After 21 days I observed that 
there was no difference in the osteolytic lesion number in the cortical bones when 
5TGM1 cells were pre-treated with an anti-N-cadherin antibody compared with control. 
In addition, I observed there was no difference in the trabecular bone volume, trabecular 
number and trabecular thickness of 5TGM1-bearing mice when cells were pre-treated 
with anti-N-cadherin antibody compared with control. These results suggested that 
blocking N-cadherin in myeloma cells with anti-N-cadherin antibody did not affect 
myeloma bone disease and this could be due to N-cadherin turn over and doubling time 
of myeloma cells. Wein et al (2010) showed that N-cadherin was efficiently knocked 
down by siRNA in human mesenchymal stromal cells after 14 hours of the transfection 
and lasted for about 7 days suggesting a high protein turn over. After 7 days the            
N-cadherin expression levels slowly normalized again. Limitation for these experiments 
is that N-cadherin was only blocked in myeloma cells before they were injected into 
mice. Normalization of N-cadherin expression could be the reason why blocking         
N-cadherin in myeloma cells with anti-N-cadherin antibody did not affect myeloma 
bone disease. To resolve this issue, in future studies an alternative approach would be to 
use stable knock down of N-cadherin in myeloma cells or treat myeloma-bearing mice 
with anti-N-cadherin antibody instead of pre-treating the myeloma cells. Another 
limitation in this experiment could be the number of animals used. I used 3 animals per 
group to determine the growth of tumours in calvariae and this was due to the cost and 
availability of animals. In addition, some published studies used 3 mice per group (Xie 
et al., 2009, Lo Celso et al., 2009, Hosokawa et al., 2010).  
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This study interestingly showed that 5TGM1-bearing mice after 21 days induced 
osteolytic bone lesions in the lower cortical bones and not in the upper cortical bones. 
This is could be due to an increase in the percentage of osteoclasts on the lower endo-
cortical surface of frontal, parietal and interparietal bones compared to the upper endo-
cortical surface as discussed in chapter 5. In addition, the brain could be contributing to 
this osteolysis in the lower cortical bones. This implication would be investigated in 
future studies.  
 
A number of conclusions can be drawn from these studies. Firstly, it is clear that         
N-cadherin is stably expressed by osteoblasts and is variably expressed by colonising 
myeloma cells. N-cadherin appears to be present at the interface between myeloma cells 
and osteoblasts but this is not exclusive. Myeloma cells away from bone also express  
N-cadherin. Attempts to block N-cadherin in these models by pre-incubation of cells 
with anti-N-cadherin antibody appeared to increase the distance of DiD labelled 
myeloma cells from bone and to produce a modest decrease in tumour volume in the 
interparietal and frontal bones, but this effect while significant was small and was not 
accompanied by decrease either cell numbers arriving or by alteration in lytic disease as 
might be expected in this model. Since this is the case, this data a preliminary and 
would gain more extensive validation with continuous blocking of N-cadherin using 
antibody systemically and with larger animal cohorts.  
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7 Chapter 7: General discussion and future work  
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7.1 General discussion 
Present treatments for MM target end stage disease but understanding how bone lesions 
are initiated may offer new approaches to prevent/suppress colonization. It is clear that 
myeloma cells form specific interactions with the bone microenvironment, where they 
can remain dormant and protected from current therapy to eventually proliferate and 
cause disease progression. The aim of this study was to test the hypothesis that 
myeloma cells utilise N-cadherin to adhere to osteoblasts in vitro and in vivo during 
colonization of myeloma cells into the bone. In general terms, the data generated tends 
to support this hypothesis.  
 
In this study, two myeloma models were used 5T33MM and 5TGM1. I have shown that 
these cells expressed N-cadherin. I used recombinant N-cadherin and calvarial mouse 
osteoblasts to study the adherence of myeloma cells in vitro. These observations 
supported the above hypothesis, as I showed that N-cadherin on myeloma cells has a 
role in the adhesion of myeloma cells to osteoblasts. My study demonstrated that there 
was a significant increase in the adhesion of myeloma cells to mature osteoblasts 
compared with immature osteoblasts as the expression of N-cadherin significantly 
increased in mature osteoblasts compared to immature osteoblasts. Blocking of           
N-cadherin by an N-cadherin specific antibody significantly decreased the adhesion of 
myeloma cells to pre-osteoblasts and mature osteoblasts in vitro.  
 
In addition, in this study I addressed the effect of blocking N-cadherin on the homing of 
myeloma cells to the bone in C57BL/KaLwRijHsd mice. This study demonstrated that 
the blocking of N-cadherin by an N-cadherin specific antibody did not affect the 
homing of myeloma cells into the BM. In contrast, quiescent myeloma cells 
significantly homed farther from the bone when N-cadherin blocked with anti-N-
cadherin antibody after 3 and 21 days in both frontal bones and interparietal bones. It 
also showed a small but significant reduction in overall myeloma tumour growth in 
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these bones at a later time point. However, this study demonstrated that there was no 
effect on the bone disease when N-cadherin was blocked by N-cadherin specific 
antibody and this could be due to N-cadherin turn over and doubling time of myeloma 
cells. As discussed in previous chapters, these finding are interesting but preliminary 
and need validation with alternative approaches to N-cadherin suppression in vivo and 
larger cohorts of animals. One approach would be to stably knock-down N-cadherin 
expression in myeloma cells and study their colonization compared to the present 
population. An alternative would be to use the N-cadherin blocking antibody or           
N-cadherin antagonist to treat myeloma-bearing mice during colonization with a 
continues dose of antibody to completely block N-cadherin and prevent N-cadherin turn 
over.  
 
Blaschuk et al (1990) reported that extracellular-1 of the N-cadherin extracellular 
domain contains a His-Ala-Val (HAV) motif sequence, which plays an important role in 
N-cadherin functions (Blaschuk et al., 1990). ADH-1, N-Ac-CHAVC-NH2, is an agent 
targeting the HAV motif on extracellular-1 of N-cadherin and was recently used as     
N-cadherin antagonist agent. Shintani et al (2008) demonstrated that using a cyclic 
pentapeptide, ADH-1, targeting N-cadherin, significantly reduced the growth and 
metastasis of pancreatic cancer cells in transgenic mice (Shintani et al., 2008). In 
addition, Augustine et al (2008) showed that targeting N-cadherin with ADH-1 
pentapeptide, in combination with a chemotherapy drug (Melphalan), was used as a 
novel therapeutic approach and significantly reduced tumour growth and enhanced the 
antitumor activity to treat melanoma (Augustine et al., 2008). Clinically, Beasley et al 
(2009) demonstrated that ADH-1 at a dose of 4000 mg in combination with melphalan 
on days 1 and 8 was used in phase I studies in melanoma patients and was a potential 
novel targeted therapy approach in melanoma (Beasley et al., 2009). In addition, 
monoclonal antibodies against the ectodomain of N-cadherin were recently used to 
target N-cadherin (Tanaka et al., 2010). Critically, no study has addressed blocking     
N-cadherin in myeloma in preclinical mouse models or in patients.  
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In HSCs, Zhang et al (2003) demonstrated that there is a correlation between an 
increase in the number of spindle-shaped N-cadherin
+
CD45
-
 osteoblastic cells and an 
increase in the number of HSCs. In addition, it was found that persistent HSCs attached 
to SNO cells via N-cadherin and β-catenin (Zhang et al., 2003). In vitro, Aria and Suda 
showed enhancements of both HSCs and stromal cell adhesion and inhibition of cell 
division of HSCs by enforced N-cadherin expression suggesting a key role of              
N-cadherin-mediated adhesion and maintaining HSCs quiescence in the osteoblastic 
niche (Arai and Suda, 2007). Using a new technology, ex vivo real-time imaging, and 
immunoassaying found that HSCs home to the ‘osteoblast niche’ via attachment to     
N-cadherin
+
 osteoblasts on endosteal bone surfaces (Xie et al., 2009). In addition, 
Hosokawa et al (2010) showed that N-cadherin is expressed in long-term HSCs and in 
the osteoblasts mediating cell adhesion in the HSC niche. Knockdown of N-cadherin in 
HSCs reduced long-term engraftment activity of HSCs in the BM in vivo (Hosokawa et 
al., 2010). More recently, Arai et al (2012) showed that N-cadherin is in HSCs that 
promote the HSCs to be quiescence. Knockdown of N-cadherin showed a reduction in 
the long-term HSCs to the endosteal surfaces (Arai et al., 2012).  
 
In contrast, Kiel et al (2009) showed that deleted N-cadherin from HSCs in adult Mx-1-
Cre
+
N-cadherin
fl/-
 mice has no effect on hematopoiesis in the bone marrow. Deleted    
N-cadherin from HSCs did not affect HSC frequency, HSC maintenance, or function 
over time suggesting that N-cadherin expression by HSCs is not necessary for niche 
function (Kiel et al., 2009). Greenbaum et al (2012) ablated N-cadherin (Cdh2) in 
osteoblasts using Cdh2
flox/flox
 Osx-Cre mice. Ablated N-cadherin did not affect HSC 
number, cell cycle status, long-term repopulating activity, and self-renewal capacity 
suggesting that N-cadherin expression in osteoblast lineage cells is dispensable for HSC 
maintenance in mice (Greenbaum et al., 2012). In my study myeloma cells could still 
colonize after treatment with N-cadherin antibody and form bone lesions. This may be 
because the efficacy of blocking was less than 100% with the approach used or could 
indicate that N-cadherin is just one of a member of molecules, such as Notch/Jag, 
Tie2/Ang-1 or CXCR4/CXCL12, required for myeloma colonization in bone.  
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Increasing evidence indicates that expression of N-cadherin in solid tumour cells 
including melanoma, breast cancer, prostatic cancer, gastric carcinoma, bladder 
carcinoma, overian carcinoma and pancreatic cancer mediates the invasion, metastasis 
and interaction of cancer cells from their primary site to establish new interactions with 
the surrounding microenvironment (Li et al., 2001, Augustine et al., 2008, Hazan et al., 
2004, Tanaka et al., 2010, Yanagimoto et al., 2001, Lascombe et al., 2006, Sarrio et al., 
2006, Shintani et al., 2008). N-cadherin has an important role in tumour development by 
forming cell-cell junctions mediating tumour cell invasion and promoting cancer cell 
survival. A cyclic pentapeptide (ADH-1, N-Ac-CHAVC-NH2, agent targeting the HAV 
motif on EC1 of N-cadherin) was recently used as an anticancer agent. Shintani et al 
(2008) showed ADH-1 (50 mg/kg, 1 per day, 5 per week for 4 weeks) significantly 
reduced growth and metastasis of pancreatic cancer cells in transgenic mice (Shintani et 
al., 2008). In addition, a monoclonal anti-N-cadherin antibody was recently used as an 
anticancer agent. Tanaka et al (2010) demonstrated that prostate cancer metastasis and 
castration resistance are mainly caused by N-cadherin. Targeting N-cadherin using 
monoclonal antibody (500 μl at 10 or 20 mg per kg twice weekly) against N-cadherin 
showed a reduction in proliferation, adhesion, invasion of prostate cancer cells and 
delays the castration resistance progression (Tanaka et al., 2010).  
 
In myeloma, Groen et al (2011) showed that myeloma cells express N-cadherin and this 
expression mediates the interaction of myeloma cells with the BM microenvironment, 
in particular the osteoblasts (Groen et al., 2011). From the above it would seem that 
targeting N-cadherin could have complex effects. On one hand, blocking tumour         
N-cadherin would be likely to reduce the numbers of cells arriving in niches but on the 
other, the lack of the growth inhibition provided by the niche, could allow those 
tumours that did arrive to proliferate. This suggests that targeting N-cadherin would 
have to be considered carefully. One approach could be to target N-cadherin to prevent 
myeloma cells residing in niche in a quiescent state and simultaneously to use cytotoxic 
drugs to target proliferating cells. This may be an approach to combat tumour dormancy 
in patients, a major problem in myeloma and other tumour types.  
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In this study, we showed that there was a positive correlation between increased          
N-cadherin mRNA expression and differentiation during osteoblastogenesis suggesting 
low levels of N-cadherin expression in pre-osteoblasts and relatively high levels of            
N-cadherin expression in mature osteoblasts. These observations are supported with 
previous work done by Ferrari et al (2000) and by Kawaguchi et al (2001) that 
demonstrated an increase in the relative expression of N-cadherin mRNA during 
osteoblastogenesis (Ferrari et al., 2000, Kawaguchi et al., 2001). In contrast, 
Greenbaum et al (2012) demonstrated a decrease in the relative expression of              
N-cadherin during osteoblastogenesis using western blot and this may be due to 
differences in culture conditions and N-cadherin analysis methods. They reported that 
osteoblasts were originated from Cdh2
flox/flox
 mice, backcrossed to more than 99% 
congenic with the C57BL/6 background. In addition, for differentiation they used 20% 
FCS, 50 µM ascorbic acid and 10 µM β-glycerophosphate (Greenbaum et al., 2012). 
However, my data clearly showed an increase in the relative levels of N-cadherin 
mRNA and protein during osteoblastogenesis in culture using TaqMan analysis, 
immunofluorescence and western blot. This may be important: in interactions with 
mature osteoblasts the attachment of myeloma cells would be likely to be less directed 
due to the ubiquitous distribution of N-cadherin.  
 
My study showed by immunohistochemistry that myeloma favoured attachment to      
N-cadherin at junctions. The functional significance of junction versus random            
N-cadherin in relation to myeloma attachment needs to be investigated. Moreover, this 
study showed that N-cadherin is expressed in murine myeloma cell lines; 5T33MM and 
5TGM1. A novel finding was that expression of N-cadherin in both 5T33MM cells and 
5TGM1 cells was focal when evaluated using immunofluorescence and 
immunocytochemistry similar to N-cadherin expression in mouse HSCs (Xie et al., 
2009) and human HSCs (Wein et al., 2010). In addition, we found that N-cadherin 
expression and surface levels of N-cadherin are higher in 5TGM1 cells than in 
5T33MM cells.  
Determining the role of N-cadherin in the formation of the myeloma niche 
  
 Page 227 
 
Groen et al (2011) showed that myeloma cells adhere to osteoblasts, and this adhesion 
could be prevented by using an N-cadherin blocking antibody (Groen et al., 2011). 
However, they did not show the differences between the adhesions of myeloma cells 
with immature or mature osteoblasts. In this study, we showed that in vitro there was a 
higher frequency of myeloma cells adherence to mature osteoblasts compared with 
immature osteoblasts. This may reflect the expression of N-cadherin which this study 
showed significantly higher in mature osteoblasts compared to pre-osteoblast. However 
as discussed above, I observed that N-cadherin was expressed at the junction between 
myeloma cells and osteoblasts, and this long term significance of attachment to cell 
surfaces or junctions is unknown in respect of control of myeloma growth or 
quiescence. Furthermore, we showed that N-cadherin blocking antibody (10 μg/mL) 
reduced the adhesion of myeloma cells to osteoblasts in vitro. Together these data 
strongly suggest that N-cadherin is an important mediator in the interaction between 
myeloma cells and osteoblasts at least in the early stages of attachment.  
 
C57BL/KaLwRijHsd mice develop high frequency of monoclonal proliferative B-cell 
disorders. Cells within BM provide a microenvironment for myeloma cells where these 
tumours can survive and drug resistance can be acquired. To study these processes, 
murine models of multiple myeloma have been developed over the last four decades. 
5TMM series a myeloma models originate from spontaneously developed MM in 
C57BL/KaLwRijHsd mice and have many of the features of the disease in humans 
(Radl et al., 1978, Radl et al., 1979, Vanderkerken et al., 1997). In this study, I analysed 
the discrete micro-anatomical sites within calvarial bones and showed that the 
interparietal bones of calvariae in C57BL/KaLwRijHsd mice have distinct micro-
anatomical features compared to frontal and parietal bones. I found that interparietal 
bones contained higher BM area compared to frontal and parietal bones. In addition, I 
found that interparietal bones contained a higher percentage of osteoblast surfaces and 
bone turnover compared with frontal and parietal bones. In contrast, interparietal bones 
contained a lower percentage of bone lining cell surfaces compared with frontal and 
parietal bones. However, there was no difference in the percentage of osteoclast 
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surfaces between frontal, parietal and interparietal bones. These defined differences 
between the calvarial bones offer an opportunity to study the different requirements for 
myeloma growth offered by these microenvironments.  
 
Oyajobi et al (2007) demonstrated the murine myeloma 5TGM1-GFP cells tumour were 
detectable in calvarial BM between 10-14 days post-inoculation suggesting that these 
myeloma cells home to calvarial BM (Oyajobi et al., 2007). However, this study lacked 
the imaging capability to study single cell arrival in calvarial BM. To date, there is no 
publication demonstrating that the murine myeloma 5T33MM cells can home to 
calvarial BM in C57BL/KaLwRijHsd mice. Previous studies demonstrated that tumour 
cells metastasize to skeletal sites with active bone turnover (Schneider et al., 2005, van 
der Pluijm et al., 2005). In this study, myeloma cells were inoculated into 
C57BL/KaLwRijHsd mice for 3 weeks. Interestingly, we showed that both 5T33MM 
and 5TGM1 form large tumours in interparietal bones and not in frontal or parietal 
bones. One potential explanation for this is that the interparietal bones contain higher 
BM area, higher bone surface area and higher bone turnover compared to frontal and 
parietal bones, but there is also another explanation: that there is a difference in the 
cellular composition, particularly in osteoblasts, between these bones.   
 
Xie et al (2009) have recently used a confocal laser scanning microscope LSM 510, 
multiphoton microscopy, to trace the homing of GFP
+
 HSCs and determining the 
distribution of these cells in the BM (Xie et al., 2009). In this study, myeloma cells were 
labelled with DiD (Invitrogen, UK), a dye bound to phospholipid bilayer membranes of 
the cells. Previous work in the Sheffield labs demonstrated that myeloma cells lose their 
DiD labelling during cell proliferation in vitro. However, some cells retained staining 
suggesting that these cells are mitotically quiescent. I found that there was an increase 
in the numbers of DiD positive, 5T33MM and 5TGM1, myeloma cells observed in the 
interparietal BM compared to the frontal and parietal BM after 3 days. In addition, I 
found that there was an increase in the numbers of DiD positive, 5T33MM and 5TGM1, 
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myeloma cells observed in the interparietal BM compared to the frontal and parietal BM 
after 3 weeks. These observations indicate that although there is an increased frequency 
of myeloma cell arrival in the interparietal bone compared to other calvarial bones, 
tumour cells nevertheless do arrive in the frontal BM and parietal BM. The frequency of 
growing tumours in these bones suggests that there are differences in activation of 
proliferation in colonizing tumour cells provided by these bone microenvironments. The 
presence of apparently quiescent cells as long as 21 days after injection is also 
interesting since it suggests that these cells are growth suppressed, possibly within 
niches, as they are present alongside rapidly growing myeloma populations.  
 
In this study, myeloma cells were inoculated into C57BL/KaLwRijHsd mice and after 7 
days mice were harvested and calvariae were dissected. Rabbit monoclonal anti-N-
cadherin antibody (Millipore, UK) (1:200 dilution) or donkey anti-rabbit IgG antibodies 
(R&D systems, UK) (1:200 dilution), isotype negative control were used to determine if 
N-cadherin was present in the points of adhesion of myeloma cells, 5T33MM and 
5TGM1 to osteoblasts in vivo. Interestingly, we found that the majority of osteoblast 
lineage cells expressed N-cadherin. This observation supported work done by Ferrari et 
al (2000) who demonstrated that N-cadherin was expressed in rat and human bone in 
vivo (Ferrari et al., 2000). In addition, we observed that N-cadherin was localized at the 
junction between myeloma cells and osteoblasts in vivo using immunohistochemistry in 
mouse sections. This observation supports work done by Groen et al (2011) who 
demonstrated that expression of N-cadherin is often localized between MM cells and the 
bone-lining cells using immunohistochemistry (Groen et al., 2011).  
 
Using ADH-1 or monoclonal antibody against N-cadherin to inhibit adhesion of 
myeloma cells to osteoblasts will produce functional information for the role of           
N-cadherin in myeloma-osteoblast interaction. In this study, 5T33MM cells were pre-
treated with 10 μg/ml of anti-N-cadherin antibody or 10 μg/ml of mouse IgG1 antibody. 
I observed that when 5T33MM cells pre-treated with anti-N-cadherin antibody, 
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myeloma cells have homed significantly further from bone compared with 5T33MM 
cells control and with 5T33MM cells pre-treated with isotype control antibody in frontal 
and interparietal bones after 3 days. These results suggested that blocking N-cadherin in 
myeloma cells may have a role in targeting the colonization of myeloma cells into the 
bone. In a separate study, 5TGM1 cells were pre-treated with 10 μg/ml of anti-N-
cadherin antibody or 10 μg/ml of mouse IgG1 antibody. Again I observed that when 
these cells were pre-treated with anti-N-cadherin antibody, they homed further from 
bone with a modest reduction in myeloma tumour size at day 21 in frontal and 
interparietal bones compared with 5TGM1 cells control and with 5TGM1 cells pre-
treated with isotype control antibody. However, immunohistochemistry using anti-
CD138 antibody would have been helpful in defining tumours in these studies but this 
was not applicable to my samples. These were preliminary studies as has been discussed 
elsewhere in this thesis. Taken together, these results while interesting need to be 
repeated and alternative approaches for myeloma N-cadherin blocking considered. 
 
In addition, I analysed the effect of blocking N-cadherin on myeloma bone disease in 
interparietal bones. I observed that there were no differences in the osteolytic lesion 
number in the cortical bones and there were no differences in the trabecular bone 
volume, trabecular number and trabecular thickness when 5TGM1 cells were pre-
treated with anti-N-cadherin antibody compared with 5TGM1-bearing mice or 
compared with 5TGM1 pre-treated with isotype control antibody in interparietal bones 
of myeloma-bearing mice after 21 days. These results suggested that blocking             
N-cadherin in myeloma cells with anti-N-cadherin antibody did not affect myeloma 
bone disease and this may be due to the efficacy of blocking with the approach used. 
Alternatively, this could be due to the N-cadherin turn over and doubling time of 
myeloma cells. This was observed previously by Wein et al (2010) who showed that   
N-cadherin was knocked down in human mesenchymal stromal cells but this was lasted 
for about a week, then the levels of N-cadherin expression slowly normalized again 
(Wein et al., 2010).  
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Recent studies have shown the early stages of myeloma development are dependent on 
the surrounding BM microenvironment. However, in late stage disease the myeloma 
cells are not BM microenvironment depended. As mentioned before, the BM 
microenvironment promotes the survival and growth of myeloma cells. Several 
molecules and cytokines have been identified that mediate MM pathogenesis by 
stimulating the expansion of myeloma cells that ultimately affects bone. Most MM 
treatment strategies focus on stopping MM activity: melphalan or zoledronic acid, or to 
stop the interaction of MM cells to BM stromal cells: Denosumab, Lenalidomide, 
Thalidomide or Bortezomib (Andrews et al., 2013). This study focused to disrupt the 
colonizing of myeloma cells by one of the molecular machinery of HSCs, N-cadherin, 
and hijack the HSC niche. I think stopping colonization of myeloma cells into the niche 
in combination with anti-tumour agent could be completely cure MM patients.  
 
In conclusion, figure 7.1 shows a model of a possible interaction between N-cadherin 
positive myeloma cells and N-cadherin positive osteoblasts in the HSC niche or bone 
microenvironment. TaqMan analysis of calvarial mouse primary osteoblast cDNA 
obtained from cultures over time courses during differentiation demonstrated that        
N-cadherin expression is increased in mature osteoblasts compared with immature 
osteoblasts. N-cadherin positive myeloma cells home to the endosteal surfaces and bind 
to an as yet undefined population of osteoblasts expressing N-cadherin. Here they 
survive in a quiescent state for extended periods. In response to an initiating event, 
myeloma cells are released from their quiescent state and start growing. My studies 
support the concept of myeloma cells interacting with osteoblasts through N-cadherin 
but the nature of the trigger for releasing attachment remains to be determined. The 
concept of myeloma quiescence and its maintenance also requires further studies. 
Targeting N-cadherin using monoclonal antibody against N-cadherin showed a 
reduction in the adhesion of myeloma cells to osteoblasts in vitro and showed some 
effects on adhesion of myeloma cells to bone and on tumour size in vivo. However, 
these finding are interesting but preliminary and need validation with alternative 
approaches to N-cadherin suppression in vivo and larger cohorts of animals.  
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Figure 7.1: Model of the possible interaction between N-cadherin
+
 myeloma and 
N-cadherin
+
 osteoblast in the HSC niche. TaqMan analysis of calvarial mouse 
primary osteoblast cDNA obtained from cultures over time course during 
differentiation demonstrated expression of N-cadherin is increased during 
osteoblastogenesis. N-cadherin
+
 myeloma cells more probably bind to a population of 
osteoblasts expressing high level of N-cadherin. Targeting N-cadherin using 
monoclonal antibody against N-cadherin showed a reduction in the tumour growth 
and adhesion of myeloma cells to osteoblasts.  
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7.2 Future work  
Future studies need to be done to more effectively block N-cadherin function in 
myeloma cells. Hosokawa et al (2010) showed that N-cadherin is expressed in long-
term HSCs and in the osteoblasts mediating cells adhesion in the HSC niche. 
Knockdown of N-cadherin showed a reduction in the long-term engraftment activity of 
HSCs in the BM in vivo (Hosokawa et al., 2010). In addition, Arai et al (2012) showed 
that Knockdown of N-cadherin reduced the long-term HSCs to the endosteal surfaces 
(Arai et al., 2012). In future work, N-cadherin should be knocked-down in myeloma 
cells and these myeloma cells inoculated into mice to determine the effect of depleting          
N-cadherin levels on myeloma colonization in bone, on tumour growth and on myeloma 
bone disease.  
 
Tanaka et al (2010) demonstrated that prostate cancer metastasis and castration 
resistance was induced by N-cadherin. Targeting N-cadherin using monoclonal antibody 
against N-cadherin showed a reduction in proliferation, adhesion and invasion of 
prostate cancer cells in vitro and delayed the castration resistance progression in vivo 
(Tanaka et al., 2010). In future work, monoclonal antibodies against the ectodomain of       
N-cadherin could be generated to treat myeloma-bearing mice instead of pre-treating the 
myeloma cells then injecting them into mice as I did, to determine the effect of            
N-cadherin on myeloma colonization in bone, on tumour growth and on bone disease. 
Alternatively, ADH-1 pentapeptide, an agent targeting ectodomain of N-cadherin, could 
be used to determine the effect of N-cadherin on myeloma colonization in bone, on 
tumour growth and on myeloma bone disease. Earlier studies by Shintani et al (2008) 
demonstrated that using the cyclic ADH-1 pentapeptide significantly reduced growth 
and metastasis of pancreatic cancer cells in transgenic mice (Shintani et al., 2008).  
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Augustine et al (2001) showed that N-cadherin was expressed in human melanoma-
derived cell lines. Targeting N-cadherin with ADH-1 pentapeptide in combination with 
chemotherapy drug (Melphalan) was used as a novel therapeutic approach significantly 
reduced tumour growth and enhanced the antitumor activity of Melphalan (Augustine et 
al., 2008). Clinically, Beasley et al (2009) demonstrated that ADH-1 at a dose of 4000 
mg in combination with melphalan on days 1 and 8 was safe and well tolerated by 
patient in phase I studies and provided novel targeted therapy approach in melanoma  
(Beasley et al., 2009). In addition, Vitovski et al (2012) demonstrated that targeting 
tumour-initiating cells with TRAIL, tumour necrosis factor-related apoptosis-inducing 
ligand, in combination with doxorubicin completely eradicated of MM cells in vivo 
(Vitovski et al., 2012). Future studies could be performed with combination treatments 
such as ADH-1 or a monoclonal antibody against N-cadherin in combination with 
chemotherapic agents such as TRAIL or doxorubicin or in combination with bone 
anabolic agents such as anti-Dkk1 or anti-Activin-A.  
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